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Abstract
Clinical trial metadata: defining and extracting metadata on
the design, conduct, results and costs of 125 randomised
clinical trials funded by the National Institute for Health
Research Health Technology Assessment programme
James Raftery,1* Amanda Young,1 Louise Stanton,2 Ruairidh Milne,1
Andrew Cook,1 David Turner1,3 and Peter Davidson1
1Wessex Institute, Faculty of Medicine, University of Southampton, Southampton, UK
2University of Southampton Clinical Trials Unit, Southampton General Hospital, Southampton, UK
3Health Economics Group, Faculty of Medicine and Health Sciences, University of East Anglia,
Norwich, UK
*Corresponding author raftery@southampton.ac.uk
Background: By 2011, the Health Technology Assessment (HTA) programme had published the results of
over 100 trials with another 220 in progress. The aim of the project was to develop and pilot ‘metadata’
on clinical trials funded by the HTA programme.
Objectives: The aim of the project was to develop and pilot questions describing clinical trials funded
by the HTA programme in terms of it meeting the needs of the NHS with scientifically robust studies.
The objectives were to develop relevant classification systems and definitions for use in answering relevant
questions and to assess their utility.
Data sources: Published monographs and internal HTA documents.
Review methods: A database was developed, ‘populated’ using retrospective data and used to answer
questions under six prespecified themes. Questions were screened for feasibility in terms of data availability
and/or ease of extraction. Answers were assessed by the authors in terms of completeness, success of the
classification system used and resources required. Each question was scored to be retained, amended
or dropped.
Results: One hundred and twenty-five randomised trials were included in the database from
109 monographs. Neither the International Standard Randomised Controlled Trial Number nor the term
‘randomised trial’ in the title proved a reliable way of identifying randomised trials. Only limited data were
available on how the trials aimed to meet the needs of the NHS. Most trials were shown to follow their
protocols but updates were often necessary as hardly any trials recruited as planned. Details were often
lacking on planned statistical analyses, but we did not have access to the relevant statistical plans.
Almost all the trials reported on cost-effectiveness, often in terms of both the primary outcome and
quality-adjusted life-years. The cost of trials was shown to depend on the number of centres and the
duration of the trial. Of the 78 questions explored, 61 were well answered, 33 fully with 28 requiring
amendment were the analysis updated. The other 17 could not be answered with readily available data.
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Limitations: The study was limited by being confined to 125 randomised trials by one funder.
Conclusions: Metadata on randomised controlled trials can be expanded to include aspects of design,
performance, results and costs. The HTA programme should continue and extend the work
reported here.
Funding: The National Institute for Health Research HTA programme.
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Scientific summary
Background
The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme,
established in 1993, has published the results of over 100 randomised controlled trials (RCTs) with some
220 more in progress. Although trial registries contain some key prospective features of trials, data are
absent on the actual conduct, performance and cost of trials.
Objectives
The aim of the project was to develop and pilot questions describing clinical trials funded by the HTA
programme in terms of it meeting the needs of the NHS with scientifically robust studies.
The objectives were:
l to develop, pilot and validate metadata definitions and classification systems to answer specified
questions within six themes
l to extract data under these headings from published RCTs funded by the HTA programme
l to analyse these data to answer specific questions grouped by theme
l to consider further development and uses of the data set, including refinements of the metadata
headings for their application to ongoing and future HTA trials.
A database was developed, ‘populated’ using retrospective data and assessed for its ability to answer
questions under six prespecified themes. The themes were:
1. How was the trial seen as meeting the needs of the NHS?
2. How well designed was the trial?
3. How well conducted was the trial?
4. Were the statistical analyses appropriate?
5. What, if any, kind of economic analysis was performed?
6. What was the cost of the trial?
Methods
Questions were screened for feasibility in terms of data available or readily extractable. Answers were
assessed by completeness, success of the classification system used and difficulty of data extraction.
Each question was scored to be retained, amended or dropped.
Results
One hundred and twenty-five RCTs were included in the database from 109 monographs. Neither the
International Standard Randomised Controlled Trial Number nor the term ‘randomised trial’ in titles proved
a reliable way of identifying RCTs. Only limited data were available on how the trials aimed to meet the
needs of the NHS. Most trials were shown to follow their protocols but updates were often necessary as
hardly any trials recruited as planned. Details were often lacking on planned statistical analyses but we did
not have access to the relevant statistical plans. Almost all the trials reported on cost-effectiveness, often in
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terms of both the primary outcome and quality-adjusted life-years. The cost of trials was shown to depend
on the number of centres and the duration of the trial. Of the 78 questions explored, 33 were answered
fully and 28 would require amendment if the analysis were to be updated. The other 17 questions could
not be answered with readily available data.
Conclusions
Metadata on RCTs can be expanded to include aspects of design, performance, results and costs. The HTA
programme should continue and expand the work reported here.
Funding
Funding for this study was provided by the HTA programme of the NIHR.
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Chapter 1 Introduction
The Health Technology Assessment programme
The Health Technology Assessment (HTA) programme, established in 1993, recently celebrated its
20th birthday, part of which included an account of its history.1 In brief, the programme funds assessments
of health technologies with the aim of meeting the research needs of the NHS with scientifically robust
evidence. These assessments take two forms: reviews of existing evidence and new research. The latter
generally takes the form of clinical trials, most but not all of which are randomised. The overarching aim of
the study is to assess the extent to which these trials contributed to meeting the needs of the NHS with
scientifically robust evidence.
These randomised controlled trials (RCTs) are of interest for several reasons. First, although over
100 projects involving RCTs had been published by the end of 2011, no systematic compilation exists.
Projects may include more than one trial. Some projects report on trials that either failed to recruit or had
to depart from plans. As over 200 RCTs funded by the programme were in progress in 2011, a systematic
list was required. Second, a small but growing literature studies RCTs. Reviewed below, this literature
highlights the desirability of having standardised descriptions of key aspects of these trials.
The RCTs funded by the HTA programme are distinctive in being pragmatic, as opposed to explanatory or
licensing trials. They aimed to evaluate the technology of interest in real-world conditions. Inclusion criteria
were wide rather than narrow. Patient-related outcomes were preferred to intermediate or surrogate
outcomes. Economic analysis was almost always included, sometimes along with qualitative studies.
As most of the guidelines for the design, conduct and performance of clinical trials were designed for
explanatory and licensing trials, their application to the pragmatic trials funded by the HTA programme
may pose problems.
Studies of randomised controlled trials funded by the Health
Technology Assessment programme
The Strategies for Trial Enrolment and Participation Study (STEPS),2 summarised in Chapter 6, reviewed
recruitment in a cohort of trials funded by the HTA programme and the Medical Research Council (MRC)
between 1994 and 2003, and showed that 80% failed to recruit 80% of planned patients.
A study of the impact of the HTA programme, published in 2007,3 reviewed all HTA-funded projects
completed between 1993 and 2005, including many which did not include clinical trials, using Buxton
and Haney’s payback method.4 Data were drawn from HTA files and monograph reports supplemented
by a survey of lead investigators and a random selection of case studies. It recommended collection of
routine data on key headings from the payback approach (all peer-reviewed publications, data on other
publications and presentations, capacity development linked to the project, etc.). The assessment of the
impact of studies on policies was limited to the lead investigators’ views, which were explored in
case studies.
One study considered how many trials funded by the programme showed a statistically significant
difference in the primary outcome.5 In the period 1993–2008 some two-thirds did not report such
a difference.5 This proportion was shown to be similar to other trial portfolios, notably that of National
Institutes of Health (NIH) cancer trials.6
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Trials that fail to show such differences can make valuable contributions via their contributions to
meta-analyses based on systematic reviews. Another study, which analysed one HTA trial and explored its
contribution to the meta-analysis, showed that, although the question posed had been important at the
time of commissioning the trial (large effect size, wide confidence interval), the reporting of six other trials
in the interim meant that its eventual contribution to the meta-analyses was limited to narrowing the
confidence intervals.7 To follow up this work, one would need to know how many clinical trials funded
by the HTA programme had both a relevant preceding and a subsequent meta-analysis.
Finally, a review of economic analyses in HTA trials showed that economic analyses were generally
included in trials funded by the HTA programme.8
Metadata
Metadata is a term commonly used with regard to digital equipment such as cameras to refer to the data
routinely recorded about each item, such as time and date. Additional data headings can be added, such
as place and persons. Any document prepared using a standard word processing package contains
metadata indicating date, person, computer, etc. Non-digital indexes such as a traditional library indexing
system can also be described as metadata.
Some databases already contain metadata on clinical trials, such as the International Standard Randomised
Controlled Trial Number (ISRCTN) register (www.controlled-trials.com) and the US ClinGov register
(https://clinicaltrials.gov). These registers, discussed more fully in Chapter 2, register trials under around
20 descriptive headings including title, start and planned completion dates, disease, intervention, primary
outcomes, planned recruitment and contacts. No headings are specified for the reporting or analysis of
results, or for the conduct or performance of the trial.
Aims
The aim of the project was to develop and pilot ‘metadata’ on clinical trials funded by the HTA
programme. In exploring how to extend the metadata held in existing clinical trial registries, we considered
two options. We could either aim to specify a comprehensive data set capable of answering all potential
questions, or design a data set to answer particular questions. We pursued the latter option, starting with
a set of themes and related questions that might plausibly be answered by such metadata.
We explored questions under six themes using classification systems in answering particular questions.
Some classification systems were simple (yes/no) and some complex (16 headings for the European
Medicines Agency guideline on handling missing data). Questions that had to do with whether or not
analyses were as planned required not only classification of the planned and actual analyses, but also
of their (dis)agreement. Data sources comprised both published and unpublished documents. Published
sources were largely those in the HTA journal monograph series but also study protocols (most but not
all published on the HTA website since 2006). Key unpublished sources included final application forms as
well as vignettes, commissioning briefs and project protocol change forms.
The project explored the extent to which metadata could provide standardised data which would be useful
not only in managing that portfolio but also in enabling assessment of the conduct, analysis and cost of
those trials. Such assessment of the trials would require high-quality data, which had been subject to
explicit quality assurance.
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The four project objectives, as stated in the final application funded by the HTA programme, were:
l to develop, pilot and validate metadata definitions and classification systems to answer specified
questions within six themes
l to extract data under these headings from published RCTs funded by the HTA programme
l to analyse these data to answer specific questions grouped by theme
l to consider further development and uses of the data set, including refinements of the metadata
headings for their application to ongoing and future HTA trials.
The protocol stated that:
Metadata would provide standardised data about the portfolio of HTA trials. These data would enable
assessment of questions such as how well the trials were conducted, and the extent to which their
results were as expected. Some limited metadata are already publicly available; their extension as
proposed here will require appropriate data headings (or classification systems), some of which would
be developed in this project.
It also stated that:
The provision of such data would enable performance of the trial portfolio to be monitored over time.
Such data would also indicate foci for improvement and help assess the contribution of the ‘needs-led’
and ‘value added’ scientific inputs. To the extent that similar data could be collated for other trials,
these could be compared with the HTA trials.
Our research themes
The themes of most immediate interest was based around the composition and performance of the
‘portfolio’ of clinical trials funded by the HTA programme. The provision of such data was seen as enabling
performance of the trial portfolio to be monitored over time. Such data would also indicate foci for
improvement and help to assess the contribution of the ‘needs-led’ and ‘value-added’ elements of
the programme.
The project proposal aimed to extend these trial registration metadata to include data required to answer
questions under the following six broad themes:
1. How was the trial seen as meeting the needs of the NHS?
2. How well designed was the trial?
3. How well conducted was the trial?
4. Were the statistical analyses appropriate?
5. What, if any, kind of economic analysis was performed?
6. What was the cost of the trial?
Themes 1 (meeting the needs of the NHS) and 5 (economics) relate to the HTA programme’s overarching
aim of meeting the needs of the NHS. Themes 2, 3 and 4 address the robustness of the scientific evidence.
Theme 6, on the cost of trials, helps explore value for money.
The choice of the above themes was that of the authors, guided by the literature and aiming to update
or replicate previous studies. Four of the authors (JR, RM, PD and AC), having worked for the National
Institute for Health Research Evaluation, Trials and Studies Coordinating Centre (NETSCC) in a range
of senior roles, identified these themes as of concern to the programme. Relevant published studies were
updated where possible. As part of the first theme (the origin of the research question), an earlier paper
by Chase et al.9 was updated. For the second theme (design of trials), previous studies by Chan et al.10
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were drawn on. For performance (the third theme), STEPS,2 which examined the recruitment success of
multicentre RCTs, was important. For the fourth theme (statistical analysis), besides Chan et al.10 and
Chan and Altman,11 the issues of concern were with the appropriate analysis of primary outcomes,
including the congruence of planned and actual analyses. For economic analysis (the fifth theme), the
widely used 1996 BMJ guideline12 provided a starting point. Few studies have been published on the costs
of trials, mainly to do with commercial trials in the USA. Guidance from the UK Department of Health
specified how non-commercial trials13 should be costed but its application had not been studied. This was
the sixth theme. Each of these themes was operationalised into more specific questions and iterated
against the data available (see Chapters 4–9).
Project team
Details of each authors’ contributions are provided in Acknowledgements (p.113). An external advisory
group, also detailed in Acknowledgements, provided valuable input for which we are grateful.
Structure of the report
The aims and objectives related to the development of the metadata were described in this chapter.
Chapter 2 provides a review of the existing databases, Chapter 3 reports on methods and Chapters 4–9
report on each of the six themes. Chapters 10 and 11 provide a discussion of the main findings, draw
conclusions for the overall project and discuss recommendations of the type of questions that are plausible
for future use in the metadata database.
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Chapter 2 Data quality and reporting in existing
clinical trial registries: a review of existing databases
This chapter briefly reviews existing databases of clinical trials, including descriptions of the maindatabases and studies which have used them, based on a systematic literature search (detailed
in Appendix 1).
Trial registries: the USA
The impetus for the US clinical trials database, ClinGov, came from legislation in 1997, against the
background of the human immunodeficiency virus (HIV) epidemic, that mandated a registry of clinical trials
for both federally and privately funded trials ‘of experimental treatments for serious or life-threatening
diseases or conditions.’14 Patient groups had demanded ready access to information about clinical research
studies so that they might be more fully informed about a range of potential treatment options,
particularly for very serious diseases. The law emphasised that the information in such a registry must be
easily accessible and available to patients, the public, health-care providers and researchers in a form that
can be readily understood.15
Previous attempts to establish clinical trials information systems had focused less on patient access than on
clinician and researcher access and use. ClinGov had been concerned that if relevant data about trials were
not published or are poorly reported, publication bias and, ultimately, poor care could result.
The design of ClinGov was guided by the following principles:
l to ensure that design and implementation was guided by the needs of the primary intended audience,
patients and other members of the public
l to get broad agreement on a common set of data elements with a standard syntax and semantics
l to acknowledge that requirements would evolve over time, implying a modular and extensible design.
A web-based system resulted, which aimed to be easy for novice users but which had extensive
functionality. As all NIH-sponsored trials were to be included, ClinGov worked closely with the 21 NIH
institutes, each of which had varying approaches to data management and collection and varying
levels of technical expertise. The 21 institutes agreed on a common set of data elements for the clinical
trials data. Just over a dozen required data elements and another dozen or so optional elements were
agreed. The elements fell into several high-level categories: descriptive information such as titles and
summaries; recruitment information to let patients know whether or not it is still possible to enrol in a trial;
location and contact information to enable patients and their doctors to discuss with the persons who are
actually conducting the trials; administrative data, such as trial sponsors and identification numbers;
and optional supplementary information, such as literature references and keywords. Table 1 lists the
15 required and 12 optional data elements.
The study sponsor was defined as the primary institute, agency or organisation responsible for conducting
and funding the clinical study. Additional sponsors could be listed in the database. Investigator names
were included at the discretion of the data provider. Data providers were asked to provide brief, readily
understood titles and summaries, including why the study was being performed, what drugs or other
interventions were being studied, which populations were being targeted, how participants were assigned
to a treatment design and what primary and secondary outcomes were being examined for change
(e.g. tumour size, weight gain, quality of life).
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Location information included contact information and status of a clinical trial at specific locations. As many
trials were being conducted at multiple locations, sometimes dozens of sites, contact information and
recruitment status for all sites had to be accurate and current. Six categories of recruitment status applied:
not yet recruiting (the investigators have designed the study but are not yet ready to recruit patients);
recruiting (the study is ready to begin and is actively recruiting and enrolling subjects); no longer recruiting
(the study is under way and has completed its recruiting and enrolment phase); completed (the study has
ended and the results have been determined); suspended (the study has stopped recruiting or enrolling
subjects, but may resume recruiting); and terminated (the study has stopped enrolling subjects and there is
no potential to resume recruiting). Information about start and completion dates of the study were
included, as was contact information including a name and a telephone number for further enquiries.
Eligibility criteria were defined as the conditions that an individual must meet to participate in a clinical
study, based on inclusion and exclusion criteria and context.
Besides clinical trials designed to investigate new therapies, nine other study types were included:
diagnostic, genetic, monitoring, natural history, prevention, screening, supportive care, training and
treatment. Study design types included randomised and observational study designs as well as methods
(e.g. double-blind method) and other descriptors (e.g. multicentre site).
ClinGov required certain items as separate data elements specifically to ensure optimal search capabilities.
These included the study phase, the condition under study and the intervention being tested. The phase
of the study was important information for patients who were considering enrolling in a particular trial.
Data providers were requested to name the condition and intervention being studied using the medical
subject headings (MeSH) of the Unified Medical Language System, if at all possible.
Optional information included references for publications that either led to the design of a study or
reported on the study results. In these cases, data providers were asked to provide a MEDLINE unique
identifier so that it could be linked directly to a MEDLINE citation record. A summary of the results could
TABLE 1 Required and optional data elements in ClinGov trial registration database
Required data elements Optional data elements
1. Study identification number 1. NIH grant or contract number
2. Study sponsor 2. Investigator
3. Brief title 3. Official title
4. Brief summary 4. Detailed description
5. Location of trial 5. Study start date
6. Recruitment status 6. Study completion date
7. Contact information 7. References for background citations
8. Eligibility criteria 8. References for completed studies
9. Study type 9. Results
10. Study design 10. Keywords
11. Study phase 11. Supplementary information
12. Condition 12. URL for trial information
13. Intervention
14. Data provider
15. Date last modified
URL, uniform resource locator.
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also be prepared specifically for inclusion in the database and the use of MeSH keywords was also
encouraged. Supplementary information could include uniform resource locators (URLs) of websites related
to the clinical trial.
The agreement of a common set of data elements was completed by the end of 1998. The next step was
concerned with methods for receiving data for inclusion in a centralised database at the National Library
of Medicine. Data were sent to ClinGov in Extensible Markup Language (XML) format according to a
document type definition (DTD). Each clinical trial record was stored in a single XML document. A validator
process performed checks on each record; each XML document was analysed and checked for adherence
to the DTD. Adherence to the DTD helped identify structural errors in the document. Once the XML
document was structurally correct, a Java object was created to facilitate content validation. Content
validation could be performed on any data elements that did not contain free text.
Trial registries: World Health Organization clinical trials
registry platform
Following the Declaration of Helsinki statement in 2000,16 the World Health Assembly vote to establish
the International Clinical Trials Registry Platform (ICTRP)17 in 2004 and the International Committee of
Medical Journal Editors (ICMJE) 2004 declaration,18 the World Health Organization (WHO) established the
ICTRP to facilitate the prospective registration of clinical trials. Trials could not be registered with WHO
but with either a primary registry in the WHO Registry Network or with an ICMJE-approved registry.
As regulatory, legal, ethical, funding and other requirements differ from country to country, the approved
registries vary to some extent. WHO specified a 20-item minimum data set. This list was very similar to that
of ClinGov but differed in several ways:
l The WHO list included sources of funding, which was not explicitly included in ClinGov.
l Primary and secondary outcomes were included by WHO but not ClinGov.
l ClinGov used eligibility whereas WHO used inclusion/exclusion criteria.
l WHO distinguished between public and scientific in both titles and contacts.
l Different identification numbers were used (ISRCTN and ClinGov).
The WHO Registry Network comprises primary registries, partner registries and registries working towards
becoming primary registries. Any registry that enters clinical trials into its database prospectively (that is,
before the first participant is recruited), and that meets the WHO Registry Criteria or is working with ICTRP
towards becoming a primary registry, can be part of the WHO Registry Network.
Primary registries in the WHO Registry Network meet specific criteria for content, quality and validity,
accessibility, unique identification, technical capacity and administration. Primary registries meet the
requirements of the ICMJE. The nine primary registries as at December 2011 are shown in Box 1.
Partner registries meet the same criteria as primary registries in the WHO Registry Network (i.e. for content,
quality and validity, etc.), except that they do not need to:
l have a national or regional remit or the support of government
l be managed by a not-for-profit agency
l be open to all prospective registrants.
All partner registries must also be affiliated with either a primary registry in the WHO Registry Network
or an ICMJE-approved registry. It is the responsibility of primary registries in the WHO Registry Network to
ensure that their partner registries meet WHO Registry Criteria. Partner registries at the end of 2011
included the Clinical Trial Registry of the University Medical Center Freiburg, German Registry for
DOI: 10.3310/hta19110 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 11
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Raftery et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Somatic Gene-Transfer Trials, the Centre for Clinical Trials, and Clinical Trials Registry – Chinese,
University of Hong Kong.
The US registry, ClinGov, is not a partner of any kind in the WHO network. Two different realms thus exist
in clinical registries: the USA and the rest of the world. Inevitably, the headings for trial registration,
although broadly the same, differ. One striking difference is that the US register does not require data on
the funding source of the trial, whereas this is required in the rest of the world. Another is that whereas
the USA has moved towards requiring the registration of results of trials, the rest of the world has not.
Trial registries: the UK
The ISRCTN, a primary partner in the WHO platform, is run by Controlled Clinical Trials, which registers any
clinical trial in the UK designed to assess the efficacy of a health-care intervention in humans. The ISRCTN
collects the 20-point WHO list and makes this available on a trial-by-trial basis on the internet. The EU
Clinical Trials Registry, a secondary partner in WHO, is confined to investigational drugs and includes the
UK Medicines and Healthcare products Regulatory Agency (MHRA) as one of its data-providing agencies.
It does not provide data on individual trials.
UK trials register mainly with ISRCTN but a proportion register with ClinGov. This appears to be partly for
historical reasons (ClinGov came first), but also because registration is free in ClinGov but ISRCTN charges
a small fee (£200 in 2012). Although this charge is met by the UK Department of Health for approved
trials [those funded by the National Institute for Health Research (NIHR), research councils or UK charities],
other trials which would have to pay may choose to register with ClinGov. A recent review of registration
of UK non-commercial trials showed a rise in the proportion registering with ClinGov to around 30%
in 2010.19
BOX 1 Primary WHO registries
Australian New Zealand Clinical Trials Registry.
Brazilian Clinical Trials Registry.
Chinese Clinical Trial Registry.
Clinical Research Information Service, Republic of Korea.
Clinical Trials Registry, India.
Cuban Public Registry of Clinical Trials.
EU Clinical Trials Register.
German Clinical Trials Register.
Iranian Registry of Clinical Trials.
EU, European Union.
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Registries and reporting of results
An exploration of the issues raised by including reporting of the findings of clinical trials in databases
under the aegis of WHO20–22 discussed issues to do with multiple outcomes and the importance of context
in interpretation of results. It noted that, historically, access to the results of a trial had been achieved
through publication in a peer-reviewed journal but that this publication model has its limitations,
particularly in an environment where the end users of research information include health-care
policy-makers, consumers, regulators and legislators who want rapid access to high-quality information in
a ‘user-friendly’ format. It noted that in the future, researchers may be legally required to make their
findings publicly available within a specific time frame (assuming any legislation created does not have
escape clauses built in). In the USA, it noted that such legislation was already in place (available at
www.fda.gov/oc/initiatives/HR3580.pdf).
Since the development of trial registration databases in 2000, research has been conducted to:
l describe the characteristics of trials registered23
l review the compliance and quality of entries in ClinGov,14 the WHO portal20–22 and several registers24
l report on scientific leadership (ISRCTN and ClinGov)
l publish results of trials registered25,26
l compare planned and actual trial analyses, including analysis of primary outcomes in major journals27
and comparisons between protocols and registered entries to published reports.28
Details of the literature searches on trial registration, uses and data quality are provided in Appendices 1–3.
In summary, many trials registered were small, with 62% of interventional trials registered in ClinGov in
2007–10 enrolling fewer than 100 patients. The quality and compliance of registration was not good, with
trials often registered late (whether defined as after recruitment had commenced or after the trial had
been completed) and with missing registration data, specifically to do with contacts, primary outcomes
and the processes of randomisation. Compliance was found to be improving, at least for the period
2005–7.21 Around one-third of registered trials had not reported 24 months after completion, with worse
performance for industry-funded trials.
Comparisons of planned and actual trial behaviour, summarised in Chapters 4–9, show that discrepancies
between protocols or trial entries and trial reports were common.
Conclusions
This brief review of the literature indicates that:
l Two main registry types have emerged – the US ClinGov and the WHO platform which provides an
infrastructure for the rest of the world.
l The data required differs between ClinGov and the WHO platform, with the latter including primary
and secondary outcomes and source of financing. The former has more detail on patient eligibility
and appears more patient oriented.
l Prospective registration of planned RCTs has become common and mandatory in many countries.
l In the UK, RCTs register mainly with the ISRCTN via Current Controlled Trials (CCT), but some register
with ClinGov.
l The quality of the data registered has been poor, with all studies indicating poor compliance.
l Both the US and WHO registries are moving towards inclusion of results, with ClinGov further
advanced owing to such reporting having become mandatory in the USA from 2006.
l No studies were identified that went beyond the minimum data set for prospective registration
to include conduct, performance, cost and results of trials.
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Chapter 3 Methods
Introduction
This chapter outlines the target ‘population’, inclusion criteria, data sources and quality assurance
methods used.
Population
The population of interest was completed RCTs funded by the HTA programme. The starting point was the
published HTA monograph series which published the results of almost all funded projects. Projects were
distinguished from trials, as projects can comprise several trials. Some trials were described as pilot or
feasibility trials.
A RCT was defined for this study as:
An experiment in which two or more interventions, possibly including a control intervention or no
intervention, are compared by being randomly allocated to participants. In most trials one intervention
is assigned to each individual but sometimes assignment is to defined groups of individuals (for
example, in a household) or interventions are assigned within individuals (for example, in different
orders or to different parts of the body).
Reproduced with permission from
www.nets.nihr.ac.uk/glossary?result_1655_result_page=R
Published HTA-funded projects which included a RCT were identified from the HTA monograph series
(www.hta.ac.uk/). The title and the ISRCTN number for each published monograph were reviewed and
cross-referenced with the HTA Management Information System (HTA MIS).
Inclusion criteria
The inclusion criteria were HTA-funded projects that had reported the results of at least one RCT and had
been published as a HTA monograph by the end of February 2011. One project which included a clinical
trial but failed to submit the draft final report and did not publish a HTA monograph was excluded on
these grounds. One hundred and nine projects were included.
These criteria implied to the inclusion of pilot and feasibility studies. This mattered to varying degrees for
the different themes. A full list of the RCTs included in the database is shown in Appendix 2.
Data sources
Data on each randomised clinical trial were extracted from seven sources:
1. the published HTA monograph (publicly available)
2. protocol changes form, if available (a confidential document submitted with the final report)
3. the final, most current version of the protocol (project protocols were not available for older
HTA-funded trials)
4. the full proposal attached to the contract of agreement (confidential document)
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5. the commissioning brief (publicly available)
6. the vignette (confidential document)
7. the HTA MIS (confidential).
As sources 2–6 above were mostly only available on paper, paper files were scanned to create electronic
portable document format (PDF) copies, which were directly linked to the database.
As the HTA programme changed the format of these sources over time, a timeline was drawn
within which each project was situated. These changes sometimes limited the data available for
particular questions.
Quality control
Our approach to quality assurance was guided by Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA), which, although designed for systematic reviews, can be applied to the processes
we used for data extraction. Out of the 27 PRISMA checklist items, 12 items are listed under ‘Methods’.
Of these 12 statements, we used six items to help define the design of the project (eligibility criteria,
information sources, search, study selection, data collection process and data items). PRISMA states:
‘Describe the method of data extraction from reports and any processes for obtaining and confirming data
from investigators’ (Liberati et al. 200929).
Data extraction forms were developed and piloted on five trials, leading to refinement. This led to the
identification of five types of data field, each with a different process of quality assurance, as shown in
Table 2 along with their relevance by theme.
Two members of the team went through discrepancies and queries relating to the complete extraction
of data, came to an explicit agreement and amended the database accordingly. The level of checking
for the 125 trials by the second team member varied; all data were checked for themes 1, 2, 3 and 4.
A percentage of data checking was completed by DT for theme 5 [40% for the BMJ checklist (BCL)] and JR
for theme 6 (40%).
Quality assurance by type of data (Table 2) was applied as follows. With a few exceptions, fields relating to
the design of the trial, conduct of the trial, statistical analysis and Consolidated Standards of Reporting
Trials (CONSORT) were classified as type 3, 4 or 5 in Table 2. All health economics fields were classified as
type 5, the cost of trials fields were classified as type 4 and the NHS need fields were classified as type 2.
Errors noted in the data extracted were corrected and the data changed were recorded in a central
Microsoft Office Excel 2010 (Microsoft Corporation, Redmond, WA, USA) spreadsheet. If the change
needed further discussion it was noted in the spreadsheet and discussed with AY and/or other members
of the steering group.
These quality assurance processes were carried out weekly to ensure issues with fields could be spotted
quickly. Monthly reports were provided to the project steering group.
Most of the fields in the database were either numeric or categorical. For categorical fields, the possible
categories for data entry were listed as a drop-down menu and locked to these codes to prevent errors.
METHODS
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Data extraction
Data extraction specification forms were developed for each question (see Appendix 3). Free-text entries
were allowed only when no classification system could be employed. Classification systems were used to
specify the forms, showing for each item the data to be extracted, the type of field and, if categorical, the
classification we planned to use. Existing classifications from the published literature were used where
possible. Where there were two competing classifications we used both, and if there was no published
classification, we used either the HTA MIS (if applicable) or, in extremis, a simple hierarchical system
(yes/no, if yes, then detail).
The forms were developed by the research fellow and statistician in conjunction with the research lead for
each theme and reviewed by the steering group. The project advisory group was sent a full list of the data
fields that were planned to be included in the metadata database for comment. The data items finally
included in the metadata database were based on consensus.
TABLE 2 Quality assurance measure used for the different types of data fields
Type of data field Description
Application
to theme Quality check
1. HTA MIS Data fields obtained directly from the
HTA MIS (read only)
37 Reasonableness, outliers
2. Straightforward fields Data fields relatively straightforward to
extract and did not usually involve a
judgement call (e.g. trial design,
number of arms, details on project
extensions, protocol changes)
60 Random sample checked against
source documents
3. Numeric Data fields where the highest level of
transcription errors (human error) were
likely to occur (e.g. in conduct
questions on number of patients
recruited/randomised/followed up and
number of centres)
284 All fields checked against source
documents [with the exception of
58 fields for the health economics
data, where a random sample was
double-checked by the health
economist (DT)]. The project
statistician (LS) checked data
extracted4. Judgement call fields Data fields which involved a subjective
judgement, for example whether or
not the researchers had adequately
specified the method of randomisation
sequence generation, reported all
CONSORT fields or the type of trial
intervention
5. Specialist data fields Data fields which required specialised
training or knowledge to understand
and extract data accurately; these
were likely to lead to the highest
errors during data extraction
(e.g. sample size calculation fields,
planned method of statistical analysis,
all health economics fields)
CONSORT, Consolidated Standards of Reporting Trials.
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Projects and trials included in the database
This section reports on the number of trials that met the eligibility criteria along with problems
encountered.
From its start date in 1997 to the end of February 2011, the HTA programme published 574 projects
in the HTA monograph series (in 15 annual volumes). The executive summary for each report was
independently reviewed by two members of the steering group to assess whether or not the monograph
included the results of a RCT. One hundred and twelve projects were identified as potentially including
a RCT. From screening, three of the projects were excluded and full data were extracted from
109 monographs (Figure 1).
The three excluded projects were:
l one report originally funded as a RCT on paramedic training for serious trauma, which failed to
randomise and went on as a non-randomised study (1998, Volume 2, Number 17)
l one economic evaluation of pre-existing RCT data, which was not funded by the HTA programme
(1999, Volume 3, Number 23)
l one report of the long-term outcomes of patients in 10 RCTs of cognitive–behavioural therapy (CBT)
conducted between 1985 and 2001 (2005, Volume 9, Number 42).
Narrowly included projects
One trial was narrowly included, in which participants were randomly assigned to be offered two different
types of hearing aids. This study of a screening programme included a small RCT, the results of which
were reported in the monograph.
No. of projects published on the
HTA website by end of February
2011 (up to Volume 15, Number 8)
(n = 574)
No. of records screened
(n = 575)
No. of records/monographs
assessed for eligibility
(n = 112)
No. of records excluded
(n = 463)
No. of records/monographs excluded
because they were not a RCT (n = 3)
Reasons:
Did not include a RCT despite having an
ISRCTN number – Volume 15, Number 7
The results were from a long-term
follow-up analyses of a trial presented
in an earlier monograph – therefore a
duplicate Volume 15, Number 12
The RCT funded did not publish a
monograph 
•
•
•
No. of additional projects
identified from HTA MIS as
including a RCT
(n = 1)
No. of projects/monographs
included records
(n = 109)
No. of RCTs included in
the database
(n = 125)
FIGURE 1 Flow diagram of included and excluded RCTs and monographs.
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Pilot and feasibility studies
Four monographs reported pilot or feasibility studies:
l The feasibility of a RCT of treatments for localised prostate cancer (2003, Volume 7, Number 14)
(trial ID15).
l A two-centre, three-arm pilot conducted to assess the acceptability of a RCT for comparing
arthroscopic lavage with a placebo surgical procedure (2010, Volume 14, Number 5) (trial ID97).
l A pilot study conducted to assess the safety and efficacy of reducing blood pressure with two types of
medication for patients with hypertension. The pressor phase of the trial was terminated owing to poor
recruitment (2009, Volume 13, Number 9) (trial ID78 and ID110).
l A pilot study on impact of early inhaled corticosteroids prophylaxis, conducted to assess recruitment
rates and project protocol, pilot assessment tools and refine the sample size calculation for a definitive
study (2000, Volume 4, Number 28) (trial ID121).
From the 109 included projects, 125 RCTs were identified and constituted the cohort of trials included in
this study. Eleven monographs included the results of more than one RCT. Five of these included three
RCTs and six included two RCTs.
Unique trial identification number
Each project funded by the HTA programme had a unique reference number (e.g. 10/07/99) given when
the outline proposal was submitted. We used this to link records in the database to the HTA Management
Information System. For the 11 projects that included more than a single RCT, we developed an additional
identifier. A free-text field was included in the database to identify the specific clinical trial. Fields were also
included in the database showing the number of trials in the monograph, listing the trial ID numbers for
those trials reported in the same monograph. For example, the HTA-funded project 96/15/05, ‘Which
anaesthetic agents and techniques are cost-effective in day surgery? Literature review, national survey of
practice and randomised controlled trial’, contained two RCTs, a two-arm trial for the paediatric population
and a four-arm trial for the adult population. This project has a single ISRCTN number (87609400). We
created one unique ID for each RCT: ID13 for the adult study and ID14 for the paediatric study.
Completeness of data sources
Data extraction took place from 6 August 2010 to 8 November 2011. Table 3 shows the completeness of
the sources of information used for data extraction.
TABLE 3 Data sources available for the included RCTs
Document Number available for data extraction (%)
Vignette 99/109 (90.8)
Commissioning brief 99/109 (90.8)
Application form (proposal) 106/109 (97.2)
Protocol 58/109 (53.2)
Monograph 109/109 (100)
Protocol change form 78/109 (71.6)
Progress reports/extension requests Multiple documents per trial available; too many to count
Total number of monographs 109
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The least complete category of documents retrieved was the project protocols (65/125, or 53%). Only
30 out of the 65 were available in the public domain (via the HTA programme website, www.hta.ac.uk/).
These were mainly linked to monographs published after 2009. Twenty-six protocols were extracted
directly from the HTA project paper folders; these were not in the public domain and were treated as
confidential. For the 60 trials lacking a protocol, we contacted the chief investigator (a) to see if a project
protocol existed; (b) if one did exist, to request a copy of the document to include in the database; and
(c) to seek permission to forward the protocol to the HTA programme. We succeeded in contacting
59 chief investigators and were unable to find current contact details for one. Of the 59 chief investigators
contacted, 35 responded (59.3%), leading to retrieval of an additional nine project protocols.
Vignettes and commissioning briefs were located for 99 projects (90.8%). Out of 109 projects,
106 application forms were retrieved. Seventy-eight projects produced a protocol changes form which only
applied to those that required such a change (for two trials, a non-standard form was used, which was
included in these figures).
Database
Data for each trial were stored in a Microsoft Access 2003 (Microsoft Corporation, Redmond, WA, USA)
database. Each clinical trial entered had a unique ID number which linked data to every table and form.
Relevant direct website links were included to assist in data entry. A hyperlink to the International
Classification of Diseases, Tenth Edition (Theme 2) (http://apps.who.int/classifications/icd10/browse/2010/en)
led to a drop-down menu for the disease chapters. Other hyperlinks included the UK Clinical Research
Collaboration (UKCRC), Health Research Classification System (HRCS) for interventions (www.hrcsonline.
net/rac/overview),30 CONSORT (www.consort-statement.org/), International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (www.fda.gov/
regulatoryinformation/guidances/ucm122049.htm) and BMJ health economics checklist (www.bmj.com/
content/313/7052/275.full).
Classification systems
Data for each question were structured and entered into a classification system. The classification
systems generated during the development of the data extraction specification forms were entered
into the tables as value lists (source type). For example, trials type was classified as 1;‘Superiority’;
2;‘Non-inferiority’;3;‘Equivalence’. Data fields sharing the same classification system were set up in an
Access table. For example, data extraction for treatment of missing data was required for the clinical
effectiveness and cost-effectiveness analysis of the trial, with 14 options to choose from. Instead of
replicating these in each of the data fields, an Access table was generated.
Data collection and management
The data extraction specification forms defined the metadata database, using Access forms. The database
was designed to directly link to the HTA programme’s MIS (also Access) so that relevant fields in the HTA
MIS could be included in the metadata database and automatically updated. The metadata database was
linked to the HTA MIS using either the project number (number given at the time of the outline proposal,
which stays with the project until publication) or priority area number (number given at the time
of commissioning).
The database was designed to be comprehensive, storing all data items and queries raised during data
extraction and decisions made in relation to these. As it linked directly to the information sources for each
trial, the database is a repository for all documents about included trials. Further, as suggested by a
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member of the advisory group, the source and page number of relevant data fields were incorporated into
the database. These measures also mean that future researchers can use the links and page numbers to
check on the accuracy of data previously extracted, indicate if there are any disagreements and include
their own comments.
An escalation process was set up to deal with uncertainty and to resolve any disagreements. The research
fellow extracted all data and recorded it in the database, with problems logged under the trial’s additional
comments section. Regular meetings were held between the research fellow and statistician to resolve
queries logged under each trial. If they could not resolve the issue, the research fellow was to discuss it
with the relevant research lead, with escalation to the steering group if necessary. Most queries were
resolved at early stages and none were escalated to the steering group.
The metadata database
The Access metadata database included 429 data fields on the 125 trials (Table 4).
Security, back up and confidentiality
The project had a dedicated research folder on the University of Southampton’s secure server. Access to
the folder was only visible to the research team. Access to the folder was not possible without permission
from AY.
Any documents containing sensitive data, such as named principal investigators or confidential
information, were stored using a protected password; only two members of the project team had these.
Other members of the research team were able to access these documents via these two people if
deemed necessary.
The HTA programme policy for access to unpublished data requires signing a confidentiality agreement.
That confidentiality agreement was signed by all members of the research team at the start of the project.
TABLE 4 Data fields in metadata database, by theme, planned and actual with sources
Theme
Actual number of
data fields Source of information
Core trial information 48 Monograph
Theme 1: meeting the needs of the NHS 22 Vignette, commissioning brief, monograph
and HTA MIS
Theme 2: design and adherence to protocol 72 Protocol or proposal, monograph and
HTA MIS
Theme 3: performance and delivery of the NIHR HTA
programme-funded RCTs
72 Protocol or proposal, monograph, HTA MIS
and protocol change form
Theme 4: statistical analyses appropriate and as
planned
97 Protocol or proposal and monograph
Theme 5: economic analyses alongside clinical trials 58 Proposal, monograph and HTA MIS
Theme 6: cost of RCTs, trends and determinants 60 Protocol or proposal and monograph
Total 429
Note
Planned number of data fields related to pre feasibility study. The actual number of data fields related to post
feasibility study.
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We suggest below that the same rules, updated as appropriate, should govern future access to the
database by other researchers.
Some data from older sources of information were deemed confidential, such as failed trials, the funding
details of particular trials and problems with the conduct of the trials. Project protocols before 2007, which
were often only in the form of proposals, might be seen as confidential as they are not in the public
domain. Since 2007, the most current version of the project protocol has been published with researchers’
consent on the NETSCC HTA programme website.
This project assumed that protocols for trials funded before 2007 should be treated as confidential.
All final proposals attached to the contract of agreement to the Department of Health were also treated
as confidential, including the vignette.
For each trial record, a drop-down menu specified whether or not the source was confidential (not in the
public domain). Data fields were positioned on the Access form based on where the information was
extracted from and by theme. Page numbers and source of information boxes determined whether or not
the data extracted were confidential.
Questions for which data should be extracted
This section outlines the method used to decide the questions for which data should be extracted.
Some questions under each theme were quickly shown as not feasible owing to lack of data or time
required to extract data. These questions are discussed under each theme in the relevant chapters
(see Chapters 4–9).
The questions deemed feasible were taken further by extracting data, entering it in the relevant
classification systems and assessing it.
For each question, a judgement was made regarding whether it should be:
i. kept
ii. amended
iii. dropped.
These options were developed from those suggested by Thabane et al.31 Three criteria were used to reach
these judgements:
(a) How complete were the data required?
(b) Were changes recommended to the classification system?
(c) What skills and resource (linked to data type and need for judgement) did the classification
system require?
The completeness of the data was measured for each question. Whether or not changes were
recommended to the classification system helped indicate if it should be amended. The final criterion,
with regard to the skills and resources, was based on records kept by AY.
The criteria were applied hierarchically, with only those for which data were available being assessed
against the other criteria. A threshold of 80% was set for data completeness on the basis of
representativeness. However, instead of applying the criteria mechanically, the steering group retained
the option to consider retaining any question that seemed particularly important.
METHODS
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Changes/deviations from the protocol for this study
Given that one of the questions explored in this project concerns protocol changes, this section discusses
changes to the protocol for this study. We deviated from our protocol twice. These deviations were
because of:
i. the number of trials included; we included 125 trials in the metadata database, more than the
120 maximum that we specified
ii. planned quality assurance; we abandoned our plan to invite chief investigators to check our data
extraction on the basis of the results of a small pilot study.
Further, the project was originally funded for 1 year to extract data on 63 RCTs. The piloting of data
extraction showed that only around 40 RCTs, or around half the total published to mid-2009, could be
done within that time scale. The steering and advisory groups agreed that the value of the database would
increase with the number of trials included. The project steering group requested and received a
1-year extension.
None of these in our opinion was likely to have introduced bias.
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Chapter 4 Theme 1: meeting the needs of
the NHS
This chapter considers questions linked to the theme: ‘How was the trial seen as meeting the needs ofthe NHS by the HTA programme?’ After a brief review of the relevant literature, it summarises available
data on how trials funded by the HTA programme could answer questions about meeting the needs of the
NHS. It explores how topics of trials were generated and prioritised. It also explores the outcomes used and
the time from prioritisation to publication of the findings. The methods used to answer each question are
described and the results are followed by analysis and discussion.
Introduction
Several terms may usefully be defined. By commissioned research, we mean research where the topics to
be researched are defined by the programme and not by the researchers who do the work. This implies
that the programme is acting on behalf of the NHS and must have mechanisms for ‘knowing’ the needs
of the NHS. This differs from both response-mode research (the traditional mode, with funders taking bids
from expert teams of researchers) and researcher-led research (HTA’s term for the work stream introduced
in 2006 where proposals are submitted by researchers but are rigorously assessed against NHS need).1
To be relevant to decision-making in the NHS, any clinical trials would need to be pragmatic as opposed to
explanatory. Pragmatic trials have been defined as those with broad inclusion criteria, carried out in many
centres and with patient-relevant outcomes.32
To employ a term given prominence in the Cooksey Report (2006),33 NHS-funded research had to be
restricted to public interest or market failure research, that is, work that the private sector would not be
interested in carrying out. This is often due to the inability to patent that which is being tested (difficult
outside new drugs or, in particular, interventions made up of services rather than tightly defined products).
As the HTA programme is a commissioned programme, one might expect it to prioritise research focused
on the needs of the NHS. A substantial literature discusses methods for research prioritisation but there is
much less on how potential topics should be identified, or on assessments of whether or not prioritised
research is indeed ‘needs-led’.9,34–37
Since its inception, the NHS research and development (R&D) has focused on identifying gaps in research
relevant to the NHS and prioritising them. Setting priorities is difficult and complex, partly because there is ‘no
agreed upon definition for successful priority setting, so . . . no way of knowing if an organisation achieves it’.38
Different methods have been suggested, such as multidisciplinary involvement, public and patient
involvement, the use of scoring systems, the Delphi process and information specialist involvement.
Economic impact approaches include the payback approach or expected value of information models.
Priority setting means an allocation of limited resources, which can be highly political and controversial.
Developing a structured topic prioritisation process helps address this challenge.
Chase et al.9 described the different sources used by the HTA programme in 1998 to identify potential
priorities. Overall, there were 1100 suggestions for the programme from four main sources:
(1) a widespread consultation of health-care commissioners, providers and patients; (2) research
recommendations from systematic reviews; (3) reconsideration of previous research priorities; and
(4) horizon scanning. Nearly half (46%) of final programme priorities were from the widespread
consultation, with 20% from systematic reviews and 10% from each of the other two areas.
(The remainder came simultaneously from more than one source.) Chase et al.9 concluded that there
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was value in having a mix of sources. One of the aims of this chapter was to apply the approach of
Chase et al.9 to all the RCTs published to mid-2011.
A small literature discussed the patient relevance of outcomes in publications, through surveys of trials
published in a particular disease area. There are three notable examples:
l Gandhi et al.39 looked at diabetes trials and found that primary outcomes were patient important in
only 78 of 436 RCTs (18%).
l Montori et al.40 also looked at diabetes trials and found that primary outcomes were patient important
in only 42 of 199 RCTs (21%).
l Rahimi et al.41 looked at cardiovascular trials and found that primary outcomes were solely patient
important (death, morbidity or patient-reported outcomes) in only 93 of 413 trials (23%).
Chalmers and Glasziou42 proposed a framework for considering avoidable waste in research, with four
stages. The first concerned whether or not the questions addressed by research are relevant to clinicians
and patients; if they are not, Chalmers and Glasziou42 argue that the research is wasted.
Although Chalmers and Glasziou42 give some examples of the ways in which research fails to address relevant
questions, they provide no quantifiable measures of waste in this stage of the framework, unlike the other three
stages (design, publication and useable report), for each of which empirical estimates of waste are provided.
The extent to which RCTs have been preceded by systematic reviews can indicate the source of the topic.
A recent review of 48 trials funded by the HTA programme between 2006 and 2008 indicated that 80%
had been preceded by a systematic review.43
Questions addressed
The questions on which data were extracted are shown in Box 2.
Methods
Nine questions were piloted in theme 1 (hereafter T1). One question (‘How was the relevance to the NHS
assessed?’) was deemed not feasible owing to lack of data. However, data were available on the work
stream (commissioned or researcher led) (T1.1), whether or not a prior systematic review existed (T1.2) and
the source of the topic (T1.3). These are explored below.
Denominators
For questions T1.1, T1.3 and T1.4 the denominator was the number of priority areas (n= 100) which
precede any call for a trial. (Note: ‘T’ refers to theme. Each of the six themes are numbered with additional
numerals referring to questions within that theme.) One hundred research suggestions/priority areas made
it through to the commissioning brief stage, which led to 107 projects being funded containing 123 RCTs.
BOX 2 The research questions answered under this theme
T1.1. Type of commissioning work stream?
T1.2. Prior systematic review?
T1.3. The source for topic identification?
T1.4. Type of HTA advisory panel?
T1.5. What was the priority given by the programme to the research?
T1.6. Did the statement of need change?
T1.7. Frequency and accuracy of reporting the primary outcome?
T1.8. Adequate reporting of the proposed and published primary outcome?
T1.9. What was the time lag between prioritisation and publication of the monograph?
THEME 1: MEETING THE NEEDS OF THE NHS
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The denominator for questions T1.2 and T1.5–T1.9 was the total number of projects (n= 109) (107 projects
via the commissioned work stream and two projects via direct commissioning).
Results
Question T1.1: type of commissioning work stream
Out of the 100 priority areas, 107 (98.2%) projects were funded through the commissioned work stream.
The other two projects were ‘directly commissioned’ {09/94/01 [head-to-head comparison of two H1N1
swine influenza vaccines in children aged 6 months to 12 years] and 99/01/01 [conventional ventilatory
support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)]}.
Question T1.2: prior systematic review
Of the 109 projects, 56% reported a prior systematic review in the published monograph.
Question T1.3: the source for topic identification
Of the four main sources of identification, ‘widespread consultation’ contributed 64 (66.7%) topics
followed by systematic reviews (25%, 24/100) and the Horizon Scanning Centre (3%, 3/100).
The balance of these sources shifted over time. When the number of trials increased in 2001–2, the
proportion of topics from systematic reviews rose to 65% (Table 5).
Question T1.4: type of Health Technology Assessment advisory panel
The source of topics varied by advisory panel (Table 6). Widespread consultation was the main
commissioning source for two of the three panels (83.3%, 15/18 and 72.2%, 39/54, respectively).
TABLE 5 Source of commissioned topic by year
Source of topic
identification
1993–4,
n (%)
1995–6,
n (%)
1997–8,
n (%)
1999–2000,
n (%)
2001–2,
n (%)
2003–4,
n (%)
2005–6,
n (%)
Total,
n (%)
Widespread
consultation
17 (89.5) 22 (84.6) 11 (73.3) 6 (66.7) 3 (15.0) 4 (66.7) 1 (100) 64 (66.7)
Systematic
reviews
2 (10.5) 2 (7.7) 3 (20.0) 2 (22.2) 13 (65.0) 2 (33.3) 0 24 (25.0)
Horizon
Scanning Centre
0 1 (3.8) 1 (6.7) 0 1 (5.0) 0 0 3 (3.1)
Reconsidered
topics
0 1 (3.8) 0 1 (11.1) 3 (15.0) 0 0 5 (5.2)
Total 19 (19.8) 26 (27.1) 15 (15.6) 9 (9.4) 20 (20.8) 6 (6.3) 1 (1.0) 96 (100.0)
TABLE 6 Number of topic suggestions by source of information and advisory panela
Source of topic
identification
Diagnostic and
screening panel, n (%)
Pharmaceutical panel,
n (%)
Therapeutic panel,
n (%)
Total,
n (%)
Widespread consultation 15 (83.3) 10 (41.7) 39 (72.2) 64 (66.7)
Systematic reviews 2 (11.1) 12 (50.0) 10 (18.5) 24 (25.0)
Horizon Scanning Centre 0 1 (4.2) 2 (3.7) 3 (3.1)
Reconsidered topics 1 (5.6) 1 (4.2) 3 (5.6) 5 (5.2)
Total 18 (18.8) 24 (25.0) 54 (56.3) 96 (100.0)
a Cross-tabulation data were not available for four projects.
DOI: 10.3310/hta19110 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 11
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Raftery et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
The exception was the pharmaceutical panel, where 50% (12/24) of the commissioned topics were from
systematic reviews.
Question T1.5: what was the priority given by the programme to
the research?
The programme prioritised 70% of projects in the top band. Of the 71 projects prioritised up to and
including 1999, 50 (70.4%) were classified as A-list topics (‘recommended for commissioning – must
commission’) and 18 (25.4%) were B-list topics (‘recommended for commissioning’ only). The HTA MIS
database did not provide sufficient information for 4.2% of trials (3/71) (Table 7).
Question T1.6: did the ‘statement of need’ change?
This question asked if researchers undertaking research drifted from the programme’s initial assessment of
NHS need for the research. The statement of need did not change between the commissioning brief and
the monograph in 101 trials (94.4%, 101/107). No data were available for the remaining six projects.
For these six projects, we were unable to compare the information reported in the commissioning brief
with that reported in the monograph for three trials (2.8%). The reasons were ‘No commissioning brief or
vignette was available’ (trials ID121 and ID122) and ‘No commissioning brief or vignette was prepared.
It was a fast track topic’ (trial ID106). For the final three projects, we were unclear about the reporting of
the statement and whether or not it changed from the advertisement to the executive summary in the
monograph (trials ID60, ID79 and ID86). Owing to the complexity of data extracted to answer this
question, it was not possible to analyse the data further. In addition, it was agreed that all data fields
related to the ‘statement of change’ question would be dropped from further analyses.
Question T1.7: frequency and accuracy of reporting the primary outcomes
The 109 funded projects included 125 clinical trials. The main primary outcome, defined as that used for
sample size calculation, was reviewed independently by two researchers (RM and AY) for the 109 projects.
Four projects lacked requisite information (the monograph did not clearly state what the main primary
outcome was nor was it possible to determine what the main primary outcome was during the data
extraction process). In this instance, consensus was reached by both researchers reviewing the monograph
(specifically, the sample size calculation section reported in the methods chapter of the monograph) to
determine the actual type of primary outcome. It was not possible to accurately identify what the main
primary outcome was for one project (trial ID68).
Seventy-eight (73%) of the 107 projects in the commissioned work stream reported sufficiently on the
proposed primary outcome. Twenty-one projects reported limited information. Eight commissioning briefs
(7.5%) contained no information about what the primary outcome was.
TABLE 7 Summary data on the priority status of the research topic up to 1999
Priority status and HTA advisory panel description n (%)
Priority band (up to and including publication date 1999)
Recommended for commissioning – must commission (A) 50 (70.4)
Recommended for commissioning (B) 18 (25.4)
Category unknown 3 (4.2)
Total 71
HTA advisory panel
Diagnostic and screening 21 (19.3)
Pharmaceutical 25 (22.9)
Therapeutic procedures 61 (56.0)
Department of Health – Direct Project Commissioned 2 (1.8)
Total 109
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Question T1.8: adequate reporting of the proposed and published
primary outcome
All projects were analysed to compare the proposed primary outcomes with those published (n= 109).
We were able to classify the proposed primary outcome for 97 projects (88.9%) and the published primary
outcome for 108 projects (99.1%) (Table 8); little changed between these two stages. Patient-important
outcomes were reported in more than half of the HTA-commissioned projects, at both the proposed and
published stages of the project (67%, 73/109 and 73.4%, 80/109, respectively). A number of outcomes
could not be classified using the Gandhi et al.39 three main headings. Fourteen proposed primary
outcomes and 18 published primary outcomes were categorised as ‘other’.
Thirteen projects (11.9%) had differences between the planned and actual type of primary outcome.
These discrepancies were mainly due to a lack of information or having no information on the primary
outcome in the planned documentation (proposal/protocol) (n= 12). The monograph was able to provide
sufficient information for 10 of these projects to enable the primary outcome to be classified accordingly.
Table 9 highlights where these discrepancies were between the planned and actual reporting of the
primary outcome.
TABLE 8 The commissioned, planned and actual primary outcomes
Type of primary outcomes reported n (%)
Type of primary outcome reported at the commissioning stagea
Patient important (including others) 75 (70.1)
Surrogate 0
Physiological/laboratory 0
Other 3 (2.8)
Limited information reported in the commissioning brief 21 (19.6)
No information available 8 (7.5)
Total 107
Type of primary outcome reported in the proposal/protocol
Patient important (including others) 73 (67.0)
Surrogate 8 (7.3)
Physiological/laboratory 2 (1.8)
Other 14 (12.8)
No information available 12 (11.0)
Total 109
Type of primary outcome reported in the monograph
Patient important (including others) 80 (73.4)
Surrogate 9 (8.3)
Physiological/laboratory 1 (0.9)
Other 18 (16.5)
No information available 1 (0.9)
Total 109
a This is applicable only to the commission-led work stream (n= 107). Researcher-led work stream does not have a
commissioning brief.
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When diagnostic and screening projects (n= 20) were excluded, patient-important outcomes increased
from 67% (n= 73) to 73% (65/89).
Over the period 1993–2002, 82.7% (67/81) of reported primary outcomes were patient important
(Table 10). The years 1993–2002 provide a more accurate report of the type of primary outcome reported
in the monograph, as a number of projects funded during the period 2003–10 have not yet published.
Question T1.9: what was the time lag between prioritisation and publication
of the monograph?
This question asked about the time taken between the programme prioritising a topic and the monograph
publishing the results. The interval was 8–10 years (Table 11). The average was 8 years for trials prioritised
in 1993 and 9 years for those prioritised in 1999.
TABLE 9 Discrepancies between the planned and actual primary outcome measure
Planned primary
outcome as
reported in the
proposal/protocol
Actual primary outcome measure as reported in the monograph
Patient
important
(including
others), n (%)
Surrogate,
n (%)
Physiological/
laboratory,
n (%)
Other, n (%) No information
available, n (%)
Total, n (%)
Patient important
(including others),
n (%)
72 (90.0) 0 0 1 (5.6) 0 73 (67.0)
Surrogate, n (%) 0 8 (88.9) 0 0 0 8 (7.3)
Physiological/
laboratory, n (%)
1 (1.3) 0 1 (100.0) 0 0 2 (1.8)
Other, n (%) 0 0 0 14 (77.8) 0 14 (12.8)
No information
available, n (%)
7 (8.7) 1 (11.1) 0 3 (16.7) 1 (100.0) 12 (11.0)
Total, n (%) 80 (73.4) 9 (8.3) 1 (0.9) 18 (16.5) 1 (0.9) 109 (100.0)
TABLE 10 Actual primary outcome as reported in the monograph by year of the topic advertisement
(excluding diagnostic and screening projects)
Type of
primary
outcome
1993–4,
n (%)
1995–6,
n (%)
1997–8,
n (%)
1999–2000,
n (%)
2001–2,
n (%)
2003–4,
n (%)
2005–6,
n (%)
2007–8,
n (%)
2009–10,
n (%)
Total,
n (%)
Patient
important
(including
others)
16
(80.0)
20
(83.4)
12
(100.0)
4 (66.7) 15
(78.9)
3 (75.0) 1
(100.0)
0 0 71
(80.6)
Surrogate 1 (5.0) 2 (8.3) 0 1 (16.7) 3 (15.8) 0 0 0 1 (50.0) 8 (9.1)
Physiological/
laboratory
0 0 0 0 0 0 0 0 1 (50.0) 1 (1.1)
Other 3 (15.0) 2 (8.3) 0 0 1 (5.3) 1 (25.0) 0 0 0 7 (8.0)
No
information
available
0 0 0 1 (16.7) 0 0 0 0 0 1 (1.1)
Total 20
(100.0)
24
(100.0)
12
(100.0)
6 (100.0) 19
(100.0)
4
(100.0)
1
(100.0)
0 2 (100.0) 88
(100.0)
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Analysis
In Chase et al.’s9 review, 46% of programme priorities in 1998 came from the widespread consultation
and 20% from systematic reviews. Our data show greater reliance on consultation but with variation from
year to year. The key question concerns what can be inferred about the importance of the HTA projects to
the NHS. It would be a mistake to equate widespread consultation with NHS relevance and systematic
reviews with academic interest. There is no reason why this should be so. The processes the HTA
programme had in place between the identification of topics and their advertisement as commissioning
briefs means that the initial topic only served as a starter for the real work on NHS relevance.
Unsurprisingly, most projects that were funded had been prioritised; 70% had been given the top band (A)
by the programme’s prioritisation processes. Band A, ‘recommended for commissioning – must
commission’, meant that the programme would ‘go the extra mile’ to ensure that research was funded in
that area. What to make of this 70% figure? The priority banding was the end of a process that started
with the source of the topic, addressed in the previous question. This process involved detailed
consideration of potential research priorities by panels of NHS experts (patients, clinicians, managers) as
well as an overarching standing group on health technologies, meeting annually for 2 days. The priority
band was a summary score produced by the whole process. The process was producing research proposals
of which 70% were thought to be of high relevance to the NHS and so of a high priority.
By contrast with the finding by Jones et al.43 that 80% of RCTs funded by the HTA programme and
published between 2006 and 2008 were preceded by a systematic review, we found that 56% of all trial
published to 2011 were preceded by a systematic review.
The finding that the statement of need did not change between the commissioning brief and that
reported in the monograph in 101 out of 107 trials (94%) suggests no evidence of ‘drift’. Unfortunately,
the data available in the database were not detailed enough to allow us to make further informative
assessments in this area.
Primary outcomes tended to be patient relevant. Excluding those projects relating to ‘diagnostic
technologies and screening’ increased these figures from 67% to 73%, much higher than previous studies
(18% in Gandhi et al.,39 21% in Montori et al.40 and 23% in Rahimi et al.41).
The lag between the programme prioritising a topic and publishing the results in the monograph series
was 8–10 years. As this measures the time to publication in the HTA journal and not to publication in any
journal, it overestimates to some extent. The key question is choice of benchmark: what is the right length
of time against which 8–10 years should be compared?
Discussion
Question T1.9 on the 8- to 10-year time lag from topic identification to monograph publication was
striking. However, we were unable to find any comparable estimate in the literature.
Although the answers to most questions were largely as expected, these questions only relate to meeting
NHS need in an oblique and indirect way. Data availability limited the questions that could be asked
regarding the core aim of the HTA programme, that is, how well the research it funds aims to meet the
needs of the NHS. This is something that the programme should consider how best to address.
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Strengths and weaknesses of the study
Addressing this overall question based on NHS need was hampered more than other questions in this
report by the limitations of the database before 2000. This is because so much of the needs-related
information is captured at the very start of a project, rather than during or at its completion.
The strength of the work has been given a new focus by the work of Chalmers and Glasziou42 in
highlighting avoidable waste in research. Their framework starts with posing questions that matter,
something that is key to the HTA programme.
This project looked only at trials funded through the HTA programme’s commissioned work stream.
Since 2006, the programme has developed a growing portfolio through its researcher-led work stream.
Proposals for this work stream are also assessed in terms of NHS need.
Recommendations for future work
Any future work will need to take account of the data limitations on how the trials funded aimed to meet
the needs of the NHS. Any future work should include seven of the questions explored in this chapter,
five as is (T1.1, T1.3, T1.7, T1.8 and T1.9) and two to be amended (T1.2 and T1.4).
Unanswered questions and future research
We offer recommendations for any future similar analyses. We found it difficult to identify data that
usefully, consistently or richly characterised the NHS need in these trials. This matters given the importance
to the HTA programme of meeting (and being seen to meet) NHS need. We recommend that NETSCC
should work with the HTA programme to develop trial metadata that more usefully, consistently and richly
characterise NHS need (linked as appropriate to potential impact and reduced avoidable waste).
DOI: 10.3310/hta19110 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 11
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Raftery et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29

Chapter 5 Theme 2: design and adherence
to protocol
This chapter considers questions regarding the reporting of HTA-funded trials. The relevant literature isnoted before summarising the piloting of the questions. The degree to which trial reports met the
CONSORT checklist is examined along with how well they reported on trial design, interventions and
controls. Comparisons are made between what was planned in protocols and what was reported in
the monographs.
Introduction
Well-conducted RCTs have become the ‘gold standard’ for evaluating interventions in health care.
The WHO defines a clinical trial as ‘any research study that prospectively assigns human participants or
groups of humans to one or more health-related interventions to evaluate the effects on health
outcomes’ [reproduced, with the permission of the publisher, from Bulletin of the World Health
Organization – Guidelines for Contributors. Geneva: WHO; 2006. URL: www.who.int/bulletin/volumes/84/
current_guidelines/en/ (accessed 3 October 2014)].
An explanatory paper to the CONSORT 2010 statement summarises why particular design features help
reduce bias and improve study power.44 Randomisation should be rigorously done and allocation to groups
should be adequately concealed from participants and researchers. Blinding (or masking) should be
maintained when possible for participants and clinicians, and particularly for observers who measure
outcomes. Participants lost to follow-up should be minimised, accounted for and analysed in their
randomised groups. Properly designed trials reduce susceptibility to bias, whether due to selection,
outcome reporting or attrition bias. The sample size should be sufficient to give adequate precision to
estimate the effect of the intervention in the relevant wider population.
The design of the trial should be fully recorded in the study protocol. That protocol should be carefully
followed. Failure to follow a protocol happens for many reasons, some beyond the control of the
investigators. For example, the introduction or removal of outcome measures later in a trial (‘post hoc’)
raises the possibility of outcome reporting bias and increases the play of chance in the trial through
multiplicity of analysis.
For a reader to judge the quality (validity) of a completed trial, the design, methods, results and
interpretation must be fully and fairly reported.
Good evidence in the literature shows that many trials are poorly planned, conducted or reported, or all of
these.44,45 This chapter describes our investigation of the design, conduct and reporting of HTA-funded
trials. We provide a descriptive analysis of the design of the interventions tested. We compare the planned
(in the protocol) and reported (published) methods to identify deviations from protocol and post-hoc
analysis. We assess the quality of reporting of the trials against the CONSORT statement.
A tool developed to enhance the quality of reporting and reduce methodological flaws, CONSORT was
established in 1996 in response to concern about the quality of reporting (www.consort-statement.org/
about-consort/history). The CONSORT statement was developed by evidence and expert consensus. Widely
used by authors and journals, it has been adopted by the HTA monograph series. Extensions to the main
CONSORT statement include the reporting of special types of trials, such as pragmatic trials, non-inferiority
or equivalence trials and cluster trials. For this study, we focus on the main CONSORT statement, which
applies particularly to parallel arm trials.
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In 2008, Enhancing the Quality and Transparency of Health Research (EQUATOR) was established to
promote accurate reporting of health research and provide an international network to improve the quality
of scientific publications. The EQUATOR website acts as a library of reporting guidelines in health research
(www.equator-network.org/).
The CONSORT statement (and particularly the checklist), although useful, has limitations. It can only list the
categories of information that should be reported in most trials; it cannot assess the completeness of that
information. Selective reporting of whole trials46 or outcomes10 leads to biased estimates of effectiveness
through ‘publication bias’ and (closely related) ‘outcomes reporting bias’, usually resulting in overestimates
of effectiveness.
Absence of publication or partial publication can only be assessed by knowing what research has or should
have been reported. Concerns over the lack of availability of trial results prompted the development
of clinical trials registers such as the ICTRP (the Registry Platform) based at the WHO. Ghersi et al.22
emphasised the need for greater accessibility of trial data such as protocols and final reports. Transparency
is needed to overcome academic and/or commercial vested interests. We address transparency by
comparing the planned research with the reported methods and results. This is usually from the study
protocol which, for recent trials, is usually in the public domain through the HTA website. For the early
trials in the cohort, conducted when submission of detailed protocols was not normally required, we used
the full application forms for grant funding. These contain a detailed description of the planned study,
but not changes that may legitimately occur before the trial starts, for instance at the request of the
ethics committee.
Any assessment tool should need to include not only the completeness of its reporting, but also an
assessment of the design or conduct of the study. The Cochrane Collaboration’s handbook47 suggests that
the assessment of validity of trials is best done in a framework rather than using a specific tool (available
from www.cochrane-handbook.org). A full assessment of the trials using such a framework was beyond
the scope of this study. Instead, we provide a descriptive analysis of the design of the trials (including the
study interventions). We also compared key features of the study design in the protocol and final report to
assess adherence to protocol and completeness of reporting of planned primary outcomes and analyses.
More detailed analysis and statistical methods are provided in Chapter 7.
Questions addressed
Box 3 shows the questions explored in this section.
Methods
Seventeen questions were piloted, as shown in Box 3. Two were considered not feasible: one on
pragmatic–explanatory continuum indicator summary (PRECIS),48 the other on complex interventions.
The PRECIS question has 10 headings with up to six subheadings requiring approximately 68 data fields,
or around one-third of the total fields for this theme. Besides requiring considerable data extraction,
matters of judgement were also likely to be required.
The issue of whether or not the intervention was complex as defined by the MRC involved four headings,
each with three subheadings, thus requiring 12 questions as well as judgements on the interactions
between them. Given the lack of data on basic aspects of the HTA RCTs, such as the number and types of
interventions, more detailed work such as that required by PRECIS48 or complex interventions seemed a
task for further work.
The main information sources were the final protocol (if this was not available, then the funding
application form) and the published monograph.
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Denominators
The unit of analysis for reporting was 123 trials, that is the 125 trials identified from the 109 monographs
but excluding two pilot trials.
Results
Question T2.1: was the trial adequately reported? (Using the revised 2010
Consolidated Standards of Reporting Trials checklist for core trial
information, methods and results)
The CONSORT checklist has six sections/topics and 37 items (the CONSORT statement checklist lists
25 items, but there are subsections listed as a or b for 12 items, making a total of 37 CONSORT items).
We extracted data on four sections: ‘title and abstract’, ‘introduction’, ‘methods’ and ‘results’. No data
were extracted for 16 of the 37 items. Out of these 16, six items were under ‘discussion’ and ‘other
information’, four were under ‘results’, five were under ‘methods’ and one was under ‘introduction’. Data
on sample size and primary outcome are further discussed in Chapter 7. The 21 items included in this
chapter are listed in Table 12.
Consolidated Standards of Reporting Trials checklist items: 1 and 2
These two sections cover the title, abstract and introduction. Of the 123 trials, 100 reported that they were
randomised clinical trials in their titles, 122 had a structured summary and all trials included their objectives
and hypotheses in the introduction (Table 13).
BOX 3 The research questions answered under this theme
T2.1. Was the trial adequately reported? (Using the revised 2010 CONSORT checklist44 for core trial
information, methods and results).
What were the design characteristics of the included trials?
T2.2. Trial design framework.
T2.3. Type of comparison.
T2.4. Type of care.
T2.5. Type of setting.
T2.6. Pilot and feasibility.
T2.7. Number of interventions.
T2.8. Whether the intervention was an ‘add-on’ or ‘substitute’.
T2.9. Type of intervention using the HRCS.30
T2.10. Type of intervention using Chalmers’ classification.
T2.11. Type of control.
Did the trial conform to the protocol?
T2.12. Type of comparison.
T2.13. The number of proposed and reported arms.
T2.14. The number of proposed and reported trial centres.
T2.15. Number of primary outcomes.
T2.16. Primary time point.
T2.17. Specifying the primary time point.
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TABLE 12 Consolidated Standards of Reporting Trials items included in this chaptera
CONSORT section/topic CONSORT checklist item
Title and abstractb Identification as a randomised trial in the title (1a)
Structured summary of trial design, methods, results and conclusions (1b)
Introduction Specific objectives or hypotheses (2)
Methods (trial design) Description of trial design (such as parallel, factorial) including allocation ratio (3a)
Important changes to methods after trial commencement (such as eligibility criteria),
with reasons (3b)
Methods (participants) Eligibility criteria for participants (4a)b
Settings and locations where the data were collected (4b)
Methods (interventions) The interventions for each group with sufficient details to allow replication, including
how and when they were actually administered (5)
Methods (outcomes) Completely defined prespecified primary and secondary outcome measures, including
how and when they were assessed (6)
Methods (sample size) How sample size was determined (7)
Methods (randomisation: sequence
generation)
Methods used to generate the random allocation sequence (8a)
Type of randomisation; details of any restriction (such as blocking and block size) (8b)
Methods (randomisation:
allocation concealment
mechanism)c
Mechanism used to implement the random allocation sequence (such as sequentially
numbered containers), describing any steps taken to conceal the sequence until
interventions were assigned (9)
Methods (randomisation:
implementation)b
Who generated the random allocation sequence, who enrolled participants and who
assigned participants to interventions (10)
Methods (blinding)d If done, who was blinded after assignment to interventions (for example, participants,
care providers, those assessing outcomes) and how (11a)
Results (participant flow)b For each group, the numbers of participants who were randomly assigned, received
intended treatment and were analysed for the primary outcome (13a)
For each group, losses and exclusions after randomisation, together with reasons (13b)
Results (recruitment) Dates defining the periods of recruitment and follow-up (14a)
Why the trial ended or was stopped (14b)
Results (baseline data)b A table showing baseline demographic and clinical characteristics for each group (15)
Results (harms)b All important harms or unintended effects in each group (19)
a Some CONSORT items were covered under other themes such as recruitment and statistical methods. Those results were
used to complete Tables 13–15.
b Data for these items are not reported in the database. We used a yes/no question to indicate whether or not the
published report included such information.
c The results for some CONORT items were disaggregated with item 9 reported in two parts and item 10 in three
(see Table 14).
d We used the blinding classification developed by Devereaux et al.49 (participant, assessor and administration)
to cover CONSORT item 11a only (blinding).
Source: Moher et al.44
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Consolidated Standards of Reporting Trials checklist items: methods (items 3–12)
Trial design
Of the 123 included trials, the unit of analysis in 111 was individual patient. Twelve trials were
cluster randomised.
Participants
One hundred and twenty-one trials reported the eligibility criteria and provided details about the setting
and location where data were collected (98.4% for both CONSORT items).
Interventions and controls
All trials provided sufficient information about the intervention groups. For drug interventions, the drug
name, dose and method of administration were provided. The reporting of the control group was,
however, less complete.
Most trials compared the intervention with ‘standard care’ (52.8%, 65/123). Next most common were
placebo (8.1%, 10/123), ‘next best service’ (2.4%, 3/123) and ‘no treatment’ (1.6%, 2/123). Forty-three
trials (35%) were classified as ‘control undefined’ as they provided insufficient detail (see Table 14).
Outcomes
Forty trials reported more than one primary outcome. Of these, it was not possible to determine the
‘main’ primary outcome from the monograph for two trials. Reporting of the primary time point was a
weakness in some trials. Eighty out of 123 trials covered this CONSORT item sufficiently (65%), the rest did
not (see Table 14).
Sample size
For the 109 superiority trials, the four elements of the sample size required by the CONSORT guidelines
(2010) were considered. Sixty per cent of superiority trials (66/109) reported all elements as detailed by the
CONSORT guidelines (see Table 14). For each of the four elements:
l 94.5% (103/109) reported the statistical power.
l 90.8% (99/109) reported the alpha error level.
l Out of the 109 trials, 45 had a binary outcome and 84.4% (38/45) sufficiently reported the estimated
outcomes in each group.
l Of the 109 trials, 53 had a continuous outcome and 56.6% (30/53) sufficiently reported the standard
deviation (SD) of the measurements.
[The remaining trials were classified as ‘time to event’ (n= 3) or ‘effect size’ (n= 6). Two trials had missing
data for the comparative analysis.]
TABLE 13 Consolidated Standards of Reporting Trials items 1 and 2
CONSORT description Yes, n (%) No, n (%) Total
Title: identified as a randomised trial in the title (1a) 100 (81.3) 23 (18.7) 123
Abstract: structured summary of trial design, methods, results and conclusions (1b) 122 (99.2) 1 (0.8) 123
Introduction: objectives and hypotheses (2b) 123 (100.0) 0 123
Source: Moher et al.44
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Sequence generation
The method used to generate the random allocation sequence was adequately described in 94.3% of trials
(116/123) (CONSORT statement 8a) and the type of randomisation including details about the restriction
(CONSORT statement 8b) was adequately reported by 86.2% of trials (106/123) (Table 14). This item was
not included in the 1996 version of CONSORT;50 however, 18 out of 21 trials using this version still
reported the item.
Consolidated Standards of Reporting Trials checklist items: results
(items 13–19)
Most trials (97.6%, 120/123) included a flow diagram. Clear improvements were evident in the reporting
of the losses and exclusions after randomisation for each intervention between the 199650 and 200151
CONSORT statements. Only 61.9% of trials (13/21) using the 1996 CONSORT statement reported group
losses and exclusions after randomisation. By comparison, of those using the 2001 revised CONSORT
statement, 85.1% of trials (86/101) reported such losses and exclusions in the participant flow diagram
(one trial used the 2010 CONSORT statement) (see Table 15). The reasons were not explored here.
Baseline data
Most trials provided information about the demographic and clinical characteristics of the patient
groups (91.9%, 113/123).
TABLE 14 Consolidated Standards of Reporting Trials items 3–12
CONSORT description Yes, n (%) No, n (%)
Unable to
report, n (%)
Trial design: Description of trial design (such as parallel, factorial),
including allocation ratio (3a)
123 (100.0) 0 0
Trial design: Important changes to methods after trial commencement
(such as eligibility criteria), with reasons (3b)
47 (38.2) 22 (17.9) 54 (43.9)
Participants: Eligibility criteria (4a) 121 (98.4) 2 (1.6) 0
Participants: Settings and locations where data were collected (4b) 121 (98.4) 2 (1.6) 0
Interventions: Interventions for each group with sufficient detail (5) 80 (65.0) 43 (35.0) 0
Outcomes: Completely defined pre-specified primary and secondary
outcomes, including how and when they were assessed (6a)
80 (65.0) 43 (35.0) 0
Sample size: How the sample size was determined (7a)a 66 (60.6) 43 (39.4) 0
Sequence generation (8a): Method used to generate the random
allocation sequence
116 (94.3) 3 (2.4) 4 (3.2)
Sequence generation (8b): Type of randomisation; details of any
restriction (such as blocking and block size)
106 (86.2) 10 (8.1) 7 (5.7)
Allocation concealment: Mechanism used to implement the random
allocation sequence (such as sequentially numbered containers) (9)
97 (78.9) 16 (13.0) 10 (8.2)
Allocation concealment: Described any steps taken to conceal the
sequence until interventions were assigned (9)
105 (85.4) 9 (7.3) 9 (7.3)
Implementation: Described who generated the allocation sequences (10) 90 (73.2) 26 (21.1) 7 (5.7)
Implementation: Described who enrolled the participants (10) 111 (90.2) 5 (4.1) 7 (5.7)
Implementation: Described who assigned participants to interventions (10) 105 (85.4) 3 (2.4) 15 (12.2)
Blinding: If done, who was blinded after assignment to interventions
(for example, participants, care providers, those assessing outcomes) (11a)
103 (83.7) 0 20 (16.3)
a This was calculated for superiority trials only (n= 109).
Source: Moher et al.44
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Harms
A notable improvement in the reporting of harms and unintended effects was found between the different
CONSORT statements. Only 38.1% of trials (8/21) using CONSORT 1996 reported all important harms,
compared with 64.4% of trials (65/101) reporting using the 2001 revised version (the one trial using the
2010 CONSORT statement did report all important harms or unintended effects). The results of 18 trials
were unclear (Table 15).
Questions T2.2–T2.11: what were the design characteristics of the
included trials?
Question T2.2: trial design framework
All 123 trials reported the design of the trial in the published monograph, with none indicating a change
in design from that planned. More than four-fifths were designed as parallel arm trials (87%, 107/123),
10 were factorial (8.1%, 10/123) and six were designed as crossovers (4.9%, 6/123). Thirteen trials
reported having included a preference arm to the main clinical trial (10.6%, 13/123).
Question T2.3: type of comparison
One hundred and nine trials (88.6%, 109/123) reported the type of comparison as superiority at the
planning (as reported in the protocol or proposal) stage of the trial. The remaining 14 trials were either
equivalence (6.5%, 8/123) or non-inferiority (4.1%, 5/123) and one trial did not report the planned type of
comparison (0.8%, 1/123). The reported type of comparison was as planned for all non-inferiority trials
(n= 5). There were three discrepant trials: two designed as superiority at the planning stage were actually
reported as equivalence trials (ID36 and ID37) and one designed as an equivalence trial at the planned
stage was actually reported as a superiority design (ID61).
Question T2.4: type of care
Eleven trials (8.9%) were reported to have been conducted in both primary and secondary care. More than
half of the trials (56.1%, 69/123) were in secondary care and one-third (33.3%, 41/123) were in primary
care. Two trials (1.6%, 2/123) were conducted in neither primary nor secondary care, one in a leisure
centre (trial ID64) and the other in a school setting (trial ID66). These were classified as ‘other’
(see Table 16).
Question T2.5: type of setting
Almost half of the trials (44.7%, 55/123) were conducted only in a hospital setting, one-quarter (24.4%,
30/123) only in a general practitioner (GP) setting and eight (6.5%) in a community setting. Thirteen were
TABLE 15 Consolidated Standards of Reporting Trials items 13–19
CONSORT description Yes, n (%) No, n (%)
Unable to
report/N/A, n (%)
Participant flow: For each group, the number of participants who
were randomly assigned (13a)
120 (97.6) 2 (1.6) 1 (0.8)
Participant flow: For each group losses and exclusions after
randomisation (13b)
100 (81.3) 18 (14.6) 5 (4.0)
Recruitment: Dates defining the periods of recruitment (14a) 105 (85.4) 18 (14.6) 0
Recruitment: Why the trial ended or was stopped (14b)a 5 (100.0) 0 0
Baseline data: A table showing baseline demographics (15) 113 (91.9) 6 (4.9) 4 (3.2)
Harms: All important harms or unintended effects (19) 74 (60.2) 31 (25.2) 18 (14.4)
N/A, not applicable.
a Only applicable to those trials that were stopped or abandoned.
Source: Moher et al.44
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categorised as ‘other type of setting/place’ (10.6%), which included settings such as non-NHS acupuncture
clinics (trial ID39), community mental health services (trial ID42) and a health psychology department for
chronic illness (trial ID60). In the remaining 17 trials, more than one type of setting was reported in the
monograph (13.8%) (see Table 16).
Question T2.6: pilot and feasibility study
The NETSCC definitions of pilot and feasibility studies were used to determine whether the trial involved a
pilot or feasibility study prior to conducting the main clinical trial (www.netscc.ac.uk/glossary). A pilot study
is a rehearsal for the main study, whereas a feasibility study estimates important parameters for a main
trial. Almost half of the trials (48%, 59/123) included a pilot study prior to conducting the main clinical
trial. Six (4.9%, 6/123) conducted a feasibility study (Table 16).
TABLE 16 Summary data of the trial characteristics
Description of data n (%)
Type of care
Primary care setting 41 (33.3)
Secondary care setting 69 (56.1)
Both 11 (8.9)
Other 2 (1.6)
Total 123
Type of place
Hospital 55 (44.7)
Community 8 (6.5)
GP 30 (24.4)
Other 13 (10.6)
More than one type of place 17 (13.8)
Total 123
Was a pilot or feasibility study conducted?
Pilot study
Yes 59 (48.0)
No 56 (45.5)
Not clear 6 (4.9)
No information available 1 (0.8)
Missing data 1 (0.8)
Total 123
Feasibility study
Yes 6 (4.9)
No 115 (93.5)
Not clear 1 (0.8)
No information available 1 (0.8)
Total 123
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Question T2.7: number of interventions
Three hundred and twenty-one interventions were reported from the 123 clinical trials (mean
2.6 interventions per trial).
Question T2.8: whether the intervention was an ‘add-on’ or ‘substitute’
Almost half (48%, 59/123) of the interventions described in the HTA monograph were reported as
substitutions for another intervention and one-quarter (26%, 32/123) were reported as additional (Table 17).
Questions T2.9 and T2.10: type of intervention using the Health Research
Classification System and Chalmers’ classification
Two classification systems were used to report the clinical trial interventions. Tables 18 and 19 illustrate
the two classifications systems used (UKCRC HRCS30 and Chalmers’ classification52) by trial.
The UKCRC HRCS30 was used to classify interventions in the included clinical trials. Twenty-two trials were
classified as treatment evaluation of pharmaceuticals (17.9%), followed closely by organisation and
delivery of services (‘health services’) (14.6%, 18/123) and treatment evaluation of medical devices
(13.8%, 17/123).
The system of Chalmers et al.52 was also used to classify interventions. For those trials in which the
technologies compared fell into the same class, the two commonest interventions were drugs (21.7%)
and devices (15.7%).
It was not possible using this classification to classify 8 of the 123 trials as the interventions included two
or more categories, such as ‘drug’ and ‘mixed and complex’; ‘drug’ and ‘service delivery’; ‘drug’ and
‘psychological therapy’; ‘drug’ and ‘education and training’; ‘surgery’ and ‘mixed and complex’;
and ‘surgery’ and ‘drug’.
The type of intervention for three trials was classified as ‘other’, which referred to ‘nutritional supplement
in addition to the normal hospital diet’ (trial ID54), ‘self-monitoring intervention’ (trial ID80) and
‘intravenous fluids were to be administered following primary patient assessment/to be withheld for the
first hour of pre-hospital care’ (trial ID122).
TABLE 17 Whether the intervention group was an ‘add-on’ or ‘substitute’
Description of data n (%)
Intervention group type
Add-on 32 (26.0)
Substitute 59 (48.0)
Neither 31 (25.2)
Missing data 1 (0.8)
Total 123
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TABLE 18 The intervention classifications using the UKCRC HRCS30 (by trial)
Description of data n (%)
3. Prevention
3.1 Primary prevention interventions to modify behaviours or promote well-being 0
3.2 Interventions to alter physical and biological environmental risks 0
3.3 Nutrition and chemoprevention 3 (2.4)
3.4 Vaccines 2 (1.6)
3.5 Resources and infrastructure 0
4. Detection and diagnosis
4.1 Discovery and preclinical testing of markers and technologies 0
4.2 Evaluation of markers and technologies 2 (1.6)
4.3 Influences and impact 0
4.4 Population screening 3 (2.4)
4.5 Resources and infrastructure 0
5. Treatment development
5.1 Pharmaceuticals 2 (1.6)
5.2 Cellular and gene therapies 0
5.3 Medical devices 1 (0.8)
5.4 Surgery 4 (3.3)
5.5 Radiotherapy 0
5.6 Psychological and behavioural 0
5.7 Physical 0
5.8 Complementary 0
5.9 Resources and infrastructure 0
6. Treatment evaluation
6.1 Pharmaceuticals 22 (17.9)
6.2 Cellular and gene therapies 0
6.3 Medical devices 17 (13.8)
6.4 Surgery 12 (9.8)
6.5 Radiotherapy 2 (1.6)
6.6 Psychological and behavioural 11 (8.9)
6.7 Physical 9 (7.3)
6.8 Complementary 2 (1.6)
6.9 Resources and infrastructure 0
7. Disease management
7.1 Individual care needs 8 (6.5)
7.2 End-of-life care 0
7.3 Management and decision-making 4 (3.3)
7.4 Resources and infrastructure 0
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TABLE 18 The intervention classifications using the UKCRC HRCS30 (by trial) (continued )
Description of data n (%)
8. Health services
8.1 Organisation and delivery of services 18 (14.6)
8.2 Health and welfare economics 0
8.3 Policy, ethics and research governance 0
8.4 Research design and methodologies 0
8.5 Resources and infrastructure 0
Trial interventions not coded – missing data 1 (0.8)
Total 123
Reproduced from UKCRC HRCS Online.30
TABLE 19 The intervention classification using Chalmers’ classification system for clinical trial intervention by triala
Description of data n (%)
Drug 25 (20.3)
Radiotherapy 2 (1.6)
Surgery 12 (9.8)
Diagnostic 9 (7.3)
Education and training 4 (3.3)
Service delivery 14 (11.4)
Psychological therapy 9 (7.3)
Vaccines and biologicals 1 (0.8)
Devices 18 (14.7)
Physical therapies 9 (7.3)
Contraception 0
Exercise 1 (0.8)
Complementary therapies 2 (1.6)
Social care 1 (0.8)
Mixed or complex 5 (4.1)
Diet 0
Perioperative 0
Other 3 (2.4)
Interventions included more than one category 8 (6.5)
Total 123
a This reflects the total number of interventions reported in the 123 clinical trials. Multiresponse set was used in Statistical
Product and Service Solutions (SPSS) version 20 (IMB Corporation, Armonk, NY, USA) to retrieve these data.
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Question T2.11: type of control
More than one-third (35%, 43/123) of controls could not be defined as placebo, standard care, no
treatment or next best (Table 20). There appeared to be no improvement over time. It was not possible,
based on the monograph, to report or extract data with certainty about the type of control used. For the
80 clinical trials where the type of control could be defined, 65 (81.3%) reported the control as standard
care and 10 (12.5%) as placebo.
Questions T2.12–T2.17: did the trial conform to the protocol?
To assess whether or not the design of the trial, as described in the protocol (or the application form)
differed from that published in the HTA monograph, we compared the type of comparison, the number of
arms and the primary outcomes.
Question T2.12: type of comparison
As shown in Table 21, 119 of 122 trials reported the type of comparison as had been planned. Three trials
changed: two designed as superiority at the planning stage reported as equivalence trials (trials ID36 and
ID37), and one designed as an equivalence trial reported as a superiority design (trial ID61). This trial
reported a protocol change relating to the design of the trial: ‘A protocol amendment to amalgamate the
two arms of the study and to compare cost-effectiveness of endoscopies in general rather than by the site
of endoscopy was approved by MREC [Multicentre Research Ethics Committee] and the HTA programme.’53
The planned type of comparison was not reported in one trial. The importance of this change was not
clear because the status of the change was not recorded in the monograph. The change of comparison
could have been agreed as part of the analysis plan by the trial Data Monitoring Committee before data
were examined.
TABLE 21 Planned and actual type of comparison discrepancies
Actual design framework
Planned design framework
Superiority Non-inferiority Equivalence Total
Superiority 107 0 1 108
Non-inferiority 0 5 0 5
Equivalence 2 0 7 9
Total 109 5 8 122a
a The design framework was not detectable for one trial at the planned stage of the clinical trial.
TABLE 20 Control type
Description of data n (%)
Placebo 10 (8.1)
Standard care 65 (52.8)
No treatment 2 (1.6)
Next best 3 (2.4)
Control undefined 43 (35.0)
Total 123
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Question T2.13: the number of proposed and reported arms
The mean number of planned arms was 2.67 (n= 328) and the number reported in the monograph was
2.63 (n= 323). One hundred and seventeen trials had the same number of arms as planned (Table 22).
The six discrepant trials (4.9%, 6/123) (trials ID2, ID4, ID19, ID21, ID86 and ID95) are explored in Table 23.
The number of arms for the 123 trials was 323. The number of interventions was 321. The difference was
due to one trial having a factorial design in which two interventions were tested on two different groups.
The design characteristics of the six trials with a discrepant number of arms (see Table 23) shows that four
were published before 2005 (trials ID2, ID4, ID19 and ID21) and the remaining two in 2009 (trials ID82
and ID95). Of the four trials published before 2005, none submitted a project protocol.
TABLE 23 Design characteristics of six trials with discrepant number of arms
Trial design
characteristics ID2 ID4 ID19 ID21 ID86 ID95
Intervention
classification
Mixed or
complex
Psychological
therapy
Service
delivery
Service
delivery
Psychological
therapy
Devices
Intervention
types
New care/
new therapy
Standard care/
existing care
New care/
new therapy
New care/
new therapy
New care/
new therapy
Standard care/
existing care
Intervention
add-on or
substitute?
Neither Substitute Substitute Add-on Add-on Substitute
Type of control Standard
care
Control
undefined
Standard
care
Standard
care
Standard care Standard care
Type of
comparison
Superiority Superiority Superiority Superiority Superiority Superiority
Type of
framework
Factorial Parallel Parallel Parallel Parallel Parallel
Preference arm No Yes No No Yes Yes
Type of place Hospital GP GP Hospital GP More than one
type of place
TABLE 22 Proposed and published number of arms
Published number of arms
Proposed number of arms
2 3 4 5 6 7 Total
2 73 3 1 0 0 0 77
3 0 24 0 0 0 0 24
4 0 0 14 0 0 0 14
5 0 1 0 5 0 1 7
6 0 0 0 0 1 0 1
Total 73 28 15 5 1 1 123
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Question T2.14: the number of proposed and reported trial centres
One hundred and three trials reported the number of proposed centres (Table 24), with a mean of 17.05
and a median of 5. One hundred and nineteen trials with available data reported the actual mean number
of centres as 26.82, median 11.
Thirty-nine trials (31.7%) had unchanged numbers of proposed centres. It was not possible to compare the
planned and actual for 22 trials (17.9%). For the remaining trials (50.4%, 62/123), the number of planned
and actual trial centres differed. Four-fifths of these (80.6%, 50/62) increased the number of centres from
that planned, whereas the rest reduced it. Table 25 provides an overview of these discrepancies.
Change in the number of centres plausibly reflects difficulties with recruitment. For those trials using fewer
centres than planned, this may reflect difficulties in obtaining the support hoped for from centres.
Changes in the number of centres may reduce generalisability if the centres lost or gained
were unrepresentative.
Question T2.15: number of primary outcomes
Two hundred and one planned primary outcomes were reported from 122 trials (no data for one trial)
(mean 1.65 and median 1 planned primary outcome per trial). Two hundred and twenty-eight primary
outcomes were reported in the monographs (mean 1.85 and median 1 primary outcome per trial)
(Table 26). Ninety-five trials (78%) reported the planned number of primary outcomes. Eighty trials (65%)
TABLE 24 Summary data for the number of arms and number of centres
Description of data Proposed number (%) Published number (%)
Number of arms
2 73 (59.3) 77 (62.6)
3 28 (22.8) 24 (19.5)
4 15 (12.2) 14 (11.4)
5+ 7 (5.7) 8 (6.5)
Total 123 123
Total number of centres
10 or fewer 69 (56.1) 59 (48.0)
11–20 9 (7.3) 15 (12.2)
21–30 8 (6.5) 13 (10.6)
31–40 4 (3.3) 4 (3.3)
41–50 2 (1.6) 5 (4.1)
51–60 1 (0.8) 5 (4.1)
61–70 4 (3.3) 3 (2.4)
71–80 1 (0.8) 2 (1.6)
81–90 1 (0.8) 5 (4.1)
91–100 4 (3.3) 2 (1.6)
101+ 0 6 (4.9)
No information reported 20 (16.3) 4 (3.3)
Total 123 123
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TABLE 26 Proposed number of primary outcomes compared with the number actually reported in the
published monograph
Actual number of primary outcomes
Proposed number of primary outcomes
1 2 3 4 5 7 Total
1 73 4 3 0 2 0 82
2 6 17 0 2 0 1 26
3 0 1 3 0 0 0 4
4 0 0 0 1 1 0 2
5 0 1 1 0 1 0 3
6 0 0 1 0 0 0 1
7 1 0 0 0 0 0 1
15 0 0 0 3 0 0 3
Total 80 23 8 6 4 1 122
Note
n= 122; one trial did not provide sufficient information to report the number of planned primary outcomes.
TABLE 25 Discrepancies reported between the proposed and published numbers of centres
Published
number of
centres
reported
Proposed number of centres reported
10 or
fewer
11–20 21–30 31–40 41–50 51–60 61–70 71–80 81–90 91–100 Total
10 or fewer 53 0 0 0 0 0 0 0 0 0 53
11–20 9 3 0 0 0 1 0 0 0 0 13
21–30 1 4 7 0 0 0 0 0 0 0 12
31–40 1 1 1 1 0 0 0 0 0 0 4
41–50 0 0 0 1 2 0 0 0 0 0 3
51–60 1 1 0 1 0 0 0 0 0 1 4
61–70 0 0 0 1 0 0 1 0 0 0 2
71–80 0 0 0 0 0 0 1 0 0 1 2
81–90 0 0 0 0 0 0 1 1 0 1 3
91–100 0 0 0 0 0 0 1 0 1 0 2
101+ 1 0 0 0 0 0 0 0 0 1 2
Total 66 9 8 4 2 1 4 1 1 4 100
Note
If any of the 123 trials did not report any information about the number of planned or actual centres they were not
included in the analysis. Twenty-three trials were therefore excluded from the cross tabulation.
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reported one primary outcome as planned. In 27 trials (22.4%), discrepancies were reported between the
proposed number of primary outcomes and that reported in the published monograph. Fourteen trials
(52%, 14/27) increased the number of primary outcomes in the published monograph from the original
proposed number, the other 13 (48%) reduced it. [The number of primary outcomes differs to that
reported in Chapter 7. This is because of the denominator of the analyses. This chapter reports on
123 trials whereas Chapter 7 reports on the full cohort (n= 125 trials).]
Three trials reported in one monograph (trials ID128, ID129 and ID134) had proposed four primary
outcomes but actually reported 15. Another trial (ID79) planned seven primary outcomes but reported only
two in the monograph.
Other changes in the primary outcomes are explored in Chapter 7 regarding statistical analysis.
Questions T2.16 and T2.17: reporting and specifying the time points of
primary outcomes
Out of the 123 clinical trials, 68 (55.3%) did and 55 (44.7%) did not specify the planned primary time point
in the protocol or application form. Of the 55 that did not specify the planned primary time point in the
protocol or application form, 36 (65.5%) did not report the actual primary time point in the published
monograph. Five trials (4.1%) reported discrepancies between the proposed and published reporting of
the primary time point. In two, the proposed time point was 12 months, yet in the published monograph
two primary time points (12 and 24 months, and 4 and 12 months, respectively) were reported (Table 27).
TABLE 27 Primary outcome time-point data
Description of data Proposed number (%) Published number (%)
Was the primary time point provided?
Yes 68 (55.3) 74 (60.2)
No 55 (44.7) 49 (39.8)
Total 123 123
If yes, how were the data presented?
Less than 1 month 7 (5.7) 8 (6.5)
1 month, up to and including 6 months 29 (23.6) 35 (28.5)
7 months, up to and including 12 months 23 (18.7) 21 (17.1)
13 months, up to and including 24 months 8 (6.5) 9 (7.3)
More than 25 months 1 (0.8) 1 (0.8)
No time frame given/stated 5 (4.1) 6 (4.9)
Unable to compare data 50 (40.7) 43 (35.0)
Total 123 123
Number of secondary outcomes published in the monograph
1–5 0 41 (33.3)
6–10 0 55 (44.7)
11–20 0 25 (20.3)
Missing data 0 2 (1.6)
Total 0 123
THEME 2: DESIGN AND ADHERENCE TO PROTOCOL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
Analysis
Adherence to those sections of the CONSORT checklist that were examined was fairly high, but with some
exceptions, including lack of detail on interventions, prespecified outcomes and sample size calculation.
About one-third of trials failed on each of these. This was a greater problem for older trials.
A high proportion (88.6%, 109/123) were designed as superiority trials with parallel arms. Almost all the rest
were equivalence or non-inferiority trials. Almost half of all trials conducted pilots but few had feasibility studies.
Around half of all interventions were substitutes for standard care and about one-third were add-ons.
More than half of controls (53%, 65/123) were standard care, but one-third of controls (35%, 43/123)
could not be classified.
Both the Chalmers and HRCS classification systems could be applied. Although some categories in the
latter were not relevant, the Chalmers system provided less detail. The more comprehensive HRCS system30
should probably be used in future.
Most trials were conducted in line with protocol and followed both the study framework and the planned
type of comparison. In six trials, the number of arms changed but it could not be ascertained if those
changes had been agreed with the programme. These trials were all in the early years of the programme.
The number of primary outcomes changed in 27 trials (half increased and half decreased). Changes were
mainly in early trials. The outcome used to plan the sample size (the most important primary outcome) was
unchanged in 106 (82%) trials.
The time point at which the primary outcome was measured was not specified in 45% (55/123) of
proposals and 40% (49/123) of monograph reports.
On average, trials needed about twice as many centres as planned to complete the study, reflecting the
difficulties in recruiting.
Discussion
Strengths and weaknesses of the study
Overall, sufficient data existed for the trials to be assessed against a selection of core CONSORT criteria.
Comparison of planned and reported analyses showed the HTA trials reporting more faithfully to protocol
than the cohort examined by Chan et al.10
The HRCS classification of interventions of the trial proved slightly more comprehensive than Chalmers’
classification and should therefore be adopted. Further work is required on the classification of controls.
Recommendations for future work
Any such further work should include 14 questions, eight to remain as they are (T2.2, T2.3, T2.4, T2.5,
T2.7, T2.8, T2.12 and T2.13) and six to be amended (T2.1, T2.6, T2.9, T2.11, T2.14 and T2.15).
Unanswered questions and future research
Should similar work be continued, the HTA programme might usefully clarify:
(a) the extent to which the programme wishes to assess the extent of compliance with CONSORT
(b) the importance it attaches to trials classifying the control group
(c) how it wishes to classify cluster trials
(d) the number of primary outcomes.
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Chapter 6 Theme 3: performance and delivery of
randomised controlled trials
This chapter considers questions under the theme of the performance of RCTs funded by the HTAprogramme. After a brief review of the relevant literature it considers data on recruitment and
follow-up, changes in team composition, extensions and protocol changes and the time taken.
Introduction
As complex, highly regulated experiments involving humans, clinical trials often experience delays and
changes in plan. The HTA programme operates a proactive monitoring system comprising welcome
meetings, monitoring visits and regular progress reports in order to ensure that trials deliver their results,
and to assist underperforming studies.54 Nonetheless, Campbell et al.2 found in 2007 that less than
one-third of UK publicly funded (NIHR/MRC) studies recruited according to plan.
Performance of trials
Once commissioned, trials move through four main phases, at each of which problems may present:
l start-up
l recruitment of both centres and patients
l delivery of the interventions, follow-up and data collection
l analysis and reporting.
Two external barriers present themselves once funding has been agreed: ethics approval and research
governance. Both can cause delays and alterations to protocol. For many years, ethics approval was the
biggest challenge facing new trials. Permission from a NHS research ethics committee is legally required
before research can take place in the NHS involving human subjects, or their tissue or data.55 Issues with
obtaining ethical approval for research have been addressed at the national level. When first introduced in
1991, NHS ethics committees dealt with research within limited geographical areas. Multicentre Research
Ethics Comnittee followed in 1997. The major change which affected HTA trials was the provision of a
single UK-wide ethics opinion in 2004. This relieved HTA trials of the necessity of obtaining ethics approval
from multiple sites.56–58 The National Research Ethics Advisory Service, established in 2007, further
improved the process of obtaining ethics approval for trials.59
The second major hurdle is local NHS R&D permissions, which must be obtained in each NHS organisation
where patients will interact with the study. A recent review of the regulation and governance of health
research highlighted that these permissions cause significant delays, duplication of checks, lack of
consistent advice and interpretation, performance variation and process inconsistency, all of which are
commonly experienced by researchers.59
The HTA programme requires triallists to predict likely recruitment and to monitor actual against predicted
recruitment. Five types of prediction models are commonly used. Most common are simple, straight line
predictions, with or without conditions. Less used are models based on Poisson processes and Baysian
approaches, and simulations based on underlying Markov models. These models can be used either before
or during a trial to predict likely recruitment, in terms of both individuals and required recruitment
duration. Those which can be adapted to developing information (the Baysian approach and to a lesser
extent the Poisson) tend to be used to inform investigators about the adequacy of an ongoing recruitment
process.60,61 Those which produce a fixed or simulated answer lend themselves to pre-trial prediction. Of
course, the second group can be used to re-estimate the point of recruitment completion midway through
an accrual period, but they do not lend themselves well to dynamic re-estimation.
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Historically, triallists funded by the HTA programme have used the unconditional model.62 This has the
advantage of simplicity and ease of use but often requires unsupportable assumptions. The major
assumption required is that all the study centres start recruiting to their maximum capacity on the first day
of a trial. No multicentre trial managed by the HTA programme has ever managed this.
Since around 2006, some applications to the HTA programme have adopted a conditional model approach
to recruitment prediction. This modifies the unconditional by varying the recruitment rate conditional on
other events,62,63 usually recruitment of centres. The investigator can apply what he or she knows or
suspects about the likely times of start-up of his or her various centres and apply this to his or her
prediction. Some groups have also added phenomena such as learning (centres learning the best ways of
recruiting patients) and fatigue (centres getting bored with a trial and becoming less efficient at
recruitment) to their conditional models.
Figure 2 illustrates the effect that adopting different prediction models can have on expectations. In the
example, a further 3 months of recruitment is predicted by the conditional model, which assumes that the
centres will gradually start recruiting over the first 6 months of the trial, rather than all on day 1.
Failure of recruitment to match predictions is often taken as a flag for the HTA monitoring process to
review and consider whether the project is at risk. More robust prediction modelling could help to prevent
these ‘false positives’.
Having managed to recruit participants into a trial, a subsequent challenge is to collect data from them at
the various study end points. Investigators normally strive to collect as many data as possible, as differential
loss to follow-up in different arms of a study can introduce bias.64
Extensions and protocol changes resulting from these challenges have different implications for
interpretation of trial results. Extensions can be due to delays arising from researchers being unfamiliar
with the particular topic and/or overconfident during the competitive bidding process. The HTA
programme attempts to put in place robust assessment for extensions and protocol changes; almost all are
reviewed by appropriate members of the secretariat with scientific expertise. Protocol changes are more
important as they could undermine the scientific validity of a study. Changes in protocol should be agreed
with the HTA programme and acknowledged in reports of findings.
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Trials involve multidisciplinary teams, which often change over lengthy trials. It has been reported that the
group which finishes a research project is often not the same as the group which starts it.24,65 This could
have a similar impact to protocol changes. Failure to report such changes is common.24
Recruitment
The challenges and deficiencies of trial accrual prediction in the UK were highlighted by STEPS.2 Campbell
et al.2 looked at a cohort of 114 multicentre trials funded by the MRC and the HTA programme, which
started in or after 1994, and were due to end before 2003. Of the 114 studies, less than one-third
recruited their target number of participants according to the original plan, and one-third required an
extension to the duration of the study.
The STEPS identified as indicators of success:
l having a dedicated trial manager
l being a cancer or drug trial
l having interventions which were only available inside the trial
l addressing a clinically important question in a timely way.
Watson et al.66 and Treweek et al.67 reviewed the published literature around improving recruitment to
trials. Watson et al.66 included 14 papers describing 20 interventions, but excluding studies assessing
recruitment to hypothetical studies. Treweek et al.67 assessed 27 trials of interventions to improve
recruitment to clinical trials, with a total of more than 26,000 participants but with wider inclusion criteria.
The trials reviewed by Treweek were essentially a superset of those assessed by Watson et al.66.
Unsurprisingly, their findings were very similar, both suggesting the following strategies which may
improve recruitment:
l telephone reminders to non-responders
l opt-out, rather than opt-in, procedures for contacting potential participants
l open designs, where participants know which intervention they are receiving
l monetary incentives
l making trial materials culturally sensitive.
Both studies reflected on issues which these approaches may raise. For example, an open design is by
necessity unmasked to the participant, with a subsequent risk of bias if the outcome measures are
anything but objective and a potential difference of response between the arms due to a ‘placebo’ effect.
They also identified remedies which have been used, but with little supporting evidence of effectiveness,
such as providing trial details through information videos and recruiter training.
The UK Collaborative Trial of Ovarian Cancer Screening set out in 2000 to recruit 202,638 women, and
met that target in 2005.68 The authors highlighted meticulous planning as key to recruitment. Of the
strategies recommended by Watson et al.66 and Treweek et al.,67 the only one adopted was an open
design, but this was necessitated by the design of the study and was not driven by the need to recruit.
They claimed that their information video was of great benefit, despite the lack of evidence identified in
the earlier review. It seems likely that the major impacts on recruitment were personalised invitation letters
and an intervention which offered a health benefit in a condition of particular concern to those invited.
Fletcher et al.’s69 systematic review in 2011 of incentivising clinicians’ recruitment to clinical trials found
that the available evidence was poor. The most promising method, they suggested, was to identify barriers
to clinician recruitment through qualitative work.
Retention and follow-up
The literature on retention is less extensive than that on recruitment, investigating more tightly defined
questions related to individual clinical areas or study methods.
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Booker et al.70 considered retention in long-term prospective cohort studies, which tend to be more
vulnerable to attrition than most clinical trials. Their systematic review considered 28 studies, of which 11
were randomised trials of retention strategies. The strategies fell into three groups: incentives (including
cash and other gifts), reminders (by letter, phone or, more recently, text message) and other (alternative
data collection). They found that incentives were the best way to ensure retention, but it was unclear
whether financial or non-financial greater-value incentives had a larger effect.
Meyers et al.71 studied issues around follow-up of minors, especially in the context of substance abuse
research, emphasising the need for intensive effort for follow-up.
Fisher et al.72 built on some of the findings from Meyers et al.’s71 work, incorporating a novel psychological
and educational model to develop a programme aimed at increasing recruitment and retention in RCTs
[anticipate, acknowledge, standardise, accept, plan (AASAP)]. Tested in a three-arm RCT of distress
reduction techniques in diabetics, the scheme improved retention.
Prostate Testing for Cancer and Treatment (ProtecT) (ISRCTN 20141297) is a large HTA trial investigating
treatments for men with localised prostate cancer.73 Men registered at randomly selected GP practices
were invited by letter to enrol.74 A cohort of 89,000 men was recruited between 1999 and 2008, with
2600 developing prostate cancer and 1672 agreeing to randomisation. The team developed a framework,
known as the Peer Review Intervention for Monitoring and Evaluating sites (PRIME), to assess site
performance, training needs and good clinical practice adherence of the recruiting sites.75 Each of the eight
sites in the trial was assessed annually, looking at its recruitment processes but also its adherence to
follow-up protocols. A review of PRIME found that it enhanced study conduct and consistency, manifested
in a more complete follow-up for ProtecT.
Delivery of trials
Transparent reporting of extensions and protocol changes
Chan and Altman11 discussed outcome reporting bias in trials by reviewing publications and surveying
authors. Incomplete reporting of trial results was common, with primary and reported outcomes often not
in compliance with the predefined protocol, but instead driven by results which might be considered
interesting. They recommended publication of all trial protocols to allow assessment of this bias by future
reviewers and decision-makers, a recommendation followed up in the 2010 revision of CONSORT.44,76
They noted that reporting bias may be promoted by the limited space available in traditional journals, a
restriction the HTA journal, with its generous with space restrictions, might be expected to overcome.
Questions addressed
We reviewed how well the included HTA randomised trials performed, including recruitment patterns,
frequency of protocol changes (and extension requests), team composition and delays to do with
obtaining permissions.
Box 4 shows the questions explored in this section.
Methods
Fifteen questions were piloted, as shown in Box 4. One question concerning delays in obtaining ethical
committee and R&D approval from trusts was dropped, for which no data were available.
Denominators
The denominator for the questions regarding recruitment, centres and follow-up was the number of trials
(n= 125). The denominator for questions regarding the team and extension/protocol changes was the
number of projects (n= 109).
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Of the 125 trials, five were reported to have been abandoned, stopped or closed down. Box 5 shows
details of these five trials, including the planned and actual recruitment. One monograph reported two
trials (ID110 and ID78), one of which (ID110) had been closed down owing to poor recruitment.
BOX 4 The research questions answered under this theme
To what degree did actual recruitment match planned recruitment?:
T3.1. Expected and reported number of participants recruited.
T3.2. Number of centres (including multicentre).
T3.3. Date when recruitment took place.
T3.4. Sample size calculation changes.
T3.5. Follow-up (including how many participants followed up).
T3.6. Recruitment comparison with STEPS.
T3.7. What was the composition of the team and did it change?
Project protocol changes and extension approvals:
T3.8. Evidence of project protocol changes.
T3.9. The number of protocol changes reported.
T3.10. The type of protocol changes reported.
T3.11. Approved extension applications submitted to the HTA programme.
T3.12. Time and cost implications.
T3.13. Number of extension request approvals for the included projects.
T3.14. Reasons given for the submission of an extension request.
T3.15. What were the planned and actual contract start and end dates for those included projects?
BOX 5 Recruitment details of abandoned trials
Trial ID62 was formally abandoned with agreement from the HTA programme and the Trial Steering
Committee. The planned recruitment number was 1000 and the actual number of participants recruited
was 208.
Trial ID75 was stopped and formal closure of the trial was initiated in May 2005 after 5 months of recruitment.
The planned recruitment number was 1002 and the actual number of participants recruited was 19. Nine
participants completed the trial.
Trial ID97 did not continue into a full trial; a pilot was conducted to see if it could continue as a full trial.
A full trial did not commence owing to low recruitment numbers and placebo control group. The planned
recruitment number was 70 and the actual number of participants recruited was nine.
Trial ID110 (linked to trial ID78) was stopped with agreement from the HTA programme 14 months after
consultation. This arm of the trial was considered inappropriate and unfeasible. The planned recruitment
number was 400 and the actual number of participants recruited was one.
Trial ID111 was stopped with agreement from the HTA programme and the Trial Steering Committee.
The planned recruitment number was 1425 and the actual number of participants recruited was 154. Despite
low recruitment, patient follow-up continued for these 154 participants, with analysis of response
remaining descriptive.
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Results
Questions T3.1–T3.6: to what degree did actual recruitment match
planned recruitment?
Question T3.1: expected and reported numbers of participants recruited
The extent to which trials recruited as planned varied, as shown in Figure 3.
The x-axis measures the proportion of the original target recruitment achieved and the y-axis measures the
proportion of trials in the cohort which achieved a certain recruitment or better. Seventy-two per cent of
trials (y-axis) managed to achieve 50% or better (x-axis) of their original target recruitment. About 40%
of studies managed to recruit to 80% or better of their original targets.
A common response to being unable to recruit to target is to revise the target. This may be justified by
consciously sacrificing power (e.g. dropping from 90% to 80%), discovering that the event rate within the
trial is different to that assumed at application or changing the hypothesised effect size sought within the trial.
Figure 4 shows the studies from Figure 3 divided into two groups. The centre line shows the success in
recruitment of the studies which did not revise their targets. The two outer lines reflect the other group,
comprising those studies which did change their recruitment target while under way. The top line shows
these studies’ performance against their new targets and the bottom line performance against their
original ones. Unsurprisingly, this group were doing far worse than the non-changers before target
revision and substantially better afterwards. However, even in studies which revised their targets, just over
80% achieved 80% of their new goals.
We observed that not achieving these targets does not mean that the studies failed. They may have ended
up being underpowered compared with what was commissioned (though the HTA process looks at the
consequences for power when taking decisions about when to extend studies), or power may have been
preserved because of unforeseen changes in event rate.
Question T3.2: number of centres
A major driver of recruitment is the recruitment of trial centres. Of the 120 trials, 112 (93.3%) were
reported to be multicentre. Half of the trials reported a difference between the planned number of centres
in the application form/protocol and that reported in the monograph (52.5%, 63/125).
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FIGURE 3 Recruitment of trials compared with original protocol.
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About 90% of trials were able to recruit the number of centres that they set out to attain during the
course of a trial (Figure 5) and about 40% over-recruited their centres. Twenty per cent recruited double
the number of centres they initially planned.
Question T3.3: date when recruitment took place
Of the 120 trials, 108 (90%) reported the planned start date of recruitment and 107 (89.2%) reported the
actual end date of the recruitment period in the published monograph. We had planned to extract the
start and end dates of recruitment from the protocol/application form but such data were lacking.
Question T3.4: sample size calculation changes
Of the 120 trials, 36 (30%) changed the sample size calculation after the trial had commenced (these are a
subset of those represented in the two outer lines in Figure 4). More than 80% of these trials (88.9%,
32/36) decreased the number of participants needed for the trial in comparison with 11.1% of trials (4/36)
which increased the numbers required. The remaining 89 trials did not report any changes to the sample
size calculation once the trial had commenced.
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The reasons why the target sample size was changed cannot be derived from the available data. Staff
involved with the HTA monitoring programme suggest that the most common reason is that the triallists
revisit target recruitment. Less commonly, this process is initiated by a Data Monitoring Ethics Committee
because it has noticed that underlying assumptions, such as the event rate, do not hold up. Five of these
125 trials were abandoned before completion (see Box 5).
Of the 36 trials that changed the sample size calculation, 34 (94.4%) completed full follow-up, one trial
did not complete full follow-up and no data were available for one trial. More than three-quarters of these
trials (77.8%, 28/36) recruited 80% or more of the total number of participants required.
Question T3.5: follow-up
Of the 120 trials, 97.5% (117/120) completed full follow-up (five trials are excluded owing to the reasons
explained in Box 5). Follow-up was not applicable to two trials as one was a feasibility study (trial ID15)
and the other had no follow-up period (trial ID113). It was not possible to determine full follow-up for one
trial (trial ID16).
Comparison between the planned and actual follow-up periods found that in 22.2% of trials (26/117) the
follow-up period had changed from that reported in the proposal/protocol. One-quarter of trials (6/26)
reported an increase in the follow-up period compared with that reported in the proposal document.
Question T3.6: recruitment comparison with the Strategies for Trial
Enrolment and Participation Study
Previous work by STEPS2 was compared with those trials included in the metadata database.
The recruitment eligibility criteria for inclusion in the STEPS study were:
l trials funded by the MRC or HTA programme
l recruitment start date from 1 January 1994
l recruitment end date, as stated in the application form or first protocol report, before 31 December 2002.
Cluster randomised design trials and single-centre trials were excluded from STEPS. Thirty-two HTA-funded
clinical trials were included in STEPS. A comparison of these with 42 later HTA-funded trials meeting the
STEPS criteria showed that of those 42 projects, 69% (29/42) recruited more than 80% of the original
target number and 92.9% (39/42) completed full follow-up (Table 28). By analysing the recruitment start
and end dates from the metadata database, we found 48 eligible projects since the STEPS. Six projects
were excluded (five were cluster randomised design trials and one was a single-centre trial).
Question T3.7: what was the composition of the team and did it change?
A comparison of applicants named on the final application form with authors of the monograph showed
changes in all projects. Out of the 107 projects legible for analysis (two had no application form), 19.6%
(21/107) were reported to have included the original proposal team applicants as well as other people as
co-authors of the monograph. The most common change from the application form to the monograph
was ‘a subset of the original team and additional team members’ (78%, 84/107). Table 29 shows the
three different compositions of the research team.
TABLE 28 Comparison of STEPS results with results in a post-STEPS cohort
Item STEPS cohort Post-STEPS cohort
Recruitment to ≥ 80% of target 54.8% 69.0%
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Some changes in the trial team are to be expected but not changes in all. Retirement and death are
unavoidable, and occasionally job changes, especially moving abroad, can lead to investigators leaving the
team. We were unable to examine whether additional investigators or authors were used to replace
expertise which was no longer available, or to supplement the team with expertise which was missing
from the original application. Difficult to assess, although important to look at, is guest authorship and
guest applicant status.
Questions T3.8–T3.14: project protocol changes and extension approvals
Question T3.8: evidence of project protocol changes
Since 2001, all projects have had to complete a protocol change form. These were located for 69.7% of
projects (76/109). (Two trials submitted a non-standard protocol change form. These were included in
subsequent analyses.) The protocol change form changed several times (three versions were identified).
Only version 3 asked if any of the project protocol changes were reported in the final report. Of the
41 projects which submitted version 3, only half (51.2%, 21/41) reported the changes in the published
monograph, one-third of projects (34.1%, 14/41) were not consistent in reporting the project protocol
changes in the monograph and 14.6% (6/41) did not report any amendments or no information was
available to report. By ‘not consistent’ in their reporting we mean that these projects may not have
reported all protocol changes in the monograph. They only reported a select number of protocol changes.
Only projects that submitted a protocol change form were included in the two subsequent analyses
(76 projects provided a protocol change form and two projects used a non-standardised form).
Question T3.9: the number of protocol changes reported
Seventy-four projects out of 78 (94.9%) reported more than one protocol change and the mean number
of changes was six (exact mean 5.97) (out of those that submitted a protocol change form; n= 78
projects). A total of 466 protocol changes were reported from the 78 projects.
Question T3.10: the type of protocol changes reported
‘Clinical assessment’ was the most reported protocol change, with 122 mentions (26.2% of all reported
changes). Examples included changes such as laboratory processes or specific diagnostic tests used.
Occasionally the staff undertaking assessments changed, for example from a doctor to a specially trained
nurse. Issues related to recruitment were reported 66 times (14.2% of changes) and patient eligibility
criteria were reported 64 times (13.7% of changes). Three project protocol changes were reported as
‘other’ and these consisted of adverse event reporting (n= 1), GPs to flag records of participants who
defaulted at 12 months (n= 1) and reduction in the amount of data verification (n= 1) (Table 30).
Question T3.11: approved extension applications submitted to the Health
Technology Assessment programme
Out of the 109 projects, 94 submitted extension request(s), which were approved by the HTA programme.
TABLE 29 Reported differences between the named applicants on the application form and authors of
the monograph
Composition of the team from proposal to monograph n (%)
Original proposal team and additional others 21 (19.6)
Subset of original team 2 (1.9)
Subset of original team and additional others 84 (78.5)
No change 0 (0)
Note
Unable to extract data owing to incomplete proposal documents for two projects (trials ID61 and ID67).
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TABLE 30 Protocol changes reported at the time of submission of the final draft report
Description of data n (%)
Were there any protocol amendments?
Yes 78 (71.6)
Not applicable 1 (0.9)
No information available 23 (21.1)
Protocol changes were reported in the monographa 7 (6.4)
Total 109
Number of protocol changes
1 4 (5.1)
2 4 (5.1)
3 9 (11.5)
4 9 (11.5)
5 11 (14.1)
6 9 (11.5)
7 9 (11.5)
8 8 (10.3)
9 7 (9.0)
10+ 8 (10.3)
Total 78
Project protocol changes record form submitted
Yes 76 (69.7)
No information submitted 31 (28.4)
Non-standard forms were used 2 (1.8)
Total 109
Type of protocol change reportedb,c
Patient eligibility criteria 64 (13.7)
Outcome measures 15 (3.2)
Intervention 13 (2.8)
Sample size 18 (3.9)
Alternations to analyses 31 (6.7)
Clinical assessment 122 (26.2)
Study design 47 (10.1)
All issues related to recruitment 66 (14.2)
Randomisation process 13 (2.8)
Trial management 52 (11.2)
Number of centres 22 (4.7)
Other 3 (0.6)
Total 466
a Although protocol changes were reported in the monograph, there was no protocol change form to compare data.
b A multiresponse in SPSS was calculated.
c A content analysis was performed to reduce the number of categories for the protocol changes reported.
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Question T3.12: time and cost implications
Seventy-seven projects (70.6%) submitted extensions for time and additional research cost compared with
eight (7.3%) which requested an extension for time only and nine (8.3%) which requested an extension
for additional research cost only.
Question T3.13: number of extension request approvals for the
included projects
Of the 94 projects, 72 (76.6%) had more than one approved extension request, with a mean of 3.03.
Two hundred and eighty-five approved extensions were reported from the 94 projects.
Question T3.14: reasons given for the submission of an extension request
Of these 285 approvals, 36 (12.6%, 36/285) referred to salary inflation and one (0.4%, 1/285) referred to
start date change. As these did not have a direct relevance to the trial itself they were excluded from the
descriptive statistics shown in Table 31 (n= 248) and any further analyses.
Adjusting for the total number of extension requests reported by each project, the most reported
extension request was based on ‘recruitment issues’, reported 107 times (43.1% of requests). All other
categories were below 10%, representing a small number of approved extension requests (Table 31).
TABLE 31 Summary data on approved extension requests
Description of data n (%)
Did the trial receive an extension request?
Yes 94 (86.2)
No 15 (13.8)
Number of extension requests
0 15 (13.8)
1 22 (20.2)
2 18 (16.5)
3 21 (19.3)
4 10 (9.2)
5 14 (12.8)
6 8 (7.3)
7 1 (0.9)
Total 109
Type of approved extension requesta,b
Recruitment 107 (43.1)
Staffing issues 18 (7.3)
Extended follow-up period 7 (2.8)
Extra drug or equipment costs 8 (3.2)
Additional work/work greater than expected 12 (4.8)
Revised project costs 12 (4.8)
Report writing 12 (4.8)
Data issues 6 (2.4)
continued
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Seventy-eight per cent of projects (85/109) submitted a time extension request to the HTA programme.
Between these 85 projects, 141 requests for additional time were submitted and approved by the
HTA programme (49.4%, 141/285 approved extensions). The mean length of time extensions was
4.06 months.
Question T3.15: what were the planned and actual contract start and end
dates for the included projects?
The mean duration of the projects (n= 109) increased from a planned 39.7 months to the actual mean
duration of 50.4 months. Almost half of the projects (49.5%, 54/109) had a different contract start date
from the original date proposed in the Department of Health contract of agreement and this was
particularly marked from 1997 to 2002.
Eighty-seven per cent of projects (95/109) had a different end date to that originally proposed and 89.5%
(85/95) had a change to the total duration of the project.
Analysis
Hardly any trials recruited as planned. Around three-quarters recruited more than 50% of their planned
sample; one-quarter recruited less than 50%. Most trials had to agree revised targets with the programme.
More, but not all, of those that revised their targets came close to meeting them, but some did not.
Considering only studies which did not change their target sample size, 50% obtained more than 80% of
their initial target sample, and over 90% obtained half their target sample.
Unsurprisingly, studies which revisited their sample size during the course of the trial tended to perform
poorly on their ability to recruit to the target in their original protocol but did much better when compared
against their revised target. The prompt to revisit the sample size, sometimes in response to a non-related
factor such as an updated external estimate of effect size, is commonly poor recruitment performance.
Recruitment of centres is a major driver for overall recruitment in multicentre studies.77 Ninety per cent of
trials in this cohort recruited their target number of centres and 50% recruited more than the initial
number that they thought they needed. Most surprisingly, 20% of studies recruited more than twice the
number of centres initially planned.
TABLE 31 Summary data on approved extension requests (continued )
Description of data n (%)
Research governance 7 (2.8)
EU directive work 13 (5.2)
New host institution 4 (1.6)
Additional support 5 (2.0)
External factors 8 (3.2)
Funding reduced 9 (3.6)
Other 20 (8.1)
Total 248
a Two hundred and forty-eight extension requests were approved for 94 projects (excluding 37 extensions that were
related to staff inflationary costs and start date change).
b Content analysis was performed to reduce the number of categories for the approved extension request.
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We have not investigated how efficient these centres were, for example to asses if this was a good use
of resources. The bulk of patients in a multicentre trial often come from a very small subset of centres.
The excess centres were perhaps needed because the bulk of the originally planned centres did not recruit
as well as expected. Alternatively, clinicians can be keen to join in with a trial that they perceive as
successful, and this may be the reason for centre over-recruitment. Either way, the efficiency of centres
could be worthy of further investigation.
A notable finding is that of all the studies in the cohort, none had the same team at the end as at the
beginning. Further work may be required to investigate the process by which teams changed, whether or
not those changes were agreed with the programme (either in approving the change, or assessing if the
changed team could still deliver the contracted work) and whether new team members replaced outgoing
ones or provided new skills missing in the original bid. The HTA programme should consider requiring
teams to explain any changes in their final reports.
Protocol changes were common and not always well reported. Thirty projects in this cohort did not
indicate using the appropriate form that there had been protocol changes at the time of submission of
their report. Despite this, seven reported changes in their monographs.
Of those projects which notified the programme of changes to protocol, it is concerning that less than
half acknowledged this in the monograph. This may have improved recently as the editorial process has
matured. It would be useful to reassess this issue with more recent projects.
The extent of a protocol change can vary from minor to major. It should be possible to categorise
proposed changes to allow a proportionate response, but consideration of this was outside the scope of
this project.
The mean duration of projects increased from a planned duration of just under 40 months to an actual
duration of just over 50 months. This delay varied over time, with a peak just after 2000, mostly resolved
by 2003.
Far more studies were affected by delays in the planned start and end dates. Important causes of delay
may be delays in obtaining ethical and governance approvals. Further, applicants tend to underestimate
the time required to recruit participating centres. Investigators often underestimate the effort required to
write the project’s final report, which will, after an editorial process, be published in Health Technology
Assessment, and many projects therefore request short time-only extensions to give more time for report
preparation. More recently, but probably not affecting this cohort of trials, studies have run into problems
obtaining excess treatment costs, that is, the clinical costs of undertaking a trial which are in excess of
those that a primary care trust (PCT) might usually expect to pay for the routine care of its population.
Discussion
Applicants need to be more realistic about trial set-up times and the programme can help by pointing out
to applicants where it feels insufficient time has been allowed; however, the fundamental problems with
the NHS’s current research approvals process can only be addressed at a national level, in much the same
way that the previous problems with ethics committees were resolved.
The issue of excess treatment costs is one which can only be solved at a national level; the programme
has no power to compel health service funders to pay excess treatment costs, despite the existence of
instructions from the Department of Health which say that they should.58,78,79
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Strengths and weaknesses of the study
The main weakness in addressing these questions derives from data limitations. The HTA MIS did not store
monthly recruitment in a machine-readable form. Even the programme’s paper records usually only noted
recruitment every 6 months. It was not possible to examine how trials’ recruitment performance varies
across time and by centre.
All trials in this cohort began before the introduction of the NIHR research networks. Newer trials will have
been able to use these networks to speed up their start-up processes.
We identified several changes which could make the routine data more relevant, mainly reconfiguration of
data collected regarding changes to projects. We have also identified some data which were less useful
and probably not worth the effort of prospective collection.
Recommendations for future work
Should similar work continue, we consider that data should be extracted for 13 questions: five to be kept
as they are (T3.3, T3.4, T3.9, T3.13 and T3.15) and eight to be amended (T3.1, T3.2, T3.5, T3.6, T3.7,
T3.10, T3.12 and T3.14).
The finding that hardly any of the included trials recruited as planned merits consideration by the HTA
programme. Although trials funded more recently may have recruited closer to planned targets,
recruitment problems are likely to remain. At the very least, the data collected routinely should take fuller
account of the knock-on effects, including on protocol changes and revised timescales.
Unanswered questions and future research
There is scope for further investigation of specific questions:
1. What is the influence of study under-recruitment on power? Following on from that, what power
should the programme expect a study to deliver?
2. Why do studies systematically overestimate their ability to recruit?
3. How can the differential effectiveness of recruiting centres be addressed, preferably by increasing the
effectiveness of the poorest performers?
4. Why do study teams change? How can that process of change best be managed?
5. How can protocol changes best be categorised, to allow the programme to respond (and assess the
changes) in an appropriate way?
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Chapter 7 Theme 4: were the statistical analyses
appropriate and as planned?
This chapter considers questions surrounding the appropriateness of the statistical analyses. After a briefreview of the relevant literature, 19 questions were explored. The results are summarised and discussed.
Introduction
Outcome reporting bias has been widely reported.10,11,27,80–87 However, only a few papers have reported
on whether or not researchers adequately specify planned analyses in the protocol and, subsequently,
whether or not they follow the prespecified analysis.88,89 This matters because failure to follow the
prespecified analysis can result in bias. One study suggested that protocols were not sufficiently precise to
identify deviations from planned analyses.89 Two reviewed whether or not sample size calculations were
adequately specified.88–90 Another recently questioned whether or not the current method of sample size
calculations was appropriate.91 These are summarised below.
The primary outcomes in protocols were compared with those in published reports for 102 trials approved
by the scientific ethics committees for Copenhagen and Frederiksberg, Denmark, between 1994 and
1995.10 Selective reporting was revealed, with 62% of trials reviewed having at least one primary outcome
added, omitted or changed.
A similar review of 48 trials funded by the Canadian Institutes for Health Research81 found that in 33% of
trials, the outcome listed as primary in the publication differed from that in the protocol. They also found
that outcome results were incompletely reported.
A pilot study conducted in 2000 reviewed 15 applications received by a single local research ethics
committee in the 1990s and compared the outcomes, analysis and sample size in the protocol with that
presented in the final study report.89 The authors found that six protocols (40%) stated the primary
outcome and, of these, four (67%) matched that in the published report. Eight mentioned an analysis plan
but only one (12%) followed its prescribed plan. The study concluded that selective reporting may be
substantial but that bias could only be broadly identified as protocols were not sufficiently precise.
In 2008, Chan et al.88 compared the statistical analysis and sample size calculations specified in the
protocol with those specified in the published paper. They found evidence of discrepancies in the sample
size calculations (18/34 trials), the methods of handling protocol deviations (18/34 trials), methods of
handling missing data (39/49 trials), primary outcome analyses (25/42 trials), subgroup analyses
(25/25 trials) and adjusted analyses (23/28 trials). These discrepancies could affect the reliability of results,
introduce bias and indicate selective reporting. They concluded that the reliability of trial reports cannot be
assessed without access to the protocol.
A 2008 comparison of the sample size calculation specified in the protocol with that in the publication
found that only 11 of the 62 trials reviewed adequately described the sample size calculation in both the
protocol and published report.88
Charles et al.,90 in a review of the reporting of sample size calculations in 215 trials published between
2005 and 2006, found that 43% did not report all the required sample size calculation parameters.
A study of 18 trials that reported on traumatic brain injury reviewed the covariates adjusted for and
subgroup analyses performed.92 Protocols could be obtained for 6 of the 18 trials and it found that all
six trials reported subgroup effects which differed from those specified in their protocols.
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In collaboration with journal editors, triallists, methodologists and ethicists, Chan et al.93,94 have launched
the Standard Protocol Items for Randomised Trials (SPIRIT) initiative to establish evidence-based
recommendations for the key content of trial protocols.
The above studies may not reflect current practice because either the number of trials reviewed was small
or the studies reviewed were relatively old (1994–5 for Chan88 and similar for Hahn89). Practice may have
improved since, following the introduction of CONSORT and other guidelines.
Our objective was to repeat these analyses on the cohort of all HTA published RCTs, assessing the extent
of these discrepancies and whether or not they improved over time.
Questions addressed
The aim was to review the appropriateness of the statistical analyses for all published HTA clinical trials,
including the sufficiency of the proposed statistical plan, handling of missing data and whether or
not there were discrepancies between what was proposed and what was actually reported in the
published monograph.
The questions posed (Box 6) fall under the following six subheadings:
i. Did the protocol specify the planned method of analysis for the primary outcome in sufficient detail?
ii. Was the analysis planned in the proposal/protocol for the primary outcome carried out?
iii. How was the sample size estimated?
iv. How adequate was the reporting of planned and actual subgroup analysis?
v. Other information: what graphical presentation of data was reported in HTA trials?
vi. Were conclusions justified given the analysis results?
Methods
Nineteen questions were piloted as shown in Box 6. Four questions were considered but not proceeded
with, regarding:
i. the number of statistical tests and number of primary statistical tests
ii. whether or not authors measured more outcomes than they reported
iii. adequate reporting of subgroup analyses
iv. whether or not the conclusions were justified given the analysis results.
Difficulties arose with each of these questions. Firstly, results were not presented in a standard format in
the monographs. Secondly, as the monographs were lengthy, data extraction meant searching and reading
through many pages. Thirdly, as the HTA trials are pragmatic, they include a large number of outcomes
measured at multiple time points, which increased the number of tables/amount of text to be reviewed.
Fourthly, extracting information on subgroup analyses planned and carried out was difficult because
authors seldomly labelled analyses as subgroup analyses. Lastly, we found it difficult to specify data that
could answer the question regarding the conclusions being justified by the analyses.
For the 19 questions explored, the methods used in the literature reviewed above were used as a
framework to detail the questions. For example, the paper by Chan et al.88 provided the key components
of data that needed to be extracted on the sample size calculation. Data on these components were
expanded to include other types of outcome measures and study designs (e.g. time-to-event data,
non-inferiority and cluster randomised trials). We extracted these data from the protocol or project
proposal (if a protocol was not available) and monograph, and analysed the data in a similar way.
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Denominators
All trials were included (n= 125). The unit of analysis for questions T4.1–T4.15 was each trial’s primary
outcome with complete analysis (n= 164 planned and n= 161 reported). The unit of analysis for
T4.16–T4.18 was the individual trial.
Results
Questions T4.1–T4.10: did the protocol specify the planned method of
analysis for the primary outcome in sufficient detail?
Question T4.1: how many specified a method of analysis for the
primary outcome?
The 125 trials included 206 planned primary outcomes and reported on 232 primary outcomes.
Of these, 164 and 161, respectively, were ‘complete for analysis’ (these are the denominators for
questions T4.1–T4.10).
BOX 6 The actual research questions answered under this theme
Did the protocol specify the planned method of analysis for the primary outcome in sufficient detail?
In relation to:
T4.1. how many specified a method of analysis for the primary outcome.
T4.2. whether or not this improved over time.
T4.3. statistical test applied.
T4.4. significance level.
T4.5. hypothesis testing.
T4.6. adjustment for covariates.
T4.7. analysis population.
T4.8. adjustment for multiple testing.
T4.9. missing data.
T4.10. sufficient detail including all of the above seven elements recorded in the protocol.
Was the analysis planned in the proposal/protocol for the primary outcome carried out? In relation to:
T4.11. statistical test/model used.
T4.12. significance level.
T4.13. analysis population.
T4.14. missing data.
T4.15. covariates adjusted for in the analysis.
How was the sample size estimated (power, confidence intervals, etc.)?
T4.16. Was sufficient information on the sample size calculation provided?
T4.17. Does the sample size calculation in the protocol match the sample size calculation shown in the
monograph? What discrepancies were found?
T4.18. What values of alpha, power and drop out were used in the sample size calculation?
T4.19. Other information: what graphical presentation of data was reported in HTA trials?
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The method of analysis was prespecified for 111 out of 164 planned primary outcomes (67.7%), with little
difference between those that did and did not have protocols (65.9%, 54/82 from the proposal and
69.5%, 57/82 from the protocol) (Table 32).
Question T4.2: has this improved over time?
There is a slight indication that the specification of the primary outcome analyses has improved over time.
This could be due to the increasing number of protocols available (Table 33 and Figure 6) but the low
numbers preclude strong conclusions.
TABLE 32 Planned primary outcome analysis specified in the protocol/proposal by whether or not a protocol
was available
Planned primary analysis
Protocol available or not?
Total, n (%)Yes, n (%) No, n (%)
Yes 57 (69.5) 54 (65.9) 111 (67.7)
No 14 (17.1) 13 (15.9) 27 (16.5)
Not clear 1 (1.2) 1 (1.2) 2 (1.2)
Not applicable 1 (1.2) 0 1 (0.6)
No information available 9 (11.0) 14 (17.0) 23 (14.0)
Total number of primary outcomes 82 (100.0) 82 (100.0) 164 (100.0)
Total number of trials 65 (52.0) 60 (48.0) 125 (100.0)
TABLE 33 Planned primary outcome analysis specified in protocol/proposal by year
Year of commissioning brief Yes, n (%) No,a n (%) Not clear, n (%) Total, n (%)
1993 12 (70.6) 5 (29.4) 0 17 (100.0)
1994 13 (52.0) 11 (44.0) 1 (4.0) 25 (100.0)
1995 19 (73.0) 7 (27.0) 0 26 (100.0)
1996 16 (55.2) 13 (44.8) 0 29 (100.0)
1997 6 (50.0) 5 (42.0) 1 (8.0) 12 (100.0)
1998 3 (75.0) 1 (25.0) 0 4 (100.0)
1999 10 (83.3) 2 (16.7) 0 12 (100.0)
2001 20 (87.0) 3 (13.0) 0 23 (100.0)
2002 3 (75.0) 1 (25.0) 0 4 (100.0)
2003 6 (75.0) 2 (25.0) 0 8 (100.0)
2005b 1 (100.0) 0 0 1 (100.0)
2009b 2 (66.7) 1 (33.3) 0 3 (100.0)
Total 111 (67.8) 51 (33.5) 2 (1.2) 164 (100.0)
a The categories ‘no information available’ and ‘no’ were merged as they were essentially the same.
b There were no trials included in the database with commissioning briefs advertised in 2006, 2007 and 2008 because all
of the trials advertised by the HTA programme had yet to publish their results at the time the metadata database was
closed in July 2011. The two trials which had a commissioning brief advertised year of 2009 were trials conducted as a
result of the flu call, which had to report within a short time frame.
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Question T4.3: statistical test applied
Of the 111 planned primary outcomes with a prespecified method, the proposed statistical test/choice of
model was described in 108 (96.4%). The most frequently reported planned methods of analysis were
logistic regression (23.4%, 26/111) and analysis of covariance (ANCOVA)/linear regression (17.1%, 19/111),
followed by t-test (14.4%, 16/111) (Table 34).
Question T4.4: significance level
Of the 111 primary outcomes with a specified method of analysis, the significance level/confidence interval
level to be used was specified in 39 (35.1%). Table 34 shows that the most commonly used level of
statistical significance was 5%.
Question T4.5: hypothesis testing
The majority did not specify whether one-sided or two-sided analysis would be performed (87.4%, 97/111)
(see Table 34).
Question T4.6: adjustment for covariates
Sixty-eight of the 111 (61.3%) planned primary outcomes specified the covariates that they planned to
adjust for in the final analysis.
Question T4.7: analysis population
The planned population for the primary analysis was not specified by 41.4% (46/111). This appears to
have improved over time (apart from anomalies in 1998 and 2003), with a big increase in 1996, the year
in which CONSORT was published.
Question T4.8: adjustment for multiple testing
Almost all studies failed to specify a method of adjustment for multiple testing (93.7%, 104/111). As HTA
trials are pragmatic as opposed to licensing trials, looking at a range of outcomes over short- and
long-term periods, adjustment for multiple testing may matter less than transparency.
Question T4.9: missing data
Most studies did not specify a method for handling missing data (74.8%, 83/111). Of those that did, the
methods used varied (see Table 34).
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FIGURE 6 Proportion of trials with a protocol available by year of commissioning brief.
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TABLE 34 Components of the analysis of the primary outcome reported in the protocol/proposal and monograph
Description of planned statistical analyses
Planned from protocol/proposal,
n (%)
Reported in the monograph,
n (%)
Planned statistical test
t-test 16 (14.4) 14 (9.4)
Chi-squared test 8 (7.2) 20 (13.4)
ANOVA 6 (5.4) 0
ANCOVA/linear regression 19 (17.1) 48 (32.2)
Logistic regression 26 (23.4) 21 (14.1)
Mixed model 5 (4.5) 18 (12.1)
Poisson regression 3 (2.7) 2 (1.3)
Cox proportional hazards 7 (6.3) 8 (5.4)
Log-rank test 1 (0.9) 4 (2.7)
Mann–Whitney 1 (0.9) 1 (0.7)
Non-parametric analyses 1 (0.9) 0
Confidence interval 11 (9.9) 9 (6.0)
Other 3 (2.7) 4 (2.7)
Not specified 4 (3.6) 0
Total 111 (100.0) 149 (100.0)
Significance level
1% 0 13 (8.7)
2.5% 2 (1.8) 1 (0.7)
5% 17 (15.3) 22 (14.8)
95% confidence interval specified 20 (18.0) 47 (31.5)
Not specified 72 (64.9) 66 (44.3)
Total 111 (100.0) 149 (100.0)
Hypothesis testing
One-sided 3 (2.7) 3 (2.0)
Two-sided 11 (9.9) 28 (18.8)
Not specified 97 (87.4) 118 (79.2)
Total 111 (100.0) 149 (100.0)
Planned covariates to adjust for
Yes 68 (61.3) 0
No 9 (8.1) 0
Not clear 3 (2.7) 0
No information available 31 (27.9) 0
Total 111 (100.0) 0
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TABLE 34 Components of the analysis of the primary outcome reported in the protocol/proposal
and monograph (continued )
Description of planned statistical analyses
Planned from protocol/proposal,
n (%)
Reported in the monograph,
n (%)
Analysis population
ITT analysis 60 (55.0) 117 (78.5)
PP analysis 0 3 (2.0)
AT analysis 0 0
ITT and PP analysis 5 (3.6) 14 (9.4)
ITT and AT analysis 0 0
PP and AT analysis 0 0
No available information 46 (41.4) 15 (10.1)
Total 111 (100.0) 149 (100.0)
Adjustment for multiple comparisons
Bonferroni correction 4 (3.6) 8 (5.4)
Bonferroni–Dunn 1 (0.9) 3 (2.0)
Other 2 (1.8) 5 (3.4)
None specified 104 (93.7) 133 (89.3)
Total 111 (100.0) 149 (100.0)
Method of handling missing data
Complete case analysis 3 (2.7) 20 (13.4)
LOCF – single imputation method 4 (3.6) 14 (9.4)
WCI – single imputation method 0 2 (1.3)
HDI – single imputation method 0 1 (0.7)
RM – single imputation method 0 5 (3.4)
Multiple imputation 0 7 (4.7)
Mixed model 3 (2.7) 6 (4.0)
Generalised estimating equation 1 (0.9) 1 (0.7)
Survival analysis 7 (6.3) 11 (7.4)
Mean – single imputation method 1 (0.9) 3 (2.0)
More than one method was used to deal with
missing data
2 (1.8) 8 (5.4)
Sensitivity analysis 7 (6.3) 9 (6.0)
None/no available information 83 (74.8) 62 (41.6)
Total 111 (100.0) 149 (100.0)
ANOVA, analysis of variance; AT, as treated; HDI, hot desk imputation; ITT, intention to treat; LOCF, last observation carried
forward; PP, per protocol; RM, regression methods; WCI, worst-case imputation.
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Question T4.10: is sufficient detail including all of the above seven elements
recorded in the protocol?
The number of protocols meeting all seven criteria was low, at 1.8% (2/111). When we limited the criteria
to three (model/test, significance level and analysis population), of the 111 primary outcomes for which a
method of analysis was specified in the protocol/proposal, 30 primary outcomes qualified (27%, 30/111).
This increased slightly over time, from 22.7% before 1998 to 35.6% after.
Questions T4.11–T4.15: was the analysis planned in the protocol/proposal
for the primary outcome carried out?
Question T4.11: statistical test/model used
Of the 82 trials whose primary outcome was as planned, the authors changed the planned method of
statistical analysis (model/test) in 20 (24.4%). Some changed to more complex methods (t-test changed to
linear regression in five instances) and others to simpler methods (in three, a chi-squared test was carried
out instead of logistic regression, linear regression was used instead of a mixed model and Fisher’s exact
test was used instead of Cox proportional hazards). These could be legitimate changes or selective
reporting depending on the results, something we did not explore (examples are given in Box 7).
Question T4.12: significance level
All but six trials used the 5% significance level. Of the six discrepancies between the significance stated in
the protocol/proposal and that used in the monograph, one led to an increase in the significance level
used but this seems to be an error (trial ID42 stated in the protocol that ‘Differences will be judged
significant at the 2.5% level to take account of two primary comparisons being drawn’; the monograph
stated that 95% confidence intervals would be calculated but a 2.5% significance level was stated in the
sample size calculation in the protocol.
Question T4.13: analysis population
Of those trials that stated the planned analysis population for the primary outcome analysis in the protocol/
proposal, 90% (56/62) followed the plan. Most carried out what they described as an ‘intention-to-treat’
analysis. In two trials, the triallists stated in the protocol/proposal that they would carry out both an
intention-to-treat and per-protocol analysis but reported only on the per-protocol analysis. Both of these
were from trial ID109, where ‘The data were analysed per protocol. As planned, no intention-to-treat
analyses were conducted, as < 10% of subjects would have been classified differently in such an analysis.’
Therefore, this change of analysis population was justified because the authors had specified in the
protocol a rule which was used to decide which population to use.
Question T4.14: missing data
Of the 28 trials for which a method of handling missing data was specified in the protocol, the method
used was different in 12 (42.9%).
BOX 7 Examples of discrepancies between statistical test/model planned in the protocol/proposal and used in
the monograph
1. In three trials (ID131, ID132 and ID133) reported in one monograph, the authors stated in the protocol that
they would analyse the primary outcome score data using logistic regression. They actually analysed the
continuous score data using ordinal regression (which they classified as linear regression).
2. Trial ID65 planned in the proposal to analyse the second primary outcome as follows: ‘Six month follow up
data, relapse rates will be analysed by comparing relapse rates between the groups by survival analysis
using cox’s regression controlling for baseline depression, age, sex and centre.’ They actually compared the
percentage relapsing in each group at the end of treatment using a Fisher’s exact test and yielding a
significant result (p< 0.005).
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Question T4.15: covariates adjusted for in the analysis
Sixty-eight of the 111 trials (61.3%) outlined their planned analysis of covariates and for 31 (27.9%)
it was unclear (Table 35). Some trials did not specify which covariates they would adjust for in the protocol
or, if they did, they failed to specify exactly which covariates would be adjusted for, for example ‘adjusting
for baseline variables’ or ‘taking into account any statistically important imbalances’. This made it difficult
to compare planned covariates with actual covariates adjusted for, in many trials.
In summary, the analyses planned in the proposal/protocol for the primary outcome were carried out in
68 of the 82 trials (76%) and changed in 20 (24%) (considering statistical test/model only). The method of
handling missing data specified in the protocol/proposal did not match what was carried out 43%
of the time. The analysis population and significance level changed 10% of the time in trials. More
detailed examination suggests that some of the changes were legitimate. Without knowing if a statistical
analysis plan was drawn up before the analysis and subsequently followed, one cannot conclude
departures from proper practice.
TABLE 35 Examples of discrepancies between covariates which trials planned to adjust for and those actually
adjusted for as specified in the monograph
Trial ID Covariates which trial planned to adjust for Actual covariates adjusted for
65 Controlling for baseline HRSD, treatment centre, age
and sex. Duration of index depressive episode, degree
of treatment resistance, psychosis, antidepressant
medication equivalents and cognitive impairment
Prerandomisation baseline HRSD scores were included
as a covariate, as were NHS trusts to adjust for centre
effects
59 No information Adjusted for age, sex, surgical status, major presumptive
clinical syndrome, SOFA score at time of randomisation
and APACHE II score at ICU admission
74 Adjusting for group differences at baseline if
necessary
With baseline HADS depression score and stratification
categories (urban/rural location; horizontal/vertical
kinship) as covariates
78 Age, sex, time to treatment and stroke type. Presence
or absence of dysphagia
Time to treatment
86 Individual-level covariates, e.g. age of mother, parity,
and health visitor confounders such as age
After adjusting for covariates such as 6-week EPDS
score, living alone, previous history of PND and any
life events experienced
90 Severity at initial presentation, age and sex None specified
94 Two stratification variables – centre and size of
ulcer – were to be adjusted for in the analyses, as
were ulcer type, duration of episodes, weight of
patient, ankle mobility and a binary variable for the
presence/absence of infection at baseline. Authors
were to present an unadjusted analysis, but the
adjusted analysis would have primacy
A Cox proportional hazards model was used to adjust
the analysis for the randomisation stratification factors
(centre, baseline ulcer area), as well as duration and
ulcer type. Actual baseline area (as measured from the
tracings) and duration of ulcer were used
103 Group, time, group by time, model using a linear
trend over time and a quadratic trend if necessary
(group by time interaction)
Adjusted for baseline HbA1c based on those who
completed their 12-month HbA1c measurement
APACHE II, Acute Physiology and Chronic Health Evaluation II; EPDS, Edinburgh Postnatal Depression Scale; HADS, Hospital
Anxiety and Depression Scale; HbA1c, glycated haemoglobin; HRSD, Hamilton Rating Scale for Depression; ICU, intensive
care unit; PND, postnatal depression; SOFA, Sequential Organ Failure Assessment.
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Questions T4.16–T4.18: how was the sample size estimated
(power, confidence interval, etc.)?
We followed the methods and tables used by Chan et al.,88 expanded to incorporate the different types
of sample size calculation observed in the HTA trials (e.g. width of confidence interval calculations,
time-to-event data, standardised effect size, non-inferiority, equivalence).
Question T4.16: was sufficient information on the sample size
calculation provided?
The results of classifying the trials by the five components suggested by Chan et al.88 are shown in Table 36.
Of the 125 trials, 75 proposals/protocols (60%) and 66 monographs (52.8%) reported all the required
TABLE 36 Reporting of sample size calculation components in the proposal/protocol and monograph
Component of sample size calculation
Number of trials reporting each component (n= 117)a
Protocol, n/N (%) Monograph, n/N (%) Both,b n/N (%)
1. Name of outcome measure 113/117 (96.6) 113/117 (96.6) 111/117 (94.9)
2. Alpha (type 1 error rate) 108/117 (92.3) 109/117 (93.2) 104/117 (88.9)
3. (a) Method of calculation: powerc 113/116 (97.4) 113/116 (97.4) 110/115 (95.7)
Continuous outcome
Minimum clinically important effect size (delta)d and 43/49 (87.8) 46/58 (79.3) 39/47 (83.0)
SD for deltad or 33/49 (67.3) 32/58 (55.2) 29/47 (61.7)
Standardised effect size 12/12 (100.0) 7/7 (100.0) 7/7 (100.0)
Binary outcome
Estimated event rate in each arme 41/53 (77.4) 37/48 (77.1) 36/48 (75.0)
Time-to-event outcome
Time-to-event dataf 2/2 (100.0) 2/2 (100.0) 2/2 (100.0)
Type of outcome not specified
No components for sample size calculation specified N/A 1/1 (100.0) 1/1 (100.0)
3. (b) Method of calculation: width of confidence interval 1/1 (100.0) 1/1 (100.0) 1/1 (100.0)
Binary outcome: event rate in each arm and
precision/width of confidence interval required
1/1 (100.0) 1/1 (100.0) 1/1 (100.0)
Continuous outcome: SD and precision/width of
confidence interval required
0 0 0
4. Calculated sample size
4. (a) Included result from sample size calculation on
number required to recruit
71/117 (60.7) 58/117 (49.6) 53/117 (45.3)
4. (b) Presented total number of participants required to
recruit
116/117 (99.1) 112/117 (95.7) 111/117 (94.9)
5. All components required 75/117 (64.1) 66/117 (56.4) 52/117 (44.4)
N/A, not applicable.
a The figures for both from 3(a) and 3(b) do not add up to 117 because 11 changed the type of primary outcome used
from the protocol to the monograph, so sample size calculations could not be compared (five from binary to continuous,
one from continuous to not specified, one from effect size to continuous).
b Including only trials that reported a sample size calculation in the protocol/proposal.
c Excluding trials that used width of confidence interval to estimate sample size calculation which does not require that
power is specified.
d For trials reporting a sample size calculation with a continuous outcome.
e For trials reporting a sample size calculation using a binary outcome.
f The components required for sample size calculations based on time-to-event data were either proportion in each arm at
particular time point, median survival in each group or median survival in one group and hazard ratio for comparison.
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sample size components. Individual components were reported in 60.7–100% of proposals/protocols and
49.6–100% of monographs. The required sample size was reported in the proposal/protocol in 93% of
trials (116/125), in the monograph in 90% (112/125) and in both in 89%. The result from the sample size
calculation was presented in the proposal/protocol in 57% of trials (111/125), in the monograph in 46%
(58/125) and in both in 42% (e.g. the sample size calculation showed that the trial will have to recruit
326 participants. Taking account of the participant dropout rate, this will increase the number needed per
arm to 350). Forty-two per cent of trials (52/125) reported all the required components of the sample size
calculation in both the proposal/protocol and monograph.
Question T4.17: does the sample size calculation in the protocol match the
sample size calculation shown in the monograph? What discrepancies
were found?
Of the 117 trials reporting a sample size calculation in both the proposal/protocol and the monograph,
we observed discrepancies between that planned and that reported in 45 trials (38.5%). A component
of the sample size calculation was reported in the monograph but not reported in the protocol/proposal
in 18 trials. In 39 trials, there was a discrepancy in at least one component reported in both the
protocol/proposal and the monograph. These discrepancies were not acknowledged in the monograph.
Where a discrepancy was observed between the number of patients, the trial planned to recruit and the
number actually recruited, this was twice as likely to be because the number specified in the monograph
was smaller than that in the protocol/proposal than vice versa (19 trials vs. 10 trials). Where a discrepancy
existed in the minimum clinically important effect size, this was also almost twice as likely to be due to the
effect size being reported as larger in the monograph than in the protocol (Table 37). These discrepancies
could be due to reductions in the planned sample size after the study started which were not reported in
the monograph, or attempts to justify the fewer patients actually recruited.
Question T4.18: what values of alpha, power and dropout were used in the
sample size calculation?
In the proposal/protocol, a 5% significance level was used in the sample size calculation 94.4% of the
time (102/108). Eighty per cent power was specified in half of the protocols (52.2%, 59/113) and 90%
power was specified in over one-third (37.1%, 42/113). The triallists inflated the sample size for participant
loss to follow-up 61.5% of the time (72/122) in the protocol/proposal and 48.3% of the time (58/120) in
the monograph (Table 38).
Question T4.19: other information – what graphical presentation of data
was reported in Health Technology Assessment trials?
We reviewed each HTA monograph and assessed whether it included a repeated measures plot, a
Kaplan–Meier plot or a forest plot, as these were the top reported figures in Pocock et al.95 (accounting for
92% of figures published in the 77 RCT reports that they reviewed in five general medical journals).
A repeated measures plot was presented in the HTA monograph for 38.4% of the trials (48/125),
followed in frequency by a Kaplan–Meier plot (20%, 25/125) and a forest plot (16.8%, 21/125) (Table 39).
A repeated measures plot was observed more frequently in the HTA monographs than in Pocock et al.’s95
sample, and a Kaplan–Meier plot less often. This could be due to differences in the types of trials
reviewed, with HTA trials more likely to involve a longer follow-up at multiple time points and less likely to
include survival outcomes.
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TABLE 37 Discrepancies in sample size calculation information reported in the proposal/protocol and monograph
Component of sample size
calculation
Number of trials reporting each component (n= 117)
Total, n/N Not prespecified,a n Different from protocol description, n
1. Name of outcome measure 18/113 2 16
2. Alpha (type 1 error rate) 7/109 5 2
3. (a) Method of calculation: power 18/113 3 15: nine larger in monograph; six larger in
protocol/proposal
Continuous outcome
Minimum clinically important
effect size (delta) and
19/46 6/46 13: five larger in monograph, three larger
in protocol/proposal and five not
comparable as primary outcomes in
protocol and monograph are different
SD for delta or 5/32 3/32 2: one larger in protocol and one not
comparable as primary outcomes in
protocol and monograph are different
Standardised effect size 1/7 0 1: one larger in protocol
Binary outcome
Estimated event rate in each arm 4/37 1 3: in one values reported were higher in
the monograph and one not comparable
as primary outcomes in protocol and
monograph are different
Time-to-event outcome
Time-to-event data 0/2 0 0
Type of outcome not specified
No components for sample size
calculation specified in
publication
1 0 1: values specified in protocol for
minimum difference aim to detect (delta),
SD for delta, alpha and power
3. (b) Method of calculation: width of
confidence interval
1
Binary outcome: event rate in each
arm and precision/width of
confidence interval required
0/1 0 0
Continuous outcome: SD and
precision/width of confidence
interval required
1/1 0 Not comparable as primary outcome in
protocol and monograph are different
4. Calculated sample size
4. (a) Included result from sample size
calculation on number required to
recruit
20/58 5 15: 10 larger in protocol and five larger in
monograph (note these figures include
six trials where the primary outcome used
for sample size calculation is different in
protocol/proposal and monograph)
4. (b) Presented total number of
participants required to recruit
30/112 1 29: 10 larger in monograph and 19 larger
in protocol/proposal (note this includes
five trials where the primary outcome used
is different so not comparable)
5. Any component 45 18 39
a Reported in the publication but not mentioned in the protocol.
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TABLE 39 Graphical presentation of data in HTA monographs compared with reports reviewed in the study by
Pocock et al.95
Description of data n (%) n (%) from Pocock et al.95
What type of figures was used to illustrate results?
Kaplan–Meier plot 25 (20.0) 32 (41.6)
Repeated measures plot 48 (38.4) 20 (26.0)
Forest plot 21 (16.8) 21 (27.3)
None of the above 31 (24.9) N/A
Total 125 73
N/A, not applicable.
TABLE 38 Sample size calculations reported in the protocol/proposal and monograph
Component of sample size calculation Protocol, n (%) Publication, n (%)
Alpha
5% 102 (94.4) 100 (91.7)
1% 3 (2.8) 3 (2.8)
Other 3 (2.8) 6 (5.5)
Total 108 109
Power
< 80% 1 (0.9) 1 (0.9)
80% 59 (52.2) 63 (55.8)
81–84% 3 (2.7) 1 (0.9)
85% 1 (0.9) 4 (3.5)
86–89% 2 (1.8) 1 (0.9)
90% 42 (37.1) 40 (35.3)
> 90% 5 (4.4) 3 (2.7)
Total 113 113
Did they consider dropout?
Yes 72 (61.5) 58 (48.3)
No 12 (10.3) 27 (22.5)
Not clear 1 (0.8) 0
No information available 37 (31.6) 35 (29.2)
Total 122 120
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Analysis
The planned method of analysis for the primary outcome was not specified in the protocol/proposal in
one-third of the 125 trials. Of those that specified a method of analysis, only two (1.8%) fully specified
the method of analysis using the six core criteria. Twenty-seven per cent met three criteria (statistical test/
model, significance level and analysis population). Improvements occurred over time from 22.7% before
1998 to 35.6% thereafter. There did not appear to be differences in the level of detail reported in
the protocol compared with the proposal, but this could be due to small numbers or confounding
(with the year the commissioning brief was advertised).
Out of the 125 trials reviewed, only 52 (41.6%) reported all the required components of the sample size
calculation in both the proposal/protocol and monograph. Of these, the information in the proposal/
protocol matched the information in the monograph in only 43 trials (34%) (see Tables 36 and 37).
Where discrepancies were observed, they were twice as likely to indicate a smaller sample size planned in
the monograph than stated as planned in the protocol.
Discussion
We were able to extract data to answer a number of questions on the planned and actual method of
statistical analysis and sample size calculation. The degree to which this study was successful varied by the
three broad sets of questions:
l Questions T4.1–T4.10: did the protocol specify the planned method of analysis for the primary
outcome in sufficient detail? The study indicated that this set of questions could be answered and
indicated some cause for concern as around one-third of trials provided insufficient detail, particularly
on planned statistical analysis.
l Questions T4.11–T4.15: was the analysis planned in the proposal/protocol for the primary outcome
carried out? We showed that it was difficult to complete this set of questions owing to lack of data.
l Questions T4.16 and T4.17: was sufficient information on the sample size calculation provided?
And does the sample size calculation in the protocol match the sample size calculation shown in the
monograph? What discrepancies were found? The study showed that it was difficult to complete this
set of questions owing to lack of data.
One general finding from this study relates to the limitation of retrospective analysis. Standards changed
over time. We were unable to discuss details with those responsible for the analyses in the trials. In
particular, we had no way of knowing if statistical analysis plans had been drawn up separately from the
protocol. We understand that such plans are common practice but often not until the trial is close to
completion. The key issue is that such plans are specified in advance before the data are examined.
We have no way of knowing if this happened.
This is the first study we are aware of that has reviewed whether or not the method of statistical analysis
was recorded in sufficient detail in the protocol, as defined by a minimum set of criteria.
Sample size calculation is a vitally important aspect of any clinical trial to ensure that the number of
patients included is large enough to answer the question reliably and as few patients as possible are
exposed to a potentially inferior treatment. It is important that all parameters used in the sample size
calculation(s) are clearly and accurately reported in both the grant proposal/protocol and final trial
publication. The level of detail reported should enable another statistician to replicate the sample size
calculation if necessary. The sample size calculation reported in the final trial protocol and final publication
should match and any changes to the sample size that were made after the trial had started should
be reported.
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We found that sample size calculation information was not being recorded in sufficient detail in both
the protocol and publication for RCTs. Where the information was recorded, the level of unexplained
discrepancies was surprisingly high. Changes to the sample size calculation after a trial has started
are allowed for much the same reasons as listed in relation to changes to the statistical analysis plan
[e.g. advances in knowledge, change in trial design or better understanding of the trial data (SD or control
group event rate)], but should be minimised as much as possible.
We observed fewer discrepancies than other studies with regard to the method of statistical analyses and
whether or not the authors followed the protocol or the sample size calculations. The discrepancies
observed could be legitimate changes not reported in the monograph or could be hiding unacknowledged
reductions in the sample size carried out after the trial started due to recruitment problems (reported in
Chapter 6), or they could be evidence of selective reporting bias indicating the results to be more clinically
meaningful than they were (e.g. by increasing clinically meaningful difference specified) or typographical
mistakes. Of these, given the large number of trials which failed to recruit the original planned sample size
as reported in Chapter 6, we think the most likely explanations are the first two listed above.
Questions T4.11–T4.15 explored potential selective reporting. We found that potential selective reporting
bias in sample size calculation information and in methods of analysis exists. This is perhaps not so serious,
as a previous review of a subset of the RCTs in this cohort found that only 24% of primary outcome
results were statistically significant.5 If there was selective reporting bias we might expect this percentage
to be higher.
Chan et al.88 found that the statistical test for primary outcome measures differed between the protocol
and publication in 60% of trials; we found a smaller percentage in our cohort of 25%. This could be
because we had access to the final version of the protocol whereas Chan et al.88 had access to the
protocol submitted to an ethics committee. In addition, Chan et al.88 studied protocols from the 1994–5
period, before CONSORT had been developed (in 1996). Chan et al.88 observed that 32.6% of protocols
described the planned method of handling missing data, higher than our finding of 25.2%.
Chan et al.88 found that 11 out of 62 trials (17.7%) fully and consistently reported all of the requisite
components of the sample size calculation in both the protocol and publication. The corresponding figure
in our sample was 34%; this is twice as large as in Chan et al.88 but is still much lower than expected.
We found a similar proportion of trials reporting all the required sample size calculation parameters as
Charles et al..90 Charles found that 57% of 206 trials reported all the required sample size calculation
parameters; we found that 56.4% of our trials did so.
The figures in the paper by Hahn et al.89 are similar to ours, although their studies were few and dated.
Strengths and weaknesses of the study
The biggest strength of this study was that we had access to a protocol/proposal for all the trials. This is
the largest cohort study that we are aware of to have compared the method of analysis and sample size
calculation planned in the protocol with that reported in a publication. This is also the first such study of
UK-funded RCTs. Further, previous studies comparing protocols with publications may not reflect current
practice because either the number of trials reviewed was small or the studies reviewed were relatively old
(1994–5 for Chan et al.88 and similar for Hahn et al.89).
A limitation of our work was that we only analysed the first sample size calculation reported and
compared that with the monograph.
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We were surprised at the lack of detail in statistical analysis plans reported in the protocol/proposal and
how few met our criteria. However, as statisticians often create statistical analysis plans separate from the
protocol prior to final analysis, these may well provide more detail.
Key questions for the HTA programme concern whether or not it requires audit of planned analyses
and, if so, how and at what level of detail. Our study shows the limits of retrospective audit based on the
protocol/application form and the monograph. More generally, the HTA programme should consider
requiring information to be recorded on the statistical test/model planned for use in the analysis, the
significance level/confidence interval level to be used and the analysis population.
Recommendations for future work
Should the database be continued, we recommend that the questions on statistical analysis are reviewed
alongside the SPIRIT checklist.94 Any further data extraction should include 13 questions: four should
remain as they are (T4.1, T4.2, T4.18 and T4.19) and nine should be amended (T4.3, T4.4, T4.7, T4.10,
T4.11, T4.12, T4.13, T4.16 and T4.17).
We observed that if trials funded by the HTA programme are to continue to qualify as one of the four
cohorts of trials included in Djulbegovic et al.,96 then data will have to be extracted on the relevant fields.5
Dent and Raftery5 assessed treatment success and whether or not the results were compatible with
equipoise using six categories: (1) statistically significant in favour of the new treatment; (2) statistically
significant in favour of the control treatment; (3) true negative; (4) truly inconclusive; (5) inconclusive in
favour of the new treatment; or (6) inconclusive in favour of the control treatment. Trials were classified by
comparing the 95% confidence interval for the difference in primary outcome with the difference specified
in the sample size calculation. The recent Cochrane Review used data extracted for this project and
combined them with the only three other similar cohorts.96
Unanswered questions and future research
We analysed whether or not the planned analyses were carried out. We did not attempt to investigate
whether or not the planned analyses were appropriate.
We compared individual components of the planned method of analysis with individual components
reported in the monograph but did not calculate how often all of the components of the analysis plan
matched those presented in the monograph. Again, this could be the subject of further work.
Small numbers constrained our analysis of trends in time. If the work continues, time trend analyses should
be repeated and extended.
Further work could explore whether or not the amount of detail provided in the protocol on planned
analyses is affected by the seniority of the statistician involved, including if he/she was a co-applicant.
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Chapter 8 Theme 5: economic analysis alongside
clinical trials
This chapter describes the economic evaluations carried out alongside the clinical trials using availabledata. The questions posed include establishing if an economic evaluation was included and, if so, what
type and whether or not the type planned was the type reported. The usefulness of the BCL for economic
submissions was explored along with more detailed questions regarding particular methods. A final
question considered the relationships between differences in costs and benefits.
Introduction
An economic evaluation considers the costs of providing a health-care intervention relative to its benefits.
It always considers at least two options, for example a new intervention versus standard care. By including
both costs and benefits it addresses issues of efficiency, that is, whether or not the intervention is a good
use of health-care resources. Economic evaluations calculate incremental costs and benefits, that is, the
extra costs and benefits generated by the intervention compared with the comparator.
The results of economic analysis can be shown graphically on the cost-effectiveness plane (Figure 7).97,98
This compares the incremental costs (y-axis) and incremental effects (x-axis) of an intervention with those
of a comparator. The position on the cost-effectiveness plane has implications for decision-making. An
intervention located in the top-left quadrant is less effective and more costly than the comparator, which
should consequently be the preferred option. An intervention that lies in the bottom-right quadrant is
more effective and cheaper and will be preferred. An intervention in the bottom-left quadrant is cheaper
and less effective. If an intervention lies in the top-right quadrant, it is more costly and more effective.
In the last two cases, the question is whether or not the intervention is cost-effective, that is, are extra
benefits gained worth the extra cost (top right) or are cost savings worth the benefits forgone (bottom left).
The dashed line in Figure 7 shows a series of points that all have the same incremental cost-effectiveness
ratio (ICER). If the ICER represented by the dashed line is an accepted value per unit of effectiveness, then
all points on or under this dashed line can be considered cost-effective.
INCREMENTAL COSTS
INCREMENTAL
EFFECTS
Intervention
less effective
and more
costly
Intervention
more effective
and more
costly
Intervention
less effective
and less costly
Intervention
more effective
and less costly
FIGURE 7 Cost-effectiveness acceptability plane.
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Different types of economic analyses, widely described in the literature (e.g. by Drummond et al.99),
are distinguished by the approach that they take to measuring outcomes. Cost–benefit analysis assigns a
monetary value to benefits. Cost–utility analysis (CUA) uses a single utility measure encompassing both
duration of life and quality of life, usually quality-adjusted life-years (QALYs). Cost-effectiveness analysis
uses some ‘natural’ unit of health as the outcome measure, for example life-years saved or cases detected.
Cost-minimisation analysis applies if two interventions have equivalent effectiveness enabling them to be
compared solely on cost. Some studies do not conduct a formal economic analysis but collect data on the
resource implications of interventions. These costing-only studies do not constitute an economic evaluation
but can provide useful information for decision-making.
Economic analyses are widely used in informing health-care decision-making. Examples include the
National Institute for Health and Care Excellence (NICE) (www.nice.org.uk), the Scottish Intercollegiate
Guidelines Network100 and the Australian Pharmaceutical Benefit Scheme.101 A cost–utility study
(cost/QALY) is favoured by NICE as it can be generalised across a range of health-care settings and
interventions.102 However, NICE also considers other factors before reaching a decision.103,104
Little has been published on the extent and types of economic evaluations included in trials funded by the
HTA programme. Further, as with statistical analyses, the intended and reported economic evaluations may
differ. For example, if the health-related quality of life measure was poorly completed, a cost–utility study
may not have been feasible. Alternatively, if the investigators found no difference in clinical outcomes they
might not have pursued the economic evaluation. It is not clear how often such changes occurred, or for
what reasons.105,106
A 2006 study107 showed that, since 1994, approximately 30% of the economic evaluations included in the
NHS Economic Evaluation Database have used data obtained from a single RCT. It is likely that more trials
include economics. A review by Barber and Thompson108 found that although 45 studies published in
1995 reported patient-level cost data, only half provided results on the comparison of costs between the
interventions. A later, similar review found 115 studies using patient-level data in 2003.109
Advantages of designing economic analyses alongside clinical trials were highlighted by O’Sullivan et al.110
First, the economic analysis benefits from the elements of trial design, such as blinding and randomisation,
which reduce the potential for bias. Second, trials provide an opportunity to collect patient-level data on
costs and outcomes. Third, the evaluation alongside the trial is likely to be less costly than funding a
stand-alone economic evaluation.
Attention has also been drawn to problems associated with carrying out economic analyses alongside
clinical trials,107,110 notably by Sculpher et al.107 Few trials directly compare all relevant options. The
maximum follow-up in the trial is often shorter than the appropriate time frame for an economic analysis.
The trial setting may not be relevant to the decision being made, for instance if a trial is run in a different
country or health-care setting where costs are likely to be different. Finally, trials are unlikely to use all
available evidence, such as the results of other trials and epidemiological data. For these reasons, the
authors suggested that the role of trials should be to provide a means for the collection of relevant
economic data. Conversely, it has been argued that although problems exist, many of these can be
addressed with careful design. A role remains for economic analyses alongside trials:
In sum, when the various challenges posed by piggyback evaluations are acknowledged and addressed
with rigor, clinical trials can indeed be an efficient and appropriate means through which to measure
the economic impact of medical interventions.
O’Sullivan et al., p. 77110
A successful economic evaluation alongside a clinical trial requires close collaboration between health
economists and clinical researchers at all stages of the design and implementation process.105,111 Since it
began, the HTA programme has funded economic evaluations alongside most trials. This has helped to
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ensure that health economists are involved in the trial design phase, contributions are properly planned
and resourced, and trial processes are designed to include relevant health economics components.
There is no established ‘gold standard’ of what constitutes a good economic study. Different organisations
have produced a range of guidelines on methods. This has led to a number of checklists for economic
evaluations, including the BCL of economic quality,12 the Consensus Health Economic Criteria112 Quality of
Health Economic Studies113 and the Drummond checklist.114 Of these, the BCL12 is widely used, not least as
it is intended to be accessible to non-economists. Published in 1996, it was the most likely to be used.
The conclusions of the clinical study and the economic study can differ. The measure of interest in the
economic evaluation, the ICER is a composite of two variables (cost and health economics outcome), and
hence this may differ from the results based on clinical outcomes alone. Further, the outcome measure
used in the economic analysis (e.g. QALY) is unlikely to be the primary outcome measure used in the trial.
Trials are likely to be powered on the clinical primary outcome measure, so the economic evaluation may
not be powered to show differences. Finally, the statistical methods differ, with clinical trials generally
being assessed on the basis of statistical significance and economic evaluations on the probability that an
intervention is cost-effective. We do not know how often the clinical and economic results differ, what
factors this is associated with and what to do if this occurs. An examination of the congruence between
clinical and economic results in the HTA programme would help to answer some of these questions.
Questions addressed
The questions for which data were extracted are listed in Box 8.
BOX 8 The research questions answered under this theme
T5.1. What is the methodological quality of HTA economic evaluations and do they adhere to good practice
guidelines for economic analysis (BCL12)?
What, if any, type of economic evaluation was included at the planning and at the reporting stages?
T5.2. Was an economic analysis performed?
T5.3. What type of economic analysis was reported at each stage?
T5.4. Did the planned economic evaluation match the actual evaluation?
Is the extraction of metadata on a small number of study characteristics useful in describing the HTA
programme of economic analyses?
T5.5. Perspective.
T5.6. Cost year.
T5.7. Data analysis and interpretation (bootstrapping and CEAC).
T5.8. Missing data.
T5.9. Utility measure.
T5.10. QALYs.
T5.11. Reporting and interpreting the ICER.
T5.12. Can the economic results be usefully shown on the cost-effectiveness plane?
CEAC, cost-effectiveness acceptability curve.
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Methods
Twelve questions were piloted as shown in Box 8. A question posed in the bid for this theme asked if the
clinical and economic results agreed. We approached this by locating the results of trials on the
cost-effectiveness plane.
To answer the questions set out in Box 8, data were extracted from the 109 published monographs, with
the exception of the planned economic analyses, which were taken from the project protocol or, if
necessary, the final application bid. For the question concerned with the cost-effectiveness plane, data
were extracted by DT and checked by AY.
Quality assurance of the question regarding the BCL involved two states: identification of questions
requiring judgements and review of these by a health economist (DT).
Denominators
Two different denominators were used: trials and comparisons. Questions relating to the conduct of the
economic evaluation focused on eligible trials, whereas those relating to the cost-effectiveness plane
looked at comparisons. Of the 125 trials, 117 (93.6%) were eligible, eight were excluded, five trials did not
include an economic analysis (trials ID2, ID63, ID97, ID109 and ID112), two trials closed owing to poor
recruitment (trials ID75 and ID110) and one trial reported the cost data poorly (trial ID62).
For the cost-effectiveness plane, 95 trials were included, with others excluded owing to lack of sufficient
detail on both costs and clinical outcomes. Of the 95 trials included, 70 trials reported one comparison,
16 trials reported two comparisons, seven trials reported three comparisons and two trials reported
four comparisons, yielding 131 comparisons.
Operationalising the BCL12 (Table 40) led to omitting one question, with regard to the congruence
between clinical and economic conclusions.
Analysis of a summary of the clinical and economic conclusions showed that results were often presented
in an arbitrary and incomplete way. We omitted three items from the BCL as uninformative: number 8,
‘the sources of effectiveness estimates used are stated’; number 9, ‘details of the design and results
of effectiveness study are given’; and number 10, ‘details of the method of synthesis or meta-analysis of
estimates are given (if based on an overview of a number of effectiveness studies)’.12 This was because all
our studies were randomised trials.
The remaining BCL questions were completed with a four-item checklist: ‘yes’, ‘no’, ‘NA [not applicable]’
or ‘not clear’. To compare the quality of different studies we compiled a numerical index of quality
{[yes/(yes+ no+ cannot tell)] × 100}. A study with a score of 100 met all relevant criteria; a study with a
score of 0 met none.
Data were extracted on costs, primary outcome and QALYs including point estimates of differences and
statistical significance. Each comparison was located on two cost-effectiveness planes, one using the
primary outcome, the other using QALYs, using the framework in Figure 8. Although this enables
comparisons to be placed on the plane, it does not enable a distinction to be made between two
comparisons placed in the same box (see Figure 8). Ranking comparisons within any one box would
require ICERs for both comparisons. Furthermore, where the effectiveness measure differs between two
ICERs, ranking would also require a valuation of both these effectiveness measures.
THEME 5: ECONOMIC ANALYSIS ALONGSIDE CLINICAL TRIALS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
TABLE 40 BMJ guidelines for authors and peer reviewers of economic submissions12
Checklist number Description
Study design
1 The research question is stated
2 The economic importance of the research question is stated
3 The viewpoint(s) of the analysis are clearly stated and justified
4 The rationale for choosing the alternative programmes or interventions compared is stated
5 The alternatives being compared are clearly described
6 The form of economic evaluation used is stated
7 The choice of form of economic evaluation is justified in relation to the questions addressed
Data collection
11 The primary outcome measure(s) for the economic evaluation are clearly stated
12 Methods to value health states and other benefits are stated
13 Details of the subjects from whom valuations were obtained are given
14 Productivity changes (if included) are reported separately
15 The relevance of productivity changes to the study question is discussed
16 Quantities of resources are reported separately from their costs
17 Methods for the estimation of quantities and unit costs are described
18 Currency and price data are recorded
19 Details of currency of price adjustments for inflation or currency conversion are given
20 Details of any model used are given
21 Choice of model used and the key parameters on which it was based are justified
Analysis and interpretation of results
22 Time horizon of costs and benefits is stated
23 The discount rate(s) is stated
24 The choice of rate(s) is justified
25 An explanation is given if the costs and benefits are not discounted
26 Details of statistical tests and confidence intervals are given for stochastic data
27 The approach to sensitivity is given
28 The choice of variables for sensitivity analysis is justified
29 The ranges over which the variables were varied are stated
30 Relevant alternatives are compared
31 Incremental analysis is reported
32 Major outcomes are presented in a disaggregated as well as aggregated form
33 The answer to the study question is given
34 Conclusions follow from the data reported
35 Conclusions are accompanied by the appropriate caveats
Reproduced with permission from Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic
submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83.12
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Results
Question T5.1: what is the methodological quality of Health Technology
Assessment economic evaluations and do they adhere to good practice
guidelines for economic analysis (BMJ checklist)?
Out of the 117 trials reporting an economic analysis in the published monograph, seven (6%) met/adhered
to all relevant checklist items (n= 32) in the BMJ guidelines for reporting an economic analysis.12 The
interquartile range was 8 and the mean quality score was 84. The majority of trials (76%, 89/117)
reported a quality score of more than 80; few trials (4%, 5/117) reported a score of less than 49.
Figure 9 shows results for the BCL for each of the 32 questions assessed here. The figure shows how many of
the 117 trials were categorised as ‘yes’, ‘no’ or ‘unclear’ for each of the BCL questions. For the majority of
categories, the HTA trials had a high degree of reporting completeness (i.e. most questions had a high number
of ‘yes’ responses). Exceptions were in relation to the discussion of the relevance of productivity changes
(discussed in around one-third of studies), details of price adjustments for inflation or currency conversions
(only discussed in approximately 40%) and reporting of discounting (included in around two-thirds).
Questions T5.2–T5.4: what, if any, type of economic evaluation was included
at the planning stage and at the reporting stage?
Question T5.2: was an economic analysis performed?
One hundred and seventeen of the 125 trials (93.6%) reported results of an economic analysis alongside
the clinical trial. Five trials did not include an economic analysis, two were closed due to poor recruitment
and the cost data were poorly reported in one.
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FIGURE 8 Framework for locating results from HTA-funded clinical trials on to cost-effectiveness planes.
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Question T5.3: what type of economic analysis was reported at each stage?
The types of analysis planned and carried out are given in Table 41. Cost–utility and cost-effectiveness
studies were planned in 70% of trials (82/117). Thirteen per cent contained insufficient information to
determine study type. In some cases this arose because the type of analysis planned was stated in advance
to depend on the results found. For example, a number of trials stated that a CUA would be performed
depending on the outcomes.
Three trials (ID75, ID97 and ID110) did not report that an economic evaluation had been planned.
Sixty trials (51.3%, 60/117) reported a CUA. Fewer (27.4%, 32/117) conducted a cost-effectiveness
analysis than planned. Cost–benefit analysis was rare, with only one reported. Out of the 117 trials
reported to have an economic analysis, 104 trials were superiority (88.9%), nine were equivalence (7.7%)
and four were non-inferiority (3.4%).
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FIGURE 9 Overall BCL quality score for trials involving an economic analysis (n= 117).
TABLE 41 Study characteristics and type of economic analysis of trials including an economic evaluation
Type of economic analysis Planned type, n (%) Reported type, n (%)
CUA 45 (38.5) 60 (51.3)
Cost-effectiveness analysis 37 (31.6) 32 (27.4)
Cost–benefit analysis 10 (8.5) 1 (0.9)
Cost minimisation analysis 3 (2.6) 8 (6.8)
Costing only 7 (6.0) 15 (12.8)
Unclear 15 (12.9) 1 (0.9)
Total 117 117
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The type of economic evaluation actually performed is given in Table 42, broken down by publication year.
No CUAs were reported for 1999–2002, after which the proportion of these rose to around 60%.
Question T5.4: did the planned economic evaluation match the
actual evaluation?
Sixty-two trials had a discrepancy between the planned and reported type of economic analysis. Of the
15 trials where evaluation type was unclear at the planning stage, only one did not report some form of
economic study. Some analyses shifted from cost-effectiveness to cost–utility. Of the 37 trials that planned
a cost-effectiveness study, 15 (41%) reported a cost–utility study. Planned economic analysis was a poor
predictor of the type of economic analysis carried out.
Questions T5.5–T5.11: is the extraction of metadata on a small number of
study characteristics useful in describing the Health Technology Assessment
programme of economic analyses?
Question T5.5: perspective
Of the 117 trials that conducted an economic analysis, 46 (39.3%) took a societal perspective, 42 (35.9%)
a NHS-only perspective and 22 (18.8%) a NHS and social services perspective, with the remainder
categorised as ‘other’ (2.6%, 3/117) or no perspective reported (3.4%, 4/117). Analysis of perspective over
time showed no clear patterns.
Question T5.6: cost year
Data on the year that cost was incurred (needed to adjust for inflation) was well reported.
Question T5.7: data analysis and interpretation (bootstrapping and
cost-effectiveness acceptability curve)
Eighty-one (69.2%) of the 117 trials reported using bootstrapping in the economic analysis and 62 (53%)
presented cost-effectiveness acceptability curves (CEACs) in the reporting of the economic analysis. Over
time, the reporting of CEACs became more prominent. From 2004 onwards, more than half of HTA
clinical trials published presented CEACs in the reporting of the economic analysis. This increased to over
70% of published HTA clinical trials in 2009 (13/18).
Question T5.8: missing data
Almost one-third of trials (31.6%, 37/117) did not report methods for handling missing data and 19 (16.2%)
did not provide sufficient information to determine whether or not they considered missing data. The
remaining 61 trials (52.1%) reported how missing data were handled during the economic analysis, including
multiple imputation (23%, 14/61) and complete case analysis (only including cases with complete data in the
analysis) (18%, 11/61). Thirteen trials (21.3%) reported more than one method for handling missing data.
TABLE 42 Actual type of economic analyses by year of monograph publication
Utility measure
Time period (monograph publication date)
Total, N (%)1999–2002, n (%) 2003–5, n (%) 2006–8, n (%) 2009–11, n (%)
CUA 0 20 (57.1) 21 (63.7) 19 (57.5) 60 (51.7)
Cost-effectiveness analysis 7 (46.7) 5 (14.3) 10 (30.3) 10 (30.3) 32 (27.6)
Cost–benefit analysis 0 0 1 (3.0) 0 1 (0.9)
Cost minimisation analysis 2 (13.3) 4 (11.5) 0 2 (6.1) 8 (6.9)
Cost only 6 (40.0) 6 (17.1) 1 (3.0) 2 (6.1) 15 (12.9)
Total 15 (100.0) 35 (100.0) 33 (100.0) 33 (100.0) 116 (100.0)
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Question T5.9: utility measure
Seventy-seven trials reported the utility measure and, of these, 16 reported using two utility measures,
with 93 responses from these 77 trials (Table 43).
The European Quality of Life-5 Dimensions (EQ-5D) was by far the most common utility measure, used in
60 trials. Thirty trials used the Short Form questionnaire-6 Dimensions (SF-6D), the majority of which
were derived from the Short Form questionnaire-36 items (SF-36) instrument and not the Short Form
questionnaire-12 items (SF-12). No trials used direct elicitation methods (standard gamble or time
trade-off). Where the EQ-5D was used as the primary instrument, it tended to be used on its own, with
only one study reporting the use of the SF-6D. Ten studies using the SF-6D as the primary measure also
used the EQ-5D. Two out of the three studies using the Health Utilities Index – Mark 3 (HUI3) also used
the EQ-5D. The EQ-5D was often used secondary to non-EQ-5D measures, raising a question of
possible redundancy.
Question T5.10: quality-adjusted life-years
More than half of the trials (56.4%, 66/117) reported an incremental QALY difference and of these
66 trials, 60 (90.9%) specified the QALY time frame, which ranged from 5 days to lifetime. The most
common time frames were 12 months (28.8%, 19/66) and 24 months (15.2%, 10/66).
Question T5.11: reporting and interpreting the incremental
cost-effectiveness ratio
Ninety-five of the 117 trials reported an incremental analysis in the published monograph (BCL item
number 32). Additional data were extracted on the two interventions being compared and the within-trial
estimate of the ICER for each comparison was reported.
Seventy trials named the two interventions being compared. Twenty-five trials reported more than one
comparison, leading to 131 cost-effectiveness comparisons.
TABLE 43 Utility measure over timea
Utility measure
Time period (monograph publication date)
Total1999–2002 2003–5 2006–8 2009–11
EQ-5D 4 17 20 19 60
SF-6D (SF-36) 3 8 7 8 26
SF-6D (SF-12) 0 3 0 1 4
HUI3 0 0 1 2 3
Total number of utility measures 7 28 28 30 93
Total number of trials 6 24 23 24 77
EQ-5D, European Quality of Life-5 Dimensions; HUI3, Health Utilities Index – Mark 3; SF-6D, Short Form questionnaire-6
Dimensions; SF-12, Short Form questionnaire-12 items; SF-36, Short Form questionnaire-36 items.
a Merged data using multiple response groups.
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Question T5.12: can the economic results be usefully shown on the
cost-effectiveness plane?
The results for clinical outcomes and cost are shown in Figure 10. A similar framework has previously
been used by Briggs and O’Brien.115 Most comparisons fell into the centre box (66/131 comparisons),
that is neither costs nor effects were significantly different. Twenty comparisons fell in the top-middle box,
with statistically significant differences in outcomes but statistically significantly more expensive.
Sixteen fell in the middle-right box, with statistically significant improvements in effectiveness but not in
costs. Comparisons in the top-right box showed statistically significant differences in both effectiveness
and costs. Only four comparisons showed an unambiguous preference for one of the comparators, that is
comparisons that fell in either the top-left (one comparison) or the bottom-right (three comparisons) boxes.
Forty comparisons showed a statistically significant increase in costs between intervention and comparator,
but only five showed a statistically significant decrease in costs. Comparisons were concentrated towards
the top right of the cost-effectiveness plane. Many interventions were likely to be both more effective and
more costly than comparators, even if many of these differences may be small and non-significant. The
appropriate use of frequentist and Bayesian approaches might usefully be clarified by the HTA programme.
A similar approach was taken to the 65 comparisons of incremental cost per QALY. Table 44 classifies
studies into the boxes shown in Figure 10, dividing comparisons by ICER into those with a cost per QALY
greater or less than £30,000 (the upper NICE threshold).102 Table 44 also indicates whether the intervention
dominates or was dominated by the comparator and when the intervention is cheaper but less effective.
The three boxes on the right of Figure 10 are of particular interest as they indicate statistically significant
improvements in outcome. We wanted to see whether or not the economic studies reached the
same conclusions.
The top right box of Figure 10 had 20 comparisons with statistically significant differences for both costs
and effects (line 5 in Table 44). Of these 20 comparisons, nine had cost–utility data. Seven comparisons
showed ICERs less than £30,000 per QALY (trials ID29, ID77, ID107, ID31, ID39, ID69 and ID99) and two
studies (ID103 and ID106) showed higher ICERs. One comparison (trial ID103) compared motivational
enhancement therapy and CBT with usual care in diabetes. This found the cost per QALY at 12 months to
be £312,000. However, as this study showed a reduction in glycated haemoglobin at 12 months, it is
possible that a longer-term study may have shown a lower ICER. A second study (trial ID106) compared
conventional ventilator support with extracorporeal membrane oxygenation for severe adult respiratory
failure. This trial found an extremely high ICER of over £1.6M per QALY at 6 months but a long-term
model showed an ICER of less than £20,000 per QALY.
1 20 20
3 66 16
INCREMENTAL
EFFECTS
1 1 3
INCREMENTAL COSTS
FIGURE 10 Results of trial comparisons: incremental costs and effects (n= 131 comparisons).
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The majority of economic analyses presented here support and reinforce the clinical conclusions, that is
not only is there evidence that these interventions may be effective, there is also evidence that they may
represent reasonable value for money, that is ICERs of less than £30,000 per QALY.
The second line in Table 44 shows 16 studies with no statistically significant difference in costs but in
which the clinical study indicated a statistically significant difference. Cost-per-QALY results for seven of
these comparisons indicated that for four out of seven comparisons (trials ID28, ID78, ID86 and ID90) the
intervention dominated the control. In two comparisons (trials ID125 and ID23) the intervention generated
QALYs at less than £30,000 per QALY. One study (trial ID17) showed non-significant reductions in
estimated QALYs and so the point estimate for the cost–utility study lay in the south-west quadrant.
As in the last example, the health economic results reinforce the clinical ones.
The most common category in Figure 10 (see Table 44) was the central box composed of those comparisons
where neither cost nor outcomes of interventions were statistically significantly different from comparators.
Sixty-six comparisons fell into this category. Of these, 29 also involved a cost–utility study. The CUA in
16 of these studies indicated that the intervention would not be cost-effective; of these, seven showed the
intervention to be dominated and nine showed ICERs greater than £30,000 per QALY. For one-third of
cost–utility studies (34.5%, 10/29), the ICER indicated that the intervention could be cost-effective even
though neither cost nor clinical outcome was statistically significantly different. For studies falling into this
category, the health economic component adds useful information. Not only was this the most common
category, it is also one where one-third of the cost–utility studies were contradicting (to some extent) the
clinical results. That is, these were cases where the clinical study had not shown a statistically significant
difference and yet the cost–utility study was indicating that these were potentially cost-effective. This is
because CUA can be based on differences that were not statistically significant.
The fourth line in Table 44 shows studies that were statistically significantly more expensive but also not
statistically significantly more clinically effective. A priori, we would expect these to have a low probability
of being cost-effective and 10 out of 13 showed CUA results that indicate either that the intervention was
dominated or that it generated QALYs at greater than £30,000 per QALY. However, even in this case,
there were three comparisons where the cost per QALY indicated potential cost-effectiveness (trials ID50,
ID71 and ID115).
Analysis
Although the BCL12 was easy to use, many questions required some skills in health economics. It was not
satisfactory as a test of methodological quality for a number of reasons. For instance, it indicated whether
or not something was done rather than whether or not it was done well. Take, for example, BCL item 17:
‘Methods for the estimation of the quantities and unit costs are described’.12 A ‘yes’ response is obtained if
the methods are described. However, this does not access the underlying strength of the methodology,
i.e. whether resource use was taken from patient self-report or notes, how outliers were handled, whether
or not the methods of costing were robust, etc.
For the BCL to be used as a measure of quality, it would need to be completed by a health economist to
assess whether or not issues were addressed well, rather than whether or not they were addressed at all.
A better way to quality assure economic evaluations might be through the current peer review process.
HTA trials are assessed by peer review at the proposal stage by external health economic peer reviewers as
well as health economists on HTA funding boards. They are also peer reviewed as part of the monograph
publication process. Either a checklist tool for health economics could be incorporated into this process,
or referees could be asked to complete a more structured report.
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Out of the 125 trials considered in this chapter, 117 (94%) included an economic evaluation or a costing
study. Reasons for not including health economics included the trial being stopped or having an
equivalence or non-inferiority design. Cost-per-QALY analysis was used in almost 60% of HTA trials
after 2002. The type of economic evaluation planned and that reported sometimes differed, usually due
to a switch from cost-effectiveness to cost–utility. The proportion of economic evaluations that were
cost–utility studies was constant over time (after 1999–2002).
Putting the results of trial comparisons on the cost-effectiveness plane was more successful when
using clinical outcomes than QALY outcomes. Most results were located in the top right quadrant
(more effective, more costly), the section where health economics is most needed. These results are not
useful in evaluating the results of one comparison against another, as it is not possible to make
comparisons between them. For making comparisons between different trials and comparisons, the
cost–utility approach is required. We were able to carry this out for 66 out of 131 comparisons (50.4%),
roughly the proportion that might be expected given that about 60% of trials perform CUA. The results
indicated that some interventions which failed to show differences that were statistically significant could
be cost-effective within a Bayesian perspective. However, more robust results would require meta-analytic
data rather than those from a single trial.
Discussion
Although we were able to apply the BCL, we query its value as it is a check of reporting completeness
rather than methodological quality. It is questionable if the information obtained would be worth the
effort required to extract it in future. If a formal assessment of the quality of any economic analysis
is required, then the HTA programme should investigate whether or not this is achievable as part of the
existing peer review process.
Only around 40% of HTA trials took a societal perspective. It is possible that important cost issues are
being missed in some trials but we did not explore the reasons given for the perspective adopted.
Advanced analytic techniques such as bootstrapping and CEACs are widely and increasingly used in HTA
trials. However, the issue of missing data is not handled well in most. The EQ-5D was the most widely
used utility measure in HTA trials. Most studies used it as the sole preference-based utility measure. When
other utility measures were used, it was usually in combination with the EQ-5D. Most studies calculated
QALYs, although the time frame varied greatly between studies.
This study demonstrated that study characteristics, such as perspective, can be successfully extracted by
a non-health economist. These are potentially a check on quality. We suggest that any future database
should continue to extract information on the characteristics of economic evaluations.
We showed that data could be extracted on incremental costs and clinical outcomes for the majority of
trials (see Question T5.12: can the economic results be usefully shown on the cost-effectiveness plane?)
and inserted on to a cost-effectiveness plane. This could be done for 131 clinical outcomes, with around
half of these also having cost-per-QALY estimates. This enabled identification of cases where economic
and clinical studies agreed or disagreed. It would be feasible to collect simple data on results of both
clinical and economic studies in future. We recommend that simple data on results be collected and used
in any ongoing work.
Strengths and weaknesses of the study
Weaknesses included the use of a cohort funded over a long period of time, which may not be
representative, and an inability to probe much beyond the BCL in relation to how well particular aspects
were performed. Strengths included access to planned and actual analyses, and a large cohort.
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Other studies have attempted to quality assess some parts of the economic analysis component of the
HTA programme of trials,8 but only in relation to resource data collection, albeit in more detail than we
have attempted.
Others have classified the results of the programme of HTA-funded clinical trials. Dent and Raftery5
compared 85 comparisons from 51 superiority studies from the HTA programme based around the
confidence interval and included six different categories. This was a more sophisticated classification than
the one used here although the current work covers more comparisons. The aim of the current approach
was limited to placing results on the cost-effectiveness plane rather than analysing the pattern of HTA
programme clinical results.
This study has shown the high importance placed on economic evaluations and costing alongside trials
funded by the HTA programme. Almost all planned and reported on an economic analysis. Most were well
reported according to the BMJ economic analysis checklist.12 The current work supports the HTA policy of
funding economic analyses alongside clinical trials. Many of the interventions evaluated in HTA trials
occurred in the top right corner of the cost-effectiveness plane, i.e. they were more effective and more
costly than comparators.
The current work also emphasises the importance of incorporating a cost–utility study alongside the
economic evaluation. Just over 51% of trials reported a cost-per-QALY analysis. This slightly improved with
later studies, but even for the period 2006–11 only around 60% of published monographs featured a CUA.
Although there may be good reasons why some trials do not carry out CUA, we favour as many studies as
possible doing so.
Recommendations for future work
Should the database be continued, we recommend that data should be extracted for 10 questions, nine
unchanged (T5.2, T5.3, T5.4, T5.6, T5.7, T5.9, T5.10, T5.11 and T5.12) and one to be amended (T5.5).
Unanswered questions and future research
If economic evaluations are included as part of any future database, methodological quality should be
considered, perhaps linked to the current refereeing process rather than a quality checklist. Data on
planned and actual economic analyses should also be retained for the database and expanded where
required (planned and actual perspective). Data on key methodological issues should be collected.
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Chapter 9 Theme 6: the cost of randomised trials,
trends and determinants
This chapter considers questions regarding the costs of RCTs funded by the HTA programme. After abrief review of the relevant literature and guidance on costing, it explores questions that might be
answered using available data. It distinguishes the roles of different types of costs, particularly ‘NHS
support costs’ and ‘NHS excess treatment costs’. Actual and planned costs are compared. The trend in
costs over time is graphed and multivariate analysis used to identify factors associated with differences in
projects’ costs.
Introduction
The sparse literature on the costs of clinical trials focuses mainly on the cost to the pharmaceutical industry
of bringing a drug to market. A series of studies by DiMasi et al.116,117 have used data supplied by
pharmaceutical companies, putting the drug-to-market cost at $800M in 2000. An update put the figure
at $1.2B.118 This approach has been strongly criticised by Light and Warburton,119 who query the many
assumptions involved. About half of the total cost estimate was due to the cost of clinical trials.
A literature search focused on the costs of clinical trials located 15 studies, only two of which concerned
UK trials. One was a case study of a lung cancer trial in 84 centres which was delayed by major differences
in approach in different centres, but did not explicitly address costs.120 The other was a case study of the
NIHR-funded Support and Assessment for Fall Emergency Referrals121 trial, evaluating different protocols
for response to 999 calls involving falls by elderly persons. Factors which delayed the trial were outlined,
leading to the recommendation that the NIHR be given sole responsibility for allocating research, excess
treatment and service support costs. A qualitative study indicated the complexity imposed by the UK
system of separately funding research, NHS support and treatment costs. This required the trial team to
negotiate with multiple funders. The divisions were ‘somewhat malleable and the funding system was
used differently in each trial.’122 Research governance has been blamed for delays leading to increased
costs of trials.123
An example from the USA shows that these complexities are not confined to the UK. The Comparison
of Age-related Macular Degeneration Treatments Trial (CATT), funded by NIH, was delayed because of
funding issues.124,125 It is generally accepted that costs which would have been incurred in the absence
of the trial should not be set against the cost of the trial. The most obvious such cost is that of treatment
that would have been provided in the absence of the trial. The comparisons in CATT were between two
similar drugs, bevacizumab (Avastin®, Roche) and ranibizumab (Lucentis®, Novartis), for age-related
macular degeneration. As ranibizumab, unlike bevacizumab, was licensed for the condition, it was deemed
the standard treatment, that is, the treatment that would have been provided in the absence of the trial.
However, CATT was delayed for a year because of difficulties in getting the Center for Medical Services,
which funds Medicare, to agree that the cost of ranibizumab in CATT should be seen as standard
treatment and funded accordingly. Although CATT and a similar UK trial, Inhibit VEGF in Age-related
choroidal Neovascularisation (IVAN), may be extreme examples (costly drugs in head-to-head trials), they
illustrate both the principle of excluding the costs of normal treatment from those of trials and the
difficulty of applying that principle in practice.124,126
In both CATT and IVAN trials, the cost of both drugs had to be funded before the trials could proceed.
Although companies often donate drugs free for use in trials, this did not apply in these examples as the
relevant companies did not wish to support the trials.
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The principle that costs which would have been incurred in the absence of the trial should not be
attributed to the trial was formally stated in the UK in 1997 NHS guidance, Attributing Revenue Costs of
Externally Funded Non-commercial Research in the NHS (ARCO),13 and reiterated in Attributing the
Cost of Health and Social Care Research and Development (AcoRD) in 2012.127 These distinguished research
costs (costs arising from the research) from treatment costs (those costs that would have been incurred in
the absence of the trial) and excess treatment costs (defined as those additional costs due to the trial).
In the CATT/IVAN example, ranibizumab would be a treatment cost (as it would be used in the absence of
the trial) and bevacizumab would be an excess treatment cost (as it was only used because of the trial).
The ARCO/AcoRD13,127 cost categories are defined in Table 45. Although the distinction between research
and treatment costs is universal, the subdivision of research costs into those directly incurred by research
and those arising from its support appears to be unique to England, and can be explained by how
research funding has evolved there. Research costs relate to the costs of the research itself, such as data
collection and analysis. NHS support costs cover extra patient tests and stays, as well as recruitment. These
also include costs concerned with governance, obtaining consent and any additional clinic visits. Support
costs since 2006 are met by the NIHR Clinical Research Network.
TABLE 45 Attributing revenue costs of externally funded non-commercial research in the NHS definitions of
research, support and treatment costs, and funder in commercial and non-commercial trials13
Type of cost Definitiona Examples
Funder in
non-commercial
trials
Research cost The costs of the R&D itself Costs of data collection, analysis and
other activities. Often include pay and
indirect costs of staff employed to
carry out the R&D, registration of
trials and publication costs
NIHR research
funder
Support cost Additional patient-related costs associated
with the research, which would end once
the R&D activity in question had stopped
Might cover extra patient tests, extra
inpatient days and extra nursing
attention. Might also include costs of
informed consent, managing and
undertaking a portfolio of projects
and research-active professionals
employed in the NHS
NIHR Clinical
Research Network
Treatment
cost
Patient care costs which would continue
to be incurred if the patient care service in
question continued to be provided after
the R&D activity had stopped
Cover all types of patient care
services, including diagnostic,
preventative, continuing care and
rehabilitative care services and health
promotion
NHS
Excess
treatment
costs
Where patient care is provided that is
either an experimental treatment or in a
different location from normal, and differs
from the normal, standard treatment for
that condition, the difference between
the total treatment costs and the costs of
the standard treatment (if any) is called
excess treatment costs. These costs are
part of the treatment costs
Might include the cost of a new
treatment
PCTs to 2013,
Clinical
Commissioning
Group from 2013
a All definitions reproduced from Department of Health. Attributing revenue costs of externally-funded non-commercial
research in the NHS (ARCO). London: Department of Health; 2005.13 © Crown copyright 2005. Contains public sector
information licensed under the Open Government Licence v3.0 (www.nationalarchives.gov.uk/doc/open-government-
licence/version/3).
Note
The PCT was responsible for funding both treatment and excess treatment costs. See also AcoRD,127 which restates ARCO.
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The ARCO/AcoRD guidance means that the HTA programme should fund only direct research costs,
leaving support costs to be met by the NHS, mainly the hospitals or other NHS organisations within which
the research occurred. The rationale for this was that a large part of the NHS R&D budget has historically
been held by NHS trusts for research support activities. Since 1996, these have gone under various titles
(Culyer, Budget 2, Support for Science).128 Following the establishment of NIHR in 2006, these costs were
to be met by the new NIHR Clinical Research Network.
The definition of excess treatment costs set out by ARCO13 meant that these had to be met by local
NHS funders, various health authorities (until their abolition in 1998), PCTs (until their abolition in 2013)
and Clinical Commissioning Groups from 2013. Excess treatment costs, according to ARCO, had to be met
by the NHS (although given that these were extra costs resulting from research, the rationale for having
the NHS meet them was unclear). In those instances where the excess treatment costs were lower than
those of the intervention it was being compared with (i.e. the control), this might not pose a problem as
the trial would reduce costs. However, problems might well arise if excess treatment costs exceeded
treatment costs, with the increased cost falling on the local NHS.
In summary, the full cost of a clinical trial in the NHS should be the sum of the research cost, the service
support cost and the excess treatment cost. Any treatment costs which would have been incurred in the
absence of the trial should be met by the NHS and not included in the cost of the trial.
As the HTA programme preceded ARCO, it had to devise its own solutions to ensure that trials had the
necessary funding. These might have sometimes involved funding what later came to be known as NHS
support costs and excess treatment costs. NHS support costs should pay for research nurses to identify and
recruit patients, but these might have sometimes been funded by the research grant. Excess treatment
costs might have sometimes been funded, notably in trials of services not routinely provided by the NHS,
such as CBT (trials ID3, ID4, ID53, ID60, ID76 and ID103), acupuncture (trials ID29 and ID39) or other novel
therapies such as larval therapy (trial ID94). This was less of a problem for low-cost interventions, but could
pose serious problems when the cost of the intervention was large and had to be met by the NHS.
Although the HTA programme was responsible only for the research cost, its application forms required
data on other costs from 2000. This was the result of one particular trial experiencing problems due to the
magnitude of support costs and excess treatment costs. Progress depended on agreement on who should
fund them. From 1998, the HTA programme required applicants to estimate the service support and excess
treatment costs incurred by their trial. It also required that bids which included either NHS support costs or
excess treatment costs should be itemised and signed off by a clinical director, R&D manager or chief
executive of the NHS trust.
However, these estimates were planned, not actual, costs. One of the surprising early findings of the
current work was that no estimates were available of the actual support costs incurred by the Clinical
Research Networks in supporting HTA programme trials. We had intended to cross-check the data on
support costs in the application form with data from NHS trusts (or later, the Clinical Research Networks),
but this was not possible as neither hospitals nor the networks collect or compile such data. The same
applies to excess treatment costs, although estimates of those actually incurred could be estimated on a
trial-by-trial basis, based on the numbers actually recruited.
Questions addressed
The aim was to review available cost data for published HTA-funded clinical trials, by attempting to answer
specific questions concerning what the data show on the different types of cost (research, research
support and excess treatment costs); how the planned and actual costs relate; the cost of additional
elements in the projects; whether or not costs are increasing; and what factors determine differences in
costs. Box 9 shows the questions explored.
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Methods
Six questions were piloted, as shown in Box 9. An attempt was made to record cost data under the five
headings on the application form – staff, travel, consumables, exceptional items and equipment – and the
40% overhead allowed on staff costs. Data extracted on a pilot basis under these headings proved
unhelpful in distinguishing types of costs for the early projects. The alternative approach was adopted of
searching under each heading for support costs, excess treatment costs, health economics or statistical
consultancy. Putative support costs were reviewed against the ARCO definition of support costs.13 Any bid
for research nurses to carry out such tasks was deemed a service support cost. Similarly, with excess
treatment costs, each application for funding intervention(s) was assessed against the ARCO definition.
From 1998, data were required in applications on support and treatment costs. Appendix A in the HTA
programme grant application form required data on two items: ‘service support costs’ and ‘excess
treatment cost’. (The form changed slightly over time. Appendix A in the HTA programme grant
application form from 1998 required data on two items: ‘service support costs’ and ‘treatment costs’,
retitled in 1999 as ‘excess costs’ and again in 2000 as ‘excess treatment costs’.) These headings were
extracted in addition to any such costs already identified in the HTA application form.
The exclusion criteria (Table 46) led to a total of 14 projects being excluded. Two were not trials (ID35) or
were marginally concerned with trials (ID67), four were pilot studies (ID15, ID78, ID97 and ID121) and one
trial was abandoned (ID75).
Seven further projects were excluded on the basis of non-standard overheads; either a lower than usual
overhead was charged (trials ID12, ID29, ID64 and ID71) or the overhead was replaced by full economic
costing (FEC) introduced in 2006 (trials ID109, ID112 and ID115). The total number of projects finally
included for costing was 95. For analysis of trends and variances, a further 10 multitrial projects were
excluded (ID3 and ID4; ID13 and ID14; ID24 and ID25; ID128, ID129 and ID134; ID35, ID36 and ID37;
ID54, ID55 and ID56; ID48, ID49 and ID50; ID51 and ID52; ID69 and ID70; ID131, ID132 and ID133),
reducing the total to 85 trials.
BOX 9 The research questions answered under this theme
T6.1. What do available data show regarding research, research support and excess treatment costs?
T6.2. What is the relationship between planned and actual costs?
T6.3. What was the cost of additional elements, such as economic and statistical analysis, within clinical trials?
T6.4. What is the trend in time for the costs of HTA-funded clinical trials?
T6.5. What factors help explain variations in the cost of individual trials?
T6.6. What is the cost per patient per year?
TABLE 46 Exclusion criteria, projects excluded and number for analysis
Exclusion criteria Trial IDs of those excluded Number of projects
Monographs 109
Not a RCT, or included small RCT ID135, ID67 107
Pilot studies ID15, ID121, ID97, ID78 103
Abandoned trials ID75 102
Overhead on staff not 40% ID12, ID29, ID64, ID71, ID109, ID112, ID115 95
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The planned cost referred to the research cost agreed at the time when the trial officially started. Many
trials changed their start dates owing to delays in ethical approval or staff recruitment. Contract variation
applied if the change of start date was more than 1 month. We took the research cost at the time of
commencement of the trial and extracted data automatically from the HTA MIS. As many trials apply
successfully for extensions with additional research costs, actual costs often exceed those planned. The
cost of these extensions is included in the final cost. The data fields used to extract data from the HTA MIS
for the planned and actual cost of the trial were verified by the HTA finance department.
The HTA application form evolved over time with variations in the questions asked about costs.
Data on costs were extracted under the following headings:
1. research cost, planned as outlined in the application form, with any amendments, along with any items
that could be termed support costs (specifying whether funded by the HTA programme or separately by
the NHS)
2. excess treatment costs (with any appropriate detail on type), again specifying whether funded by the
HTA programme or the NHS
3. health economics, statistics, surveys, qualitative research or other additional items, noting any costs
attributed to them in the application form
4. actual cost of the project from NETSCC records.
We reported whether or not the application form requested the following information:
i. service support costs
ii. treatment costs
iii. excess treatment costs.
For final application forms submitted from October 1994 up to and including February 1998,
no information about treatment cost or service support costs was requested. For these trials, the ‘no
information available’ code entry was used from the standardised ‘yes’/‘no’ table. However, during the
period from March 1998 to January 1999 there were two versions of the application form being
submitted. Although version 2 included support costs, errors were found in the application form section
for applicants to provide cost data on support costs, treatment costs and excess treatment costs. Version 3
was therefore implemented and in use from June 2000 onwards.
For those application forms submitted post 1998, the ‘no information available’ code entry was used to
refer to projects where we were unable to retrieve the full application form.
More than half of these projects (56.3%, 9/16) were based in a primary care setting using primary care
networks, made up of ‘research practices’. The remaining projects were divided, with 5 out of 16 (31.3%)
in secondary care and 2 out of 16 (12.4%) in both primary and secondary care.
Costs in different years were expressed in 2010 prices using the Higher Education Institutions pay
expenditure index.129 This was chosen as most of the funding awards were to universities. A comparison
with the NHS price index showed little difference between the two indices.
Data were reviewed on an Excel spreadsheet and examined for gross outliers. Two very low planned/actual
cost estimates were investigated (trials ID87 and ID100), shown to be incorrect from the application form
and corrected.
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Denominators
The unit of analysis depended on the question. For some it was the project, for others the trial. The
109 projects included 125 trials. For analysis of trend and variance (including two questions: cost factors
and patient cost), the analysis was single-trial projects. Examples of multitrial projects include one that
randomised adults and children separately to different dosages (trial ID13). Other trials randomised mild,
moderate and severe patients separately to different interventions (trials ID128, ID129 and ID130). Had the
interventions not been different for each of these groups, the trials would have been single trials with
stratification by adults/children or by severity.
Results
Question T6.1: what do the available data show regarding research,
research support and excess treatment costs?
The mean total cost per included project, along with its breakdown by support and treatment cost, is
shown in Figure 11. This varied between £0.5M and £2.4M at current prices between 1995 and 2005.
In all years but 2000, which had a peak of £2.4M, the mean total was below £1.6M. The peak in 2000
was due to one project with particularly high treatment costs. Leaving 2000 aside, the trend in mean total
cost was upwards, with 4 out of 5 years after 2000 above £1M, and none above that figure before 2000.
Research cost, as funded by the HTA programme, accounted for some 70% of the total cost in every year
but 2000. Support costs were higher than treatment costs in all years but 2000 (Table 47).
The HTA programme funded what appear to be support costs in 65 out of 95 projects, or roughly
two-thirds. These costs amounted to almost half (45.4%) of the planned cost on average for those
projects (mean cost £560,000). Some of these were concerned with trials based in primary care, which
included payment to GP practices for their involvement, which could be seen as a form of NHS support
cost. Out of the 95 projects, 16 (16.8%) included funding to GPs.
Excess treatment costs were also funded nearly as often by the programme (40/95 projects, or just over
40%) and accounted for a similar share of planned cost: £144,033 against a mean of £346,664 (or 41.5%).
When support and excess treatment costs were funded by the NHS, the following applied.
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FIGURE 11 Health Technology Assessment-funded projects 1995–2005, by cost component (HTA research cost,
HTA-funded support cost, HTA-funded excess treatment cost, externally funded support or externally funded
excess treatment cost). For abbreviations see Table 47 (current prices).
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Support costs were noted in 13 projects, with a mean planned cost of £125,808 and externally funded
support costs of £155,236, or 123% of the direct research cost funded by the HTA programme.
NHS-funded excess treatment costs were noted for 19 projects, with a mean cost of £165,426 and a
mean excess treatment cost of £786,977, or 476%. This included one outlier with excess treatment costs
of £12M. After its exclusion, the mean project cost was £150,261, with a mean excess treatment cost of
£157,966, or 123%.
The outlier in 2000 was trial ID106 [Conventional ventilator support versus extracorporeal membrane
oxygenation for severe adult respiratory failure (CESAR)]. This project was commissioned on request by the
HTA programme for the National Specialist Commissioning Advisory Group, which funded the excess
treatment costs.
Question T6.2: what is the relationship between planned and actual costs?
The planned and actual mean project research cost, as funded by the HTA programme, is shown in
Figure 12 for each project by year of funding. The mean cost in 2010 prices rose from around £0.5M in
1994 to just over £1M in 2000, after which it fell back to between £0.7M and £0.8M. A wide dispersion
existed around these means (see Figure 12).
The actual cost exceeded the planned cost in almost all instances, with a mean difference of 21%
(range 0–74%). Of the 95 projects, 74 (78%) had actual costs that exceeded the planned cost. Of these,
54 exceeded by 10% or more, 11 exceeded by 50% or more but none exceeded by 100%. The
relationship between planned and actual mean cost of HTA-funded clinical trial projects, by year, shows
the actual higher than the planned each year, with the difference widening up to 2002 and then declining
slightly (see Figure 12).
Question T6.3: what was the cost of additional elements, such as economic
and statistical analysis within clinical trials?
The contribution of health economics was separately identified in 65 projects. It had a mean cost of
£47,618 compared with the mean HTA programme-funded cost per project of £577,798, or 8.2%.
The projects that did not itemise health economics costs provided that input by other means, often by
having a health economist funded as a co-applicant.
Similarly, the contribution of statistician input, which was identified in 43 projects, had a mean cost of
£34,251 compared with the mean HTA programme-funded cost per project of £377,699, or 9.1%.
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FIGURE 12 Planned and actual mean project cost, by start year, 1995–2005.
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Question T6.4: what is the trend in time for the costs of Health Technology
Assessment-funded clinical trials?
The actual cost to the HTA programme of its funded projects in constant 2010 prices (Figure 13) varied
widely by project but with an upwards, if uneven, trend. The range of project costs was from £0.25M to
almost £2.5M, or 10-fold. The mean cost rose each year from around £0.5M in 1993 to £1.2M in 1998,
after which it fell slightly and levelled off at just over £1M.
The effect of including externally funded support and excess treatment costs in the HTA programme
costed annual averages is shown in Table 48 to have relatively little impact on the mean cost of
HTA-funded projects from 1997, with the exception of 2000, when the ratio of total to research costs
jumped. This, however, was due almost entirely to the impact of a single project which had very large
excess treatment costs (trial ID106). For the other years after 1997, the ratio ranged between 106%
and 135%.
The mean cost per year is shown in Figure 14, with the dots representing mean values weighted by the
number of project trials starting in each year. The progressively increasing costs after 2000 look now more
like a series of continuously increasing total project costs over time.
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FIGURE 13 Health Technology Assessment trial mean and individual project costs, by start year, 1995–2005.
TABLE 48 Health Technology Assessment and total (HTA+ externally funded NHS support and excess treatment)
cost of HTA projects, 1995–2005 (by start year)
Year HTA cost (£) Total cost (£) Ratio of total to HTA (%)
1995 536,968 536,968 100
1996 703,866 703,866 100
1997 936,444 936,444 100
1998 880,435 880,435 100
1999 605,744 607,915 100
2000 1,027,382 2,366,637 230
2001 1,129,612 1,255,844 111
2002 914,092 929,240 102
2003 1,105,317 1,172,847 106
2004 909,804 993,424 109
2005 1,163,631 1,276,765 110
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Question T6.5: what factors help explain variations in the cost of
individual trials?
The three different definitions of cost led to three analyses: planned project costs to the HTA programme,
actual costs to the HTA programme and a wider definition made up of actual costs to the HTA
programme plus externally funded planned support and excess treatment costs. As this wider definition of
costs was the most comprehensive, and the findings were similar for the other cost definitions, only the
results of the widest definition are reported here.
Univariate analysis of costs (wide definition) indicated correlations with recruitment, number of centres
and duration of trial. Multivariate regression, based on transforming the skewed distribution of costs, used
generalised linear models (GLMs) to explore how six different models fitted the data (combination of
identity, square root or log link functions, normal or gamma distributions).
Fourteen variables were included after three had been excluded because of collinearity (care in both
primary and secondary settings, GP practice and UKCRC Health Services category).
A square root transformation of cost data produced the distribution closest to normal (lowest chi-squared)
compared with other common transformations, yet not achieving normality. For the GLMs estimated, the
Akaike information criterion (AIC) was used as a measure of goodness of fit (based on information loss after
model fit; the lower, the better). The square root link function under a normal distribution seemed to fit the
data well (AIC=28.76); however, the identity link function under the normal distribution (equivalent to
common ordinary least squares) produced a slightly lower loss of data than the rest (AIC=28.70) (Table 49).
The coefficients and their statistical significance identified two parameters – the actual number of centres
and trial duration – as statistically significant in all six models. A few additional explanatory variables were
also significant in some but not all models. The proportion of the variance explained in the best models
was 40% (R2= 0.40). The relation between the cost predicted by the best model and actual costs (wide
definition) is shown in Figure 15.
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FIGURE 14 Health Technology Assessment-funded project costs, 1995–2005. Mean cost in 2010 prices is shown, with
the size of each dot proportional to the number of projects started by year.
TABLE 49 Results of six different models on goodness of fit (AIC)
Link
distribution
Square root
(normal)
Identity
(normal)
Log
(normal)
Square root
(gamma)
Identity
(gamma)
Log
(gamma)
AIC 28.758 28.704 28.758 29.414 29.400 29.464
Note
The AIC is a common measure of goodness of fit, indicating information loss after model fit, hence the lower, the better.
Normal distribution seems to fit the data best and the identity link function produces a slightly lower loss of data
than the rest.
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Question T6.6: what is the cost per patient per year?
As the cost per patient recruited is sometimes considered for benchmarking, these data are analysed here.
As a comparison of cost per patient recruited was very little different using HTA actual costs or using the
wider definition (HTA actual plus planned service support and excess treatment costs), only the latter
is reported.
The mean costs, along with minimum and maximum values, are shown in Table 50 for the same 84 trials
analysed above (excluding one outlier, trial ID106). The same data are shown in Figure 16 along with
outliers and one SD from the mean. The mean cost per patient rose in constant 2010 prices from under
£1500 in 1995 and 1996 to over £2500 in each of 1997 and 1998, with a fall to just under £2000 in
1999. From 2000, it exceeded £3000 in all years except 2005, when it was just over £2000. The range of
the mean cost per patient was wide, as shown in Figure 16.
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FIGURE 15 Actual and predicted HTA project costs (wide definition).
TABLE 50 Mean annual cost (wide definition) per patient recruited to HTA-funded projects, 1995–2005, with
minimum and maximum values
Actual start year Number of trial Mean cost per patient (£) Minimum (£) Maximum (£)
1995 7 1220 124 1900
1996 6 1490 309 2472
1997 4 2755 539 6457
1998 9 2971 826 9199
1999 13 1853 207 4909
2000 10 3907 43 15,295
2001 8 3451 97 16,510
2002 9 4830 995 10,457
2003 10 3228 1475 5552
2004 4 3741 568 5618
2005 4 2206 24 4476
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Analysis
The feasibility study was helpful in refining one question and dropping the question regarding payments to
centres. Consideration might be given, should the database continue, to exploring inclusion of data on
how centres are remunerated for recruitment to clinical trials funded later than those reviewed here.
The data on costing of projects were complex owing to the HTA programme only funding one element,
the research cost, with the support costs and treatment costs each funded by different bodies. Projects
varied, with around half incurring neither support nor excess treatment costs. For those that did, these
costs accounted for around 40% of the HTA grant. Although the HTA programme funding was confined
to research costs, it sometimes funded what appears to be support and/or excess treatment costs
according to the ARCO definitions.13 From 1998, the HTA application form began to collect data on
externally funded support and excess treatment costs, but only on planned costs. The HTA programme
continued to fund what appear to be support and excess treatment costs, but interpretation of these
depends on the nuances of the ARCO rules.
Data on actual and planned costs were available only for research costs, with no data on actual costs
available for support or excess treatment costs. The actual research cost exceeded the planned cost in 78%
of projects, with a mean excess of 25% for those projects and 21% for all projects. All cost increases were
agreed with the HTA programme secretariat.
Data on the cost of health economics and statistical advice, although not required on the application form,
are often bid for on a consultancy basis. The data for those projects that itemised these costs put the cost
of health economics at 8% of research costs and the equivalent figure for statistics was 9%.
The cost of HTA-funded projects varied widely, as shown by a wide spread around the mean value each
year, but with an increase each year from 1993 to 1998, after which the mean value fell slightly and
levelled off. Inclusion of externally funded planned support and treatment costs increased the totals for
years after 1998, but, with the exception of one project with very high cost in 2000, made little difference
to the trend over time.
In all multivariate analyses, two factors were shown to be statistically significant: the number of centres
and the duration of the trial. The proportion of variance explained – at best 42% – was similar but slightly
lower for the narrowed cost definitions. Further consideration of the use of the model for benchmarking
the cost of bids to the HTA programme seems worthwhile.
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FIGURE 16 Mean cost (wide definition) per patient recruited to HTA-funded projects, 1995–2005 (n= 84), with one
SD and outliers.
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The mean cost per patient rose most years to a peak of just under £5000 in 2002, after which it fell to just
over £2200 in 2005. The dispersion around the mean was wide. The number of patients was shown not
to be a statistically significant predictor of the total cost of the trial in the multivariate analysis. This may be
due to the heterogeneity of the trials analysed. Cost per patient may be more useful for comparing trial
costs within more homogeneous trials.
Discussion
If further work is to continue to collect data on HTA programme-funded trial-related projects, it should
collect data on all the relevant costs, including NHS support and excess treatment costs. Although the
externally funded support and excess treatment costs in the projects analysed were as planned in the HTA
application forms, rather than actual costs, at some stage actual support costs (and perhaps excess
treatment costs) may become available. Similarly, the analyses presented above predated the change
from overheads to FEC, with three projects being excluded on account of having used FEC. The most
appropriate way to extract FEC data should be piloted on a selection of projects and the results integrated
into the database.
The collection of data on the cost of health economics and statistics could be dropped as these elements
are relatively small and difficult to extract. The finding that each of health economics and statistics cost,
on average, around 10% of the HTA grant might be used to benchmark costs.
More generally, the findings that the main predictors of the cost of the HTA grant were number of centres
and duration of project might be used to provide predicted costs for use in benchmarking bids.
Strengths and weaknesses of the study
Weaknesses surrounding this theme relate mainly to the complexity of the cost data. Projects were very
heterogeneous in terms of their costs, with some involving large and others no support/excess treatment
costs. The interplay between ARCO guidance and practice was unclear. Only planned, not actual, costs
were available for both externally funded support costs and excess treatment costs.
We know of no other such study.
Recommendations for future work
Any further work should extract data on the cost of trials on four questions: two as they currently are
(T6.3 and T6.4) and two to be amended (T6.1 and T6.2).
Full costing data were not requested to 1998 and remained planned rather than actual. The lack of any
facility to monitor and manage support costs inevitably reduces the power of both the HTA programme
and researchers to manage the projects. Provision of actual support costs seems a priority.
Unanswered questions and future research
The heterogeneity of trials and the implication of this for cost analysis remains a topic to be explored in
future research.
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Chapter 10 Discussion of main findings
Introduction
This chapter discusses the main findings in relation to the six themes and identifies which questions can
readily be answered should the database continue. It considers the strengths and limitations of the study
before considering how it might be used by other funders of randomised trials.
Before discussing the implications of the pilot, one general point should be made. Neither the ISRCTN nor
the titles of the projects proved reliable in identifying RCTs. Although titles may have improved owing to
the CONSORT requirements44 for titles, our initial reliance on titles led to considerable delays. The HTA
programme and NETSCC should consider its policy on how the trials it funds can best be identified.
Enforcement of the CONSORT requirement that the title should include the words ‘randomised trial’ would
go some of the way, but not sufficiently unless an indication is also given when the project includes more
than one RCT.
The review of the extent to which the trials could be seen as meeting the needs of the NHS (see Chapter 4)
showed that basic data were lacking. Improved ways are required of recording the source of commissioned
topics, how they are prioritised and how they have an impact on the NHS. This requires clarification by the
programme as to how this might best be recorded. One way of assessing the importance of the trial to
the NHS might be through assessing its impact on guidelines such as those issued by NICE, and on
meta-analyses such as those of the Cochrane Collaboration. Work is ongoing assessing the impact of
particular trials on relevant meta-analyses,130 and their impact on guidelines.
Trials were shown to comply with the CONSORT reporting requirements,44 at least in general. Adherence
to those sections of the CONSORT checklist examined was fairly high, but with some exceptions, including
a lack of detail on interventions, prespecified outcomes and the basis for the sample size calculation.
About one-third of trials failed on each of these. The number of primary outcomes changed in 27 trials
(in half the number increased and in half it decreased). The time point at which the primary outcome was
measured was not specified in 45% of proposals and 40% of monograph reports. Although these
weaknesses were mainly in early trials, they continued to appear in those that were funded later.
Almost half of trials conducted pilots but few had had feasibility studies. Around half of all interventions
were substitutes for standard care and about one-third were add-ons. Almost two-thirds (64%) of the
controls were standard care, but one-third of controls could not be classified.
Most trials were conducted in line with the protocol and followed both the study framework and the
planned type of comparison. For those variations from the protocol that could cause bias, the results
compare well with those reported for other cohorts of trials, such as in the study by Chan et al.10,11,88
This may reflect the monitoring programme and publication requirements of the HTA programme.
On average, trials needed about twice as many centres as planned to complete the study, but this may
reflect the practical difficulty of running large trials.
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Chapter 5 showed that although reporting checklists such as CONSORT44 and ICH131 can be
operationalised, assessing compliance is difficult. Compliance in terms of ‘yes/no’ often required closer
examination, expertise and interpretation. Although a ‘yes/no’ response in an author’s checklist may
provide a useful reminder, it is difficult for an outside assessor to interpret compliance without further
detail. Comparing planned and reported analyses showed that a higher proportion of the HTA
programme’s trials reported as planned than in the cohort examined by Chan et al.10,88 Another key point
was that many ‘audit’-type questions could not be answered owing to incomplete data. If audit is
required, this study shows that it cannot be achieved retrospectively from published reports. The HTA
programme needs to decide if it wants to assess compliance with CONSORT and other relevant checklists,
such as the PRECIS tool,48 as well as the extent to which it wishes to compare planned and actual
reported analyses.
The performance of trials centres on recruitment (see Chapter 6), is almost always underachieved.
Modelling of the factors linked to recruitment was shown to be rare. Estimates of recruitment were
almost always overoptimistic. However, the development of the NIHR Clinical Research Network
(www.crncc.nihr.ac.uk/), with responsibility for recruitment, happened after most of the trials included in
this study had started. Any future questions to do with recruitment need to be framed with the role
of those networks in mind.
The statistical analysis of primary outcomes (see Chapter 7) had to be limited as many trials had more than
one primary outcome. This was surprising and may be something the HTA programme should review.
Comparing planned and actual statistical analyses of the primary outcomes proved difficult and required
statistical expertise. More importantly, a key document, the statistical plan, was not available. Such plans
are not included in either the bid or the protocol, but are often prepared close to the end of the trial but
before unblinding. If analysis of the statistical analysis is required, then such plans will have to be collected.
The review of economic evaluation (see Chapter 8) showed that it was included in almost all trials
funded by the HTA programme. The BCL12 was silent on many of the more recent developments in
cost-effectiveness analysis. Further, it could only indicate if something had been done, not how well it was
done. Much more detail would be required to establish the latter. This chapter showed the value of
separate presentation of differences in costs and outcomes. A previous analysis (by LS and JR) of the first
65 HTA-published trials found no statistically significant difference in their primary outcomes in two-thirds.5
This work led to inclusion of those trials as one of four cohorts in an international review of old versus new
interventions in trials.96 (This Cochrane Review showed that it identified four such cohorts globally, one
based on US NIH cancer trials, one on 30 UK MRC trials and another on a cohort of 30 Canadian trials.
The fourth cohort was made up of some 60 HTA-funded trials based on the previous work by JR and LS.)
One reason for continuing the metadata database would be to enable that analysis to be updated and for
ongoing comparisons to be made.
The analysis of the cost of trials (see Chapter 9) showed that basic data were absent, notably on NHS
support and excess treatment costs. Without such data, the total cost of RCTs cannot be determined.
Only estimates of planned support and treatment costs are available. A key issue for the HTA programme
involves collection of actual as opposed to planned NHS support and excess treatment cost data. As with
data on recruitment, closer links with the NIHR Clinical Research Network seem appropriate.
The overarching aim of this study was to assess the extent to which the HTA programme trials were
helping to meet the needs of the NHS with scientifically robust evidence. The results indicate more
difficulties in answering questions concerned with meeting the needs of the NHS than with scientific
evidence. This is to some extent inevitable. Although data could be improved on how trials aimed to meet
the needs of the NHS, answering this question properly requires the trial to have completed. Assessing the
scientific quality of the trials is, by contrast, an easier task.
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Continuation of the database?
We recommend that the answers to the recommended questions be updated as more trials are completed
and that the included trials be extended to all those funded by NIHR research programmes.
A key question relates to whether or not the metadata database should be maintained and, if so, by who
and with what terms of reference. We recommend that it continue to be maintained on the grounds of
the relevance to the programme of the questions that were shown to be answerable. If it were to be
continued, this study has shown which questions should be included in any further database.
Limitations of the study
Limitations include:
l this review being limited to a cohort of HTA programme projects funded between 1993 and 2003,
which may be atypical of trials funded later, mainly as these included a new researcher-initiated
work stream
l reliance, for around half of the included trials, on data from application forms rather than protocols
l reliance on ‘insiders’ (several of the research team are or were NETSCC employees) who may have
biases (offset to some extent by the advisory group and by quality assurance)
l reliance on a fairly limited number of questions determined largely by data availability.
The strengths largely mirror the weaknesses:
l Given that some 220 similar trials were funded by the HTA programme by the end of 2011 using
similar criteria, the trials included in this database are likely to be typical of the programme, if not
more generally.
l Although the application form was the source for around half the included trials, protocols were
increasingly common from 2000. Although the application form changed over time, those changes
were confined to costs and involved the addition of questions rather than changes to
existing questions.
l The authors were well informed because they were ‘insiders’ with good access to documents and
detailed working knowledge of many of the trials. This enabled a focus on the data required to answer
particular questions, which might have delayed a less experienced team.
l Finally, the database is unique in going well beyond the metadata in trial registries to include source of
topic, adherence to protocol, planned and actual recruitment, quality of statistical and economic
analyses and costs.
Implications for other funders
The findings of this study on the kinds of metadata that can be collected has implications for other
research funders (research councils, medical charities), most obviously other NIHR research programmes but
also other UK funders as well as funders in other countries.
The NIHR funds RCTs through programmes other than the HTA programme, including the Public Health
Research (PHR), Efficacy and Mechanism Evaluation (EME) and Health Services and Delivery Research
(HS&DR) programmes (all managed by NETSCC), as well as the Programme Grants for Applied Research
(PGfAR). As the NIHR Journals Library will publish these, data will be available. A strong case exists for
the database covering all NIHR-funded trials. However, given the different types of trial (EME funding
early-stage RCTs, and PGfAR funding pilots and feasibility studies as well as RCTs), the types of questions
may need to be revisited.
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Other UK funders include the medical charities and the MRC; trials funded by each of these tend to be
earlier stage than those of the HTA programme. As with such trials funded by NIHR, some revision may
be required if the database is to cover these.
International funders, particularly in the USA, given the requirement for the results of trials to be
registered, may be able to benefit from the work reported here. This may apply to large pragmatic trials of
the sort likely to be funded by the Patient-Centered Outcomes Research Institute (www.pcori.org/).
Further research/implementation
Further research might usefully:
l Compare this portfolio of HTA-funded trials with trials funded by others. Extension of the database to
include all NIHR-funded trials would be an obvious step, as would extending it to include those trials
funded by charities, the second biggest funder of non-commercial trials.
l Consider extending the CCT registration to include results on the headings specified here. Given that
ClinGov has moved towards requiring inclusion of results, CCT may move in a similar direction, in
which case some of the headings in the database could be used.
l Make comparisons with other research, such as the cost casemix study of RCTs in the USA132 and the
analysis of cohorts of RCTs (as in the Cochrane Review by Djulbegovic et al.96).
l Explore the implications of adding questions to the database, such as regarding the role and type of
patient and public involvement, and similarly with regard to peer review.
l Research the effectiveness of tick box checklists, such as CONSORT and the BMJ economic analysis
checklist, for quality assurance versus more detailed analysis.
Concluding remarks
The overall finding on RCTs funded by the HTA programme might be ‘good, but could do better’.
The main topics for improvement concerned data on the ways in which the programme met the needs
of the NHS and on the overall cost of the trials it part funds.
The main finding on the database is that the set of metadata headings presently used in trial registries
could be expanded to include aspects of design, performance, results, analyses and costs. This study
showed that much of the data required could be extracted on a routine basis from administrative systems,
but mainly from the application forms, protocols and monographs.
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Chapter 11 Conclusions
Introduction
This project has shown that the ‘metadata’ collected in trial registries can be expanded to include aspects
of performance, conduct, results and costs. It has also indicated the limits of available data.
Recommendations for the future metadata database
The main recommendation is that the metadata should continue to be extracted in order to update the
answers to the questions we have posed. Such data can make a substantial contribution to understanding
each of the six themes. If NIHR is to maximise the added value of funding of trials to meet the needs of
the NHS with high-quality science, then metadata on those trials is likely to play a key role.
We suggest that the cost of maintaining the database could be minimised by integrated data collection
into NETSCC’s MIS and publication processes. However, this would need some dedicated resource as well
as commitment from the HTA and other NIHR research programmes.
We also recommend that any future data extraction should include all NIHR-funded RCTs. We included
125 completed HTA trials. Any future data extraction should include data on the 220 other HTA-funded
trials that were active at the end of December 2012. As other NIHR research programmes also fund RCTs,
notably the PHR, EME and HS&DR programmes, but also the PGfAR, inclusion of all RCTs by these funders
would greatly enhance the value of the database.
Recommendations have been offered on how the database might be refined to learn from the experiences
reported here. If the database is to be continued, we recommend that the changes suggested for
particular classification systems should be piloted using the 20 or so trials published since the cut-off date
for this project. We have also recommended that the database be extended in relation to its inclusion of
sufficient data on differences in results between new and old interventions, to enable it to remain part
of the portfolio of cohorts of trials included in the ongoing Cochrane Review.96
We recommend that the database be made available to other researchers, subject to similar confidentiality
agreements that governed the present project (similar because the rules governing data access have
changed since this project began). We also recommend that the database include aspects aimed at
enabling the quality of its data to be improved by such use. Given the inclusion of all source documents
within it, future users could have the facility and the requirement to note any differences of data extraction
and/or interpretation. This would need careful piloting but could provide a unique feature that would
enhance the value of the database to NETSCC as a scientific secretariat.
Other relevant research noted previously includes work on the factors associated with differences in the
cost of trials.132 This work, being carried out for NIH in the USA using a portfolio of commercially funded
trials, should be monitored and compared.
The metadata database is unique in extending well beyond trial registration databases and in including
source documentation. We believe it addresses key issues for any research funder and we recommend that
it continue in the ways discussed above.
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This project also indicated the limits of available data. For each theme, several important questions were
deemed not feasible owing to lack of data or difficulties in their extraction. The most important of these
concerned how the programme was meeting the needs of the NHS. Data on the factors leading to a
proposed trial being prioritised and funded will inevitably be limited in relation to the eventual impact of
that trial. However, Chapter 4 suggests that the programme could improve the data it collects on
these factors.
Reflections by the team on the project
Classification systems proved key to the database as they provided the options within boxes. Relatively few
well-established, relevant classification systems could be identified as we had to sometimes improvise.
This contributed to the finding that around one-third of our questions required amendment.
Our methods, in retrospect, could have been better specified. We aimed to construct a database, use it to
answer questions and, based on that experience, make recommendations for how the database might be
further developed. Doing this with six lead researchers, each with different degrees of detailed knowledge
and commitments, proved challenging. In retrospect, each of the unfunded research leads would have
benefited from having had specific funded time. This would also have facilitated project management.
Further, the process of iteration and piloting might have been better specified and ‘protocolised’.
We carried out two small micro-pilot studies, one concerned with extracting data on trial results from
academic journals rather than the monographs, and the other relating to having principal investigators
quality assure the data extracted. Neither of these proved a success and neither was proceeded with. Many
of the academic articles could not be readily accessed. The process of having a principal investigator quality
assure the data extracted proved laborious. However, the time required for this might be reduced if it
could be done contemporaneously. To do so with trials, some of which had been started up to 20 years
ago, was never likely to be feasible.
In retrospect, the database should have included questions on results similar to those in the Cochrane
Review of new versus old interventions.96 As two of us (LS, JR) had extracted and classified data on
65 published HTA programme trials, this would have been a considerable but not major challenge. Given
that those 65 trials made up one of only four such cohorts globally, it is unfortunate that all 125 trials in
the database cannot constitute an update on that earlier work. We recommend that the database is
expanded to include the relevant questions.
Finally, we underestimated the work involved in piloting the database in ways that were rigorous and
transparent. We should have developed earlier criteria linked to the aims of the project which
discriminated success and failure.
On the positive side, we were able to identify weaknesses in the data and how they might be classified.
One of the surprises was that such databases are very uncommon, with the research referred to above
indicating that the HTA cohort of studies was not only one of four existing globally, but also that it
was the second largest. Interest in assessing the costs and benefits of publicly funded RCTs is likely to
grow. We hope that the work reported here will facilitate the inclusion of trials funded by the HTA
programme in those assessments.
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Appendix 1 Literature search strategy
Uses and limitations of trial registration databases
Date searched: 9 February 2012.
Sources searched:
Ovid MEDLINE(R) without Revisions (1996 to February week 1, 2012) Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations Ovid EMBASE (1996 to week 5, 2012) Cochrane Methodology Register.
Database: Ovid MEDLINE(R) without Revisions
(1996 to February week 1, 2012)
Search strategy
1. Randomized Controlled Trials as Topic/ or Clinical Trials as Topic/ (141,375)
2. Database Management Systems/ (5285)
3. Registries/ (32,826)
4. (trial* adj3 regist*).ti,ab. (14,862)
5. clinicaltrials.ti,ab. (46)
6. 2 and 4 (3)
7. (trial registries or trial registers).ti,ab. (318)
8. evaluation studies.pt. (157,963)
9. 7 and 8 (5)
10. from 9 keep 3,5 (2)
11. 1 and 3 (1292)
12. International Committee of Medical Journal Editors.mp. (160)
13. 7 and 12 (3)
14. from 13 keep 1-3 (3)
15. (evaluation or usability).ti,ab. (398,106)
16. 7 and 15 (20)
17. 3 and 15 (1724)
18. from 16 keep 13 (1)
19. 1 and 3 (1292)
20. usability.ti,ab. (2559)
21. 19 and 20 (1)
22. "Databases, Factual"/ (29,221)
23. limitation*.ti,ab. (101,377)
24. 1 and 3 and 22 (103)
25. 23 and 24 (4)
26. from 21 keep 1 (1)
27. from 25 keep 3 (1)
28. current controlled trials.ti,ab. (707)
29. clinicaltrials gov.ti,ab. (13)
30. 28 or 29 (720)
31. 7 and 28 (2)
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32. 10 or 14 or 18 or 26 or 27 (8)
33. 8 and 11 (13)
34. from 33 keep 10 (1)
35. comparative study.pt. (830,359)
36. 11 and 35 (144)
37. from 36 keep 8-9,11,26,72 (5)
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Appendix 2 Full list of randomised controlled
trials included in the metadata database
The following is a list of all published HTA-funded RCTs included in the metadata database project(Table 51). The year, volume and issue of the HTA report is included along with description details
where funded projects reported more than one trial. The list is in chronological order by HTA publication.
TABLE 51 Description of all HTA projects included in the metadata database
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 1999, 3, 4 A randomised controlled trial of
different approaches to universal
antenatal HIV testing: acceptability,
costs and benefits
2 1
HTA 2000, 4, 6 The costs and benefits of post-natal
midwifery support – a randomised
controlled trial
7 2
HTA 2000, 4, 19 Effectiveness of counselling,
cognitive behavioural therapy and
GP care for depression in general
practice
3 3 Randomised three-way
(GP, CBT and non-directive
counselling)
HTA 2000, 4, 19 4 3 Randomised two-way
(CBT and non-directive
counselling)
HTA 2000, 4, 20 Is the outcome for patients with
low back pain influenced by GP’s
referral for plain radiography?
5 4
HTA 2000, 4, 28 Early asthma prophylaxis, natural
history, skeletal development and
economy (EASE)
121 5
HTA 2000, 4, 31 A randomised controlled trial
of infusion protocols in adult
pre-hospital care
122 6
HTA 2000, 4, 36 A randomised controlled trial
to evaluate the efficacy and
cost-effectiveness of counselling
with patients with chronic
depression and anxiety
6 7
HTA 2001, 5, 20 Multi-centre randomised controlled
trial of nurse practitioners and
pre-registration house officers in
pre-operative workup
8 8
HTA 2001, 5, 27 The cost-effectiveness of MRI for
investigation of the knee joint
9 9
HTA 2001, 5, 30 A randomised controlled trial
to assess the effectiveness,
cost-effectiveness and cost benefit
of routine referral for lumbar spine
radiography in patients with low
back pain
10 10
HTA 2002, 6, 20 Clinical medication review by a
pharmacist of patients on repeat
prescriptions in general practice
11 11
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2002, 6, 27 A randomised crossover trial of
nurse versus doctor-led outpatient
care in a bronchiectasis clinic
12 12
HTA 2002, 6, 30 Which anaesthetic agents and
techniques are most cost-effective
in day surgery?
13 13 Adult population
HTA 2002, 6, 30 14 13 Paediatric population
HTA 2002, 6, 34 A comparative study of hypertonic
saline, daily and alternate day
rhDNase in cystic fibrosis
123 14
HTA 2003, 7, 8 A multi-centre randomised
controlled trial assessing the costs
and benefits of using structured
information and analysis of
women’s preferences in the
management of menorrhagia
20 15
HTA 2003, 7, 14 The feasibility of conducting a
multicentre randomised trial of
treatment for localised prostate
cancer: early detection, recruitment
strategies and a pilot study
15 16
HTA 2003, 7, 24 Cost–benefit evaluation of routine
influenza immunisation in subjects
65–74 years of age
16 17
HTA 2003, 7, 28 Randomised controlled trial to
assess the impact of a package
comprising a patient-orientated,
evidence-based self-help guidebook
and patient-centred consultations
on disease management and
satisfaction in inflammatory bowel
disease
17 18
HTA 2003, 7, 36 Central line insertion project (CLIP) 18 19
HTA 2003, 7, 37 Redesigning postnatal care: a
randomised controlled trial of
protocol-based, midwifery-led care
19 20
HTA 2004, 8, 8 Psychological treatment in the
regulation of long-term hypnotic
drug use
31 21
HTA 2004, 8, 14 Extending midwife/nurse roles in
the routine examination of the
newborn: randomised controlled
evaluation and cost-effectiveness
(EMREN trial)
21 22
HTA 2004, 8, 16 A multi-centre randomised
controlled trial of minimally invasive
bypass grafting vs angioplasty with
stenting for single vessel disease
of the left anterior descending
coronary artery
22 23
HTA 2004, 8, 17 Does early imaging influence
management and improve outcome
in patients with low back pain?
23 24
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2004, 8, 26 A randomised trial to assess
the effectiveness, costs and
cost-effectiveness of laparoscopic,
vaginal and abdominal
hysterectomy
24 25 Laparoscopic hysterectomy
and abdominal
hysterectomy
HTA 2004, 8, 26 25 25 Laparoscopic hysterectomy
and vaginal hysterectomy
HTA 2004, 8, 29 A randomised controlled trial of
two bandages for treating venous
leg ulcers
26 26
HTA 2004, 8, 32 Randomised controlled trial and
economic evaluation of two
alternative strategies of providing
support for socially disadvantaged
inner city families with infants
27 27
HTA 2004, 8, 34 Diagnosis of endometrial
abnormality: comparison of
outpatient procedures within
cohorts defined by age and
menopausal status
128 28 Moderate-risk group
HTA 2004, 8, 34 129 28 High-risk group
HTA 2004, 8, 34 134 28 Low-risk group
HTA 2004, 8, 46 A randomised controlled trial of
intensive physiotherapy vs a
home-based exercise treatment
programme in knee osteoarthritis
28 29
HTA 2004, 8, 48 Acupuncture for migraine and
headache in primary care: a
pragmatic, randomised trial
29 30
HTA 2004, 8, 50 Virtual outreach: a randomised
controlled trial and economic
appraisal
30 31
HTA 2005, 9, 1 Identification of the most
cost-effective, microbiologically safe
antimicrobial treatments for acne
32 32
HTA 2005, 9, 3 Improving the referral process for
familial breast cancer genetic
counselling: an evaluation of
complementary interventions
35 33 Primary care trial –
Aberdeen only
HTA 2005, 9, 3 36 33 Nurse counsellor trial in
Aberdeen (trial 1)
HTA 2005, 9, 3 37 33 Nurse counsellor trial in
Cardiff (trial 2)
HTA 2005, 9, 4 Randomised evaluation of
alternative electrosurgical
modalities to treat bladder outflow
obstruction in men with benign
prostatic hyperplasia (BPH)
44 34
HTA 2005, 9, 5 A pragmatic randomised controlled
trial of the cost-effectiveness of
palliative therapies for patients with
oesophageal cancer
47 35
HTA 2005, 9, 16 A randomised controlled trial to
compare the cost-effectiveness of
tricyclic antidepressants, selective
serotonin re-uptake inhibitors and
lofepramine (AHEAD)
33 36
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2005, 9, 18 A controlled comparison of
alternative strategies in stroke
rehabilitation
34 37
HTA 2005, 9, 31 Randomised controlled trial of the
cost-effectiveness of water-based
therapy for lower limb osteoarthritis
(ROAR)
38 38
HTA 2005, 9, 32 Longer term clinical and economic
benefits of offering acupuncture to
patients with chronic low back pain
39 39
HTA 2005, 9, 33 Wessex epidural steroids trial
(WEST)
40 40
HTA 2005, 9, 34 The British Rheumatoid Outcome
Study Group (BROSG) trial of
symptomatic versus aggressive
therapy in established rheumatoid
arthritis
41 41
HTA 2005, 9, 37 Trial of problem-solving by
community psychiatric nurses
(CPNs) for anxiety, depression and
life difficulties among general
practice patients
42 42
HTA 2005, 9, 39 Is hydrotherapy cost-effective?
The costs and outcome measures
of hydrotherapy programmes
compared with physiotherapy
land techniques in children with
rheumatoid conditions
43 43
HTA 2005, 9, 40 Randomised controlled trial and
cost-effectiveness study of targeted
screening versus systematic
population screening for atrial
fibrillation in the over 65s: the SAFE
study
45 44
HTA 2005, 9, 41 Scottish trial of arthroplasty or
reduction for subcapital fractures
(STARS)
46 45
HTA 2006, 10, 2 FOOD: a multicentre international
randomised trial to evaluate
percutaneous endoscopic
gastrostomy and nasogastric tube
feeding in patients admitted to
hospital with a recent stroke
54 46 Trial 1: normal hospital
diet vs. normal hospital
diet plus oral supplements
HTA 2006, 10, 2 55 46 Trial 2: early enteral tube
feeding vs. avoid enteral
tube feeding
HTA 2006, 10, 2 56 46 Trial 3: nasogastric tube
feeding vs. percutaneous
endoscopic gastrostomy
tube feeding
HTA 2006, 10, 13 Assessment of cost-effectiveness of
the treatment of varicose veins
48 47 Clinical group 1
HTA 2006, 10, 13 49 47 Clinical group 2
HTA 2006, 10, 13 50 47 Clinical group 3
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2006, 10, 17 Cost utility of the latest
antipsychotics in severe
schizophrenia (CUtLASS): a
multi-centre, randomised,
controlled trial
51 48 Band 1 compared older,
inexpensive conventional
drugs with new atypical
drugs (broadly defined)
HTA 2006, 10, 17 52 48 Band 2 compared the new
(non-clozapine) atypical
drugs with clozapine
(narrowly defined)
HTA 2006, 10, 19 Cognitive behavioural therapy
versus antispasmodic therapy for
irritable bowel syndrome in primary
care
53 49
HTA 2006, 10, 21 Health benefits from anti-viral
therapy for mild chronic hepatitis C
57 50
HTA 2006, 10, 22 Randomised controlled trial
comparing alternating pressure
overlays with alternating pressure
mattresses for pressure sore
prevention and treatment
58 51
HTA 2006, 10, 29 An evaluation of the clinical and
cost-effectiveness of pulmonary
artery flotation catheters
(PAC-Man) in intensive care
59 52
HTA 2006, 10, 37 Cognitive behavioural therapy in
chronic fatigue syndrome: a
randomised controlled trial of an
outpatient group programme
60 53
HTA 2006, 10, 40 What is the cost-effectiveness of
endoscopy undertaken by nurses?
A multi-institution nurse endoscopy
trial (MINUET)
61 54
HTA 2006, 10, 43 Randomised controlled trial of
asynchronous and synchronous
telemedicine in dermatology –
RCT-ASTID
62 55
HTA 2006, 10, 50 Amniocentesis results: investigation
of anxiety (ARIA)
63 56
HTA 2007, 11, 8 A study to evaluate the most
cost-effective way to screen for
chlamydia trachomatis genital tract
infection and reduce its prevalence
and associated burden of disease
(ClaSS)
126 57
HTA 2007, 11, 10 EXERT (exercise evaluation
randomised trial) – randomised trial
comparing leisure centre-based
exercise on prescription,
home-based walking and usual
advice in primary care
64 58
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2007, 11, 24 Clinical effectiveness and cost of
repetitive transcranial magnetic
stimulation versus ECT in severe
depression: a multi-centre
randomised controlled trial and
economic analysis
65 59
HTA 2007, 11, 25 An RCT and economic evaluation
of direct versus indirect and
individual versus group modes of
speech and language therapy for
children with primary language
impairment
66 60
HTA 2007, 11, 31 The PRIME breast cancer trial
(postoperative radiotherapy in
minimum-risk elderly)
67 61
HTA 2007, 11, 35 Birmingham rehabilitation uptake
maximisation study (BRUM).
Home-based versus hospital-based
cardiac rehabilitation in a
multi-ethnic population:
cost-effectiveness and patient
adherence
68 62
HTA 2007, 11, 37 A randomised controlled trial of
longer-term clinical outcomes and
cost-effectiveness of standard and
new antiepileptic drugs (SANAD)
69 63 Arm A: carbamazepine as
standard drug
HTA 2007, 11, 37 70 63 Arm B: valproate as
standard drug
HTA 2007, 11, 49 The cost-effectiveness of functional
cardiac testing in the diagnosis and
management of coronary heart
disease
71 64
HTA 2007, 11, 16 Efficacy and cost-effectiveness of
physiotherapy for children less than
four years old with cerebral palsy
127 65
HTA 2007, 11, 42 Acceptability, benefit and costs of
early screening for hearing disability
135 66
HTA 2008, 12, 4 Does befriending by trained lay
workers improve psychological
well-being and quality of life for
carers of people with dementia,
and at what cost? A randomised
controlled trial
74 67
HTA 2008, 12, 13 STOOL – Stepped Treatment of
Older adults On Laxatives
75 68
HTA 2008, 12, 14 Randomised trial of fluoxetine and
cognitive behavioural therapy
versus fluoxetine alone in
adolescents with persistent major
depression
76 69
HTA 2008, 12, 22 Are topical or oral Ibuprofen
equally effective for the treatment
of chronic knee pain in older
people (Topical or Oral Ibuprofen)
72 70
HTA 2008, 12, 23 A prospective randomised
comparison of minor surgery in
primary and secondary care
73 71
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2008, 12, 29 Absorbent products for urinary/
faecal incontinence: A comparative
evaluation of key product
categories
131 72 Clinical trial 1, module 3:
a comparison of the
performance and
cost-effectiveness of
disposable and washable
designs for light
incontinence when used
by women living in the
community
HTA 2008, 12, 29 132 72 Clinical trial 2a, module 2:
a comparison of the
performance and
cost-effectiveness of
disposable and washable
designs for moderate/
heavy incontinence when
used by men and women
living in the community
HTA 2008, 12, 29 133 72 Clinical trial 2b, module 1:
a comparison of the
performance and
cost-effectiveness of
disposable designs for
moderate/heavy
incontinence when used
by men and women living
in nursing homes
HTA 2008, 12, 31 The place of minimal access surgery
amongst people with gastro-
oesophageal reflux disease (GORD) –
a UK collaborative study
77 73
HTA 2009, 13, 9 Controlling hypertension and
hypotension immediately post
stroke (CHHIPS) trial
110 74 Pressor arm of the trial
HTA 2009, 13, 9 78 74 This describes the
depressor limb only
HTA 2009, 13, 13 A randomised controlled trial to
estimate the clinical and
cost-effectiveness of four different
methods of mechanical support in
severe ankle sprains (CAST)
79 75
HTA 2009, 13, 15 A randomised controlled trial to
determine the effect of blood
glucose self-monitoring in people
with type 2 diabetes (DiGEM)
80 76
HTA 2009, 13, 19 Development and randomised
controlled trial of dipsticks and
diagnostic algorithms for the
management of UTI
81 77
HTA 2009, 13, 21 Neuroleptics in adults with
aggressive challenging behaviour
and intellectual disability
(NACHBID)
82 78
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2009, 13, 22 Randomised controlled trial to
determine the cost-effectiveness of
fluoxetine for mild to moderate
depression with somatic symptoms
in primary care – THREshold for
AntiDepressant treatment
(THREAD)
125 79
HTA 2009, 13, 27 Ibuprofen and paracetamol in
combination and separately for
fever in pre-school children
presenting to primary care: a
randomised controlled trial (PITCH)
84 80
HTA 2009, 13, 28 A randomised controlled trial to
compare minimally invasive glucose
monitoring devices to conventional
monitoring in the management of
insulin-treated diabetes mellitus
(MITRE)
85 81
HTA 2009, 13, 30 Psychological interventions for
postnatal depression – randomised
controlled trial and economic
evaluation (PONDER)
86 82
HTA 2009, 13, 33 Randomised controlled trial of
continuous positive airways
pressure and non-invasive positive
pressure ventilation in the
management of patients presenting
with acute cardiogenic pulmonary
oedema (3CPO)
87 83
HTA 2009, 13, 37 A double-blind randomised
placebo-controlled trial of topical
nasal steroids in 4- to 11-year-old
children with persistent bilateral
otitis media with effusion (OME) in
primary care
88 84
HTA 2009, 13, 39 Rehabilitation of older patients: day
hospital compared to rehabilitation
at home
89 85
HTA 2009, 13, 47 Use of aciclovir and/or prednisolone
for the early treatment of Bel’s
palsy: the Bells study
90 86
HTA 2009, 13, 51 A randomised trial of human
papilloma virus testing in primary
cervical screening (ARTISTIC)
91 87
HTA 2009, 13, 53 A randomised preference trial of
medical versus surgical termination
of pregnancies less than 14 weeks’
gestation (TOPS)
92 88
HTA 2009, 13, 54 Randomised controlled trial of the
use of three dressing regimens in
the management of chronic ulcers
of the foot in diabetes
93 89
HTA 2009, 13, 55 VenUS II: larval therapy venous
ulcer study
94 90
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2009, 13, 56 Randomised controlled trial and
economic modelling to evaluate the
place of antimicrobial agents in the
management of venous leg ulcers
(VULCAN)
95 91
HTA 2010, 14, 1 Multi-centre randomised controlled
trial examining the cost-effectiveness
of contrast-enhanced high field
magnetic resonance imaging in
women scheduled for wide local
excision (COMICE)
96 92
HTA 2010, 14, 5 Effectiveness and cost-effectiveness
of arthroscopic lavage in the
treatment of osteoarthritis of the
knee (the KORAL study)
97 93
HTA 2010, 14, 6 A randomised 2 × 2 trial of
community versus hospital
rehabilitation, followed by
telephone or conventional
follow-up: impact on quality of life,
exercise capacity and use of health
care resources
98 94
HTA 2010, 14, 13 North of England study of
tonsillectomy and adeno-
tonsillectomy in children (NESSTAC)
99 95
HTA 2010, 14, 14 Multi-centre randomised controlled
trial of the cost-effectiveness of
infra-inguinal percutaneous
transluminal angioplasty (PTA)
versus reconstructive surgery for
severe limb ischaemia (BASIL)
100 96
HTA 2010, 14, 15 A randomised controlled
multicentre trial of treatments for
adolescent anorexia nervosa
including assessment of
cost-effectiveness and patient
acceptability – the TOuCAN trial
101 97
HTA 2010, 14, 20 Antenatal screening for
haemoglobinopathies in primary
care: a cluster randomised trial to
inform a simulation model (SHIFT)
102 98
HTA 2010, 14, 22 A randomised controlled trial of
cognitive behaviour therapy and
motivational interviewing for
people with type 1 diabetes
mellitus and suboptimal glycaemic
control (ADaPT)
103 99
HTA 2010, 14, 23 A single blind randomised
controlled trial to determine the
effectiveness and cost utility of
manual chest physiotherapy
techniques in the management of
exacerbations of chronic obstructive
pulmonary disease (MATREX)
104 100
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TABLE 51 Description of all HTA projects included in the metadata database (continued )
HTA publication
(year, volume, issue) Project title
Trial ID
number
Journal series
ID number Description of trial
HTA 2010, 14, 26 What is the clinical effect and
cost-effectiveness of treating
upper limb spasticity due to stroke
with botulinum toxin?
105 101
HTA 2010, 14, 35 Conventional ventilatory support
versus extracorporeal membrane
oxygenation for severe adult
respiratory failure (CESAR)
106 102
HTA 2010, 14, 41 A multicentred randomised
controlled trial of a primary
care-based cognitive behavioural
programme for low back pain
(UK-Best)
107 103
HTA 2010, 14, 43 Antidepressant drug therapy vs a
community-based psychosocial
intervention for the treatment of
moderate postnatal depression: a
pragmatic randomised controlled
trial (RESPOND)
108 104
HTA 2010, 14, 46
(1–130)
Head-to-head comparison of two
H1N1 swine influenza vaccines in
children aged 6 months to 12 years
109 105
HTA 2010, 14, 52 LIFELAX – Diet and lifestyle vs
laxatives in the management of
constipation in older people
111 106
HTA 2011, 14, 55 A randomised, partially observer-
blind, multicentre, head-to-head
comparison of a two-dose regimen
of Baxter and GSK H1N1 pandemic
vaccines, administered 21 days
apart
112 107
HTA 2011, 15, 3 A comparison of automated
technology and manual cervical
screening (MAVARIC)
113 108
HTA 2011, 15, 8 Randomised controlled trial of
ion-exchange water softeners for
the treatment of atopic eczema in
children (SWET)
115 109
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Appendix 3 Data extraction specification form
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